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Foreword
As the Nation’s prevention agency, the Centers for Disease Control and Prevention (CDC) and the Agency for Toxic Substances Disease Registry (ATSDR) develop, endorse, and disseminate guide­lines as a crucial means of improving preventive health care programs and of exercising leadership in public health policy development and implementation. Guidelines translate research findings about the effectiveness and economic impact of prevention programs into accessible and useable informa­tion for public health practice. Increasingly, practitioners, the public, and experts in guidelines devel­opment methods are demanding practice guidelines that are clear, practical, and based on compelling scientific evidence. CDC must adopt the emerging standards of quality for the guide­lines we produce or endorse if it is to maintain its leadership role in public health policy develop­ment.
This guide was prepared by a multidisciplinary working group of CD C staff and reviewed by public health and scientific professionals (from federal and state agencies and the private sector) with skill and experience in planning and developing guidelines. They synthesized the best available advice in order to offer CD C staff a set o f recommendations and “points to consider” in the planning and exe­cution o f each of 13 primary tasks associated with the guideline development process. I encourage you to use this document to train CDC staff and participants in the guideline development process, establish a common language and frame o f reference for planning and developing guidelines, and pursue research priorities in the area of guidelines development methods. In addition, I have asked our Centers, Institutes, and Offices to implement the recommendations. I look forward to your full cooperation as we put in place a vigorous regimen o f training, technical assistance, and monitoring o f results agency-wide. Together we must continually ensure that the guidelines we develop or en­dorse are science-based, clear and practical. This reaffirms the agency’s commitment to excellence.
-t-
David Satcher, M D, PhD DirectorCenters for Disease Control and Prevention, and AdministratorAgency for Toxic Substances Disease Registry
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Executive Summary
CDC GUIDELINES: Improving the Quality is a guide to improve the development processes, content, and value o f CDC-sponsored practice guidelines. The guide presents “points to consider” and “recommenda­tions” which should be given careful attention by CDC staff responsi­ble for developing guidelines. To prepare the guide, a working group of CD C staff synthesized the best advice on guideline development methods available in published journal articles and reports. This sum­mary describes the agency’s history with guideline development, each of 13 primary tasks associated with the guideline development process, and important “ points to consider” when developing practice guide­lines. Table 1 associates each task in the CD C guideline development process with the participants and task-specific products.
CD C develops a broad range o f guidelines which offer advice to clini­cians, public health practitioners, managed care organizations, and the public on how to improve the effectiveness and impact o f public health interventions. Guidelines developed by CD C over the years gen­erally have been highly regarded within and outside the health care and public health communities, and may frequently be considered the standard of preventive health care. CD C guidelines are currently devel­oped by chartered advisory committees, ad hoc groups, and CDC staff. The processes used vary widely across topics which generally re­flect the agency’s programmatic responsibilities. The rationale for rec­ommendations ranges from expert opinion to “best available evidence” as determined by explicit rules o f evidence.
The authors recognize that a single approach to guideline development at CD C cannot accommodate all situations because o f the tremendous range o f topics, varying levels o f scientific data, and urgency for devel­opment of some guidelines. However, CD C must do better for the fol­lowing reasons. First, the process for developing the guidelines and the rationale for the recommendations are not always made clear to the user. Second, the format and content o f CDC guidelines have never been standardized. Third, plans for disseminating the guidelines are sometimes not formulated in advance. Fourth, the extent to which CD C guidelines are followed varies greatly. Fifth, there is no stand­ardized approach to assessing the impact o f CD C guidelines; although many CD C programs have used surveillance systems, surveys, or other indicators to measure impact.
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The C D C  guideline development process is divided into 13 discrete tasks.
1. Planning and coordinating the process. Define the objectives, mo­bilize resources, and oversee activities to ensure timely and efficient achievement o f defined objectives.
Recommendations:
• Identify and summarize existing guidelines on potential topics.
• Select a guideline topic.
• Select a panel structure with guidance from OGC.
• Select panel members and chairperson.
• Define the purpose and scope o f the guideline.
• Collect and synthesize evidence.
• Devise a method to deliberate and then make judgments and rec­ommendations.
• Write, edit, and format the guideline for review.
• Provide for peer review, legal review, and input from private citi­zens who have an interest in the topic. Document the planned re­view process, including the criteria for selecting reviewers.
• Prepare completed guideline for dissemination and follow up.
2. Assessing user needs. Find out about the nature, extent, and deter­minants o f current practices regarding the candidate intervention, tech­nology, or health problem of interest in the population o f primary guideline users; and gauge the level of common concern and consensus on the potential utility of the proposed guideline.
Recommendations:
• Supplement presumptive indicators of need with empirical evi­dence o f need.
• Seek empirical evidence o f need from surveillance data, surveys, fo­cus groups, opinion polls, claims, and other administrative data­bases.
• Weigh the potential costs and benefits o f using empirical versus presumptive indicators o f need.
• Consider the cost, feasibility, and potential utility of telephone sur­veys and focus group techniques for collecting empirical evidence o f need.
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• Give first priority to meeting the needs of the primary audience for most CDC-sponsored guidelines-one or more categories of public health practitioners.
3. Choosing guideline topics. Decide on the topics that should be given priority for guideline development and explain the rationale for each choice.
Recommendations:
• Adopt a formal, explicit topic selection process.
• Document the procedures and criteria for selecting topics.
• Consider appropriate criteria for topic selection such as contro­versy, inappropriate current practice, discrepancies between appro­priate care defined by meta-analyses and actual practice, practice variation, magnitude of morbidity, mortality, preventability, and cost to society.
• Select topics for which sufficient data are available to provide evi­dence for a guideline except in unusual circumstances, such as emergencies or for unique new technologies.
4. Selecting Guideline Panels. Choose a panel structure, and partici­pants who will assess the scientific evidence and formulate guideline recommendations.
Recommendations
• Consider whether guidelines should be developed internally or ex­ternally. If  externally, determine whether the group must be char­tered under the Federal Advisory Committee Act. If  a non-chartered group is preferred, consult with the Office of the General Counsel for guidance. The type of group used may im­pact which methods of group interaction and decision-making will be appropriate.
• The selection process for panel members will vary depending on the type of panel being used. Advisory Committee members are se­lected through a formal process, and are appointed as Special Gov­ernment Employees or representative members. The selection of regular employees and other experts for non-chartered panels will be accomplished in a less formal process.
• Choose panelists who represent relevant technical disciplines rather than specific organizations.
• Include panelists who serve as liaisons with affected private and governmental groups to assure a voice for the relevant viewpoints, if  undue influence can be avoided.
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• Ensure that panelists who are experts on a particular technology or practice give appropriate weight to evidence that contradicts a pub­licly stated point of view.
• Experts in reviewing and weighing evidence, who may or may not be subject matter experts, may be in the best position to consider the evidence presented.
• Outside experts (non-panelists) should be solicited to assure that all relevant scientific evidence was considered and interpreted cor­rectly.
• Where applicable, Individuals must comply with the Government Ethics Laws and Standards o f Conduct with regard to conflicting financial interests and other appearances of bias. For non-employ­ees, procedures should be established to identify and appropriately deal with individual conflicts o f financial interest or other poten­tial sources o f bias.
• Invite panelists with vested interests in a topic to serve as non-vot­ing resources to assure completeness of evidence presented and considered.
• Include panelists with methodologic expertise in assessing scien­tific evidence, and representatives of likely primary users of the guidelines.
• Include consumers in appropriate situations.
• Document procedures and criteria for selecting panel members.
5. Defining the scope of guidelines. Delimit the target population, outcomes, and interventions which are (1) o f greatest interest to spe­cific practitioners, the public, and other users, (2) most amenable to clarification by means of systematic assessment and synthesis o f scien­tific evidence, and (3) capable o f being fully explored and resolved into clear and specific advice within the limitations o f time and re­sources.
Recommendations:
• Planning staff should make preliminary decisions about target population, outcomes, interventions, best-practice criteria, poten­tial users, time and resources, and relevance o f existing guidelines early in the planning process.
• Planning staff should assess expected quantity of evidence o f effec­tiveness for alternative guidelines whose scope varies from nar­rower to broader.
• The official decision-making body (panel or task force) should ac­cept or revise the preliminary decisions made by the guideline plan­ning staff as soon as possible after the former is convened.
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Guidelines should address issues o f safety and effectiveness of rele­vant high-volume practices in widespread use.
• Consider implementation issues (cost, cost-effectiveness, staffing, insurance coverage, and patient preferences) whether or not they are used to define best-practices.
6. Clarifying the method and analytic framework. Justify the use ofone or more guideline development methods (informal consensus, for­mal consensus, evidence-based, or explicit) and describe or illustrate the chain of causal reasoning which links the recommended health practice to the desirable health outcomes in a defined individual or population by means of credible evidence of effectiveness.
Recommendations:
• Base prevention guidelines on relative benefits, harms, and costs, whenever possible.
• Consider evidence-based methods (arguably more valid and cred­ible) in preference to consensus methods (informal or formal), if both are feasible.
• Train participants, especially for evidence-based methods, as early in the guideline planning process as is feasible.
• Make the services of a guideline development methodologist avail­able to the panel.
• Prepare and use a written analytic framework (narrative, algo­rithm, decision model, etc.).
• Use a suitable form of exposition to describe the logical link be­tween practice recommendations, evidence o f effectiveness, and de­sirable health outcomes.
• Consider the rules and regulations of other agencies when develop­ing guidelines in areas o f common interest. Specifically, CD C staff and expert panels working on vaccines, drugs, and medical devices, should be trained to use the biostatistical regulatory model o f the Food and Drug Administration (FDA).
7. Identifying and synthesizing the evidence. Seek, collect, and assess the quality and quantity o f empirical evidence o f the effectiveness o f a proposed intervention for ensuring a desirable health outcome in a de­fined population. Empirical evidence o f effectiveness must be system­atically identified, synthesized, and documented using methods that minimize bias and maximize precision.
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Recommendations:
• Develop all CD C guidelines on the basis of data synthesis includ­ing a systematic review of the literature, and where relevant and feasible meta-analysis.
• Panelists should be involved in specifying the project format, re­sponsibilities, tasks, and questions to be addressed. Panels should address specific and manageable questions.
• Panelists should be provided with the most comprehensive scien­tific data possible. A summary description of the available studies should be provided and cited in the final panel statement.
• Document process methodology, facts, assumptions, estimates, cri­teria for findings, and rationale for recommendations. Include esti­mates o f outcomes expected if  the panel’s recommendations are followed.
8. Aiding group interaction and decision making. Use formal tech­niques to maximize the contributions of all participants in the guide­line development process. Group interaction methods add clarity and explicitness to group decision making, balance power among partici­pants, minimize bias, and ensure documentation of decision rules and products.
• Provide appropriate training in group interaction techniques for C D C staff and panelists.
• CD C staff should plan for group interaction activities, assigning activities to groups which are appropriate for group work.
• Guideline planning staff should select group interaction tech­niques appropriate to the specific tasks to be accomplished and the nature o f the group or panel.
• Circulate materials in advance for review. (For specific techniques such as Delphi, follow protocol.)
• Use skilled facilitators who are trained in the group process tech­nique selected for the group activity, not invested in a particular outcome, and perceived as neutral and professional by group mem­bers. A facilitator with an understanding of the particular topic, but not necessarily an expert, may also serve as the working group coordinator.
• Specify an operational definition o f consensus as well as how to present less than full agreement o f the panel’s findings.
• Maintain good written documentation o f the group interaction process; and keep in mind that such documents are in the public domain. Use group interaction methods which produce written documentation.
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• Avoid voting as a method of seeking consensus. A better approach is to rank ideas and to encourage participants to react and add to the work o f others. I f  consensus is appropriate, use mediation tech­niques. I f  consensus is desired, consider using mediation tech­niques such as those o f negotiated rule making.
9. Identifying a research agenda. Identify a list o f study questions or areas o f inquiry that should receive high priority for scientific investiga­tion and funding. The primary source o f study questions is the ana­lytic framework, its assumptions, and presumed causal linkages for which existing evidence is inadequate.
Recommendations:
• Identify and clarify the relative importance o f controversies or gaps in knowledge about desired practices and the best implementation strategies.
• Recommend research needed to resolve issues of importance, espe­cially those for which full agreement was not reached.
• Establish a mechanism for periodically assessing progress in find­ing answers to key questions on the research agenda.
10. Updating the guideline. Decide on a timetable for revising the guideline to reflect new scientific knowledge. The timetable is deter­mined by the strength o f current supporting evidence and expectations about new discoveries, effectiveness of the guideline, and changes in the practice environment.
Recommendations:
• Include a statement, based on the best available information at the time the guideline is issued, that indicates a timetable for revisiting the guideline.
• Review and update the guideline when new evidence suggests that its recommendations are incorrect, ineffective, or can be strength­ened.
• Consider the timetable for updating guidelines in relation to the re­search agenda.
11. W riting the guideline. Prepare a document written with unambi­guous language and easy-to-follow logic that provides clear recommen­dations and documents the rationale on which the recommendations are based.
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Recommendations:
• Employ writers and editors who are familiar with the subject mat­ter (medical or scientific writing) or who are able to comprehend, interpret, and explain it after a short learning period.
• Match the document’s length, format, layout, and style with the audience needs, subject matter, intention o f the guideline, and dis­semination vehicle.
• Develop and implement a time-phased work plan to keep the pro­ject on schedule.
• CD C public health practice guidelines should address certain basic components: the relevance o f the health problem, the magnitude o f the problem, the nature of the intervention, the guideline devel­opment methods, the strength o f the evidence, the cost effective­ness, a discussion of implementation issues, evaluation issues, and the recommendations o f others. Provide a brief but complete sum­mary and the name of a contact person.
12. O btaining critical reviews. Obtain input from content and policy experts, practitioners, advocates, and the public about the scientific ac­curacy, completeness, and ease of implementation o f the draft guide­lines. Revising the draft guideline in response to such feedback from potential users and other interested persons can increase the credibility of the guidelines.
Recommendations:
• Use experts on subject matter and methods to review draft guide­lines and alert developers to challenges in implementation, credibil­ity, and perceptions o f utility.
• Involve a multidisciplinary working group, taskforce, or expert panel which represents all stakeholders to encourage acceptance of the guidelines.
• Seek review by relevant content experts to ensure epidemiological, statistical and clinical validity as well as by relevant organizations and agencies to provide broad input on content and policy issues.
• Arrange for public input, if appropriate.
13. Encouraging adoption o f the guideline. Ensure that the guideline is appealing, widely disseminated, and encourages potential users to ac­cept and implement the recommended practices.
Issues and M ethods:
• To ensure relevance, clarify the users and populations for whom the guidelines apply.
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• Describe the health importance o f the proposed interventions or practices from a range o f relevant perspectives.
• To ensure credibility and improve confidence in the guideline, de­scribe the methods, scientific evidence, participants (individuals and institutions), and relationship to existing recommendations.
• To enhance feasibility o f adoption, aim to address a single, well- defined practice (when possible), increase user performance at all levels, and allow practitioner judgment that is consistent with the evidence of effectiveness in different populations.
• To highlight the value of implementing a guideline, present the costs and benefits from all relevant perspectives (societal, public health clinics, local government, managed care organizations, pri­vate practitioners); encourage purchasers and providers of care to establish financial and administrative incentives for use o f the guideline; and consider the legal implications.
• Plan and implement active dissemination strategies, when possible, including the use o f local information networks, respected col­leagues, consumer information campaigns, and administrative mechanisms; keep the electronic Prevention Guidelines Data Base current as a venue for guideline dissemination (see Appendix D).
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Table 1. Model of CDC Guideline D evelopm ent Process, Participants, and Products
Process Participants Product(s)
Planning & coordinating CIO staff Plan & budget
Assessing user needs CIO staff; Constituents Statement of user needs
Choosing a topic CIO staff; Constituents; Panel chair; Methodologist Initial topic statement
Selecting a panel CIO staff; Constituents ;Panel chair;Methodologist Roster of panelists and alternates
Defining the scope CIO staff; Panelists; Methodologist Statement of guideline scope
Clarifying the method & analytic framework CIO staff; Panelists; Methodologist; Consultant (subject matter expert) Analytic framework linking proposed actions,desirable outcomes, and evidence of effectiveness.
Identifying & synthesizing the evidence CIO staff; Panelists; Methodologist; Consultant (librarian) Summary Evidence Tables
Aiding group interaction and decision making CIO staff; Panelists; Methodologist Consultant (group process expert) Decision rules; Minutes of group deliberations. Draft recommendations and rationale
Identifying a research agenda CIO staff; Panelists; Methodologist Consultant (subject matter expert) List of important unanswered questions in order of priority. Strategic plan for filling knowledge gaps in order of priority.
Updating the guideline CIO staff; Constituents; Panel chair; Methodologist Update plan and schedule.
Writing the guidelines CIO staff; Panelists; Methodologist; Consultant ( writer/editor) Outline of primary guideline document.Drafts of recommendations and supporting documents.
Obtaining critical reviews & public comment CIO staff; Panelists; Methodologist; CDC/ADS;CDC/OPPE;CDC/OGC Final draft of guidelines and supporting documents
Encouraging adoption CIO staff; Panelists; Methodologist; Consultant (publicist) Publication and promotional plan.
Introduction
The purpose o f this guide is to encourage CD C staff responsible for developing practice guidelines to (1) take a standardized and compre­hensive approach to guideline planning and development, (2) docu­ment the scientific rationale for the public health actions being recommended, and (3) make both the process for development o f the guideline and the rationale for the recommendations clear to the end user. The authors hope that guideline developers will use the docu­ment to:
• Encourage ongoing self-assessment o f the agency’s progress toward increasing excellence in guidelines development.
• Train CD C staff and participants in the guideline development process.
• Establish a common language and frame of reference for planning and implementing the guideline development process.
• Remind guideline developers of important issues to consider so that the resulting guidelines will be optimally effective in influenc­ing public health practice.
• Guide the establishment o f research priorities in the area of guide­lines development methodology.
The guide was developed in response to the growing recognition that:
• The science and art o f guidelines development are advancing rap­idly.
• Guidelines are expected to play an increasingly important role in efforts to improve the effectiveness and cost-effectiveness o f public health practice.
• The utility and effectiveness of CDC-developed practice advisories are likely to increase if they adhere to a standard o f excellence that reflects the state-of-the-art and science o f guideline development.
The guide will be disseminated in this and other formats through a va­riety o f communications channels including professional conferences and workshops.
In April, 1995, the Associate Director for Science (ADS), Office o f the Director, Centers for Disease Control and Prevention (CDC), and the Chief, Prevention Effectiveness Activity (PEA), Office o f the Director, Epidemiology Program Office (OD/EPO), began working with repre-
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sentatives o f the Centers, Institutes, and Offices (CIO) to prepare this guide on guideline development methods.
A CDC-wide Guidelines Methodology Working Group (GMWG) was established (members are listed on page iv) and held its first meet­ing April 18, 1995. Subsequently, the committee met once every two to four weeks to develop a first draft o f the guide. The guide was re­viewed (reviewers are listed on page v) and revised based on feedback from CD C leadership, CD C technical staff whose work is expected to be influenced by its content, and selected outside experts on guideline development methods.
The primary audience for this document is staff of the Centers for Dis­ease Control and Prevention (CDC) who are responsible for develop­ing public health practice guidelines. However, CD C pursues its mission in partnership with governmental and non-governmental health agencies at the federal, state, and local levels and with health care providers working in a variety of clinical settings, including man­aged care organizations. Consequently, staff members responsible for implementing public health guidelines in partnership settings are a sec­ondary audience, to ensure that our partners are aware o f the princi­ples and frames o f reference which shape C D C ’s approach to the development and sponsorship of practice guidelines.
Other secondary audiences also may include (1) members o f advisory groups, convened to develop guidelines, who may need a common framework for pursuing their charge; and (2) groups which develop guidelines that may affect the public’s health whether or not the docu­ments are prepared in partnership with CDC.
The scope of this document is limited to practical and scientific issues of particular relevance to the C D C ’s mission o f providing national leadership in developing practice guidelines for population-based health promotion and disease prevention. The practical issues relate to planning, implementing, supporting and documenting the process, and to communicating the product to potential users. The scientific is­sues relate to the central analytic tasks o f guideline development, viz.:
• Reviewing the literature.
• Recording evidence o f prevention effectiveness.
• Weighing the evidence o f effectiveness.
• Considering costs and effectiveness of intervention programs.
• Explaining the scientific rationale o f recommendations that appear prudent based on the evidence o f effectiveness, and perhaps, cost- effectiveness.
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This document is not intended primarily to serve as a comprehensive manual on how to develop, disseminate, and implement practice guidelines; nor is it intended to prescribe a “one size fits all” approach to developing guidelines for all problems and in all situations.
In this document, the term guideline, which includes advisory, guide, guidance, guideline, and recommendation, means “advice about the ap­propriateness o f taking some action to prevent or ameliorate the conse­quences of a public health problem in a defined population.” This document is referred to as a guide and the product o f the guideline de­velopment process as a public health practice guideline merely as a se­mantic device to distinguish between the two documents. O ther key terms are defined in the glossary o f terms beginning on page 107.
Term inology  
and Usage
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Background
Members o f the GMW G believe that recommendations which are linked to strong scientific evidence o f effectiveness by clear and con­vincing logic are more likely to be implemented and to improve health than recommendations based entirely on current practice, expert opin­ion, or anecdotal experience. We recognize, however, that evidence of effectiveness may not always exist especially when dealing with new medical devices, emerging infections, or recently discovered diseases. Because the literature reveals little empirical evidence about what makes guidelines useful and effective (Field and Lohr, 1992; p 196), we believe further that:
• Use of this document will lead to improved guideline development capability among CDC staff over time.
• Improved guideline development capability among CD C staff will lead to improved CDC-sponsored public health practice guide­lines which display the eight attributes of good guidelines (Appen­dix C) (Field and Lohr, 1990; Field and Lohr, 1992).
• Improved practice guidelines will enable individuals and organiza­tions (health departments, managed care organizations, and com­munity-based organizations) to develop and implement more cost-effective prevention programs.
• More cost-effective prevention programs will lead to improved community health status at affordable levels of resource use.
The sequence o f activities which leads to a set o f guidelines includes ac- tivational work (organizing a group to develop practice guidelines), analytic work (reviewing scientific evidence, developing recommenda­tions, and explaining the rationale), editorial work (writing the docu­ment) and diffusion work (the review, dissemination, and adoption of guidelines by the user audience). W oolf and others contend that the analytic work is clearly the most important and complex task affecting the quality of practice guidelines (Woolf, 1994).
Some background information about the agency is important to under­stand guidelines development at the CD C and the Agency for Toxic Substances and Disease Registry (ATSDR). CDC and a T sD R  are agencies o f the US Public Health Service within the Department of Health and Human Services (DHHS). These sister agencies have a common leadership, complementary missions, and a single organizing vision. For CDC that vision is “Healthy people in a healthy world through prevention.” In 1994, C D C ’s name was changed to “Centers
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for Disease Control and Prevention” to underscore its focus on preven­tive interventions. CD C is primarily a public health agency, i.e., it con­siders the community as the patient, identifies important community health problems, and seeks to develop community interventions to ad­dress those problems. Some of C D C ’s areas o f interest are (1) infec­tious diseases, (2) chronic diseases, (3) environmental health, (4) occupational health and safety, (5) injury prevention and control, (6) health statistics, and (7) international health.
In addition, CDC trains public health workers in epidemiology and other applied public health areas and responds to public health emer­gencies, e.g., epidemic investigations, Health Hazard Evaluations, and Crisis Response Teams. CD C accomplishes its mission through a vari­ety of activities including research, public health surveillance, outbreak investigation, evaluation of interventions, public health capacity build­ing, and national leadership. National leadership includes developing guidelines. Approximately 80% of C D C ’s budget is spent extramurally through grants, cooperative agreements, and contracts. Congress tar­gets much of C D C ’s money to program-specific areas (e.g., immuniza­tions, human immunodeficiency deficiency virus (HIV), sexually transmitted diseases (STD), tuberculosis (TB), and lead poisoning, etc.) and to specific entities such as health departments and commu­nity-based organizations.
CD C does not operate independently; it places strong emphasis on partnerships. These partners include (1) state and local health, educa­tion, and public safety departments, (2) other federal and international agencies, (3) academic institutions, (4) labor and management, (5) health maintenance organizations (HM O), hospitals, and other health care provider groups and institutions, (6) philanthropic foundations,(7) professional societies, (8) voluntary and community-based organi­zations, (9) physicians and other health care providers, (10) laboratory personnel, (11) and the general public. The list is neither exhaustive nor mutually exclusive.
The IO M  defines clinical practice guidelines as “systematically devel­oped statements to assist practitioner and patient decisions about ap­propriate health care for specific clinical circumstances.”
Because public health practice is not limited to clinical circumstances, the IOM  definition is expanded here to include public health circum­stances. For the purposes o f this guide, public health practice guide­lines are defined as systematically developed statements to help policy-makers, public health practitioners, clinical practitioners, health agencies, and the public decide the appropriate actions to (1) promote health, (2) prevent disease, disability, and premature death, and (3) im­prove quality o f life o f members o f a defined population. Appropriate actions may target individuals or whole communities at risk for ad­verse health outcomes. Public health practice guidelines may refer to
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clinical preventive services which are defined as recommendations for clinical practice on preventive interventions— screening tests, counsel­ing interventions, immunizations, and chemoprophylactic regimens—  for target conditions among asymptomatic individuals o f all age groups and risk categories (U.S. Preventive Services Taskforce, 1989).
The IO M  proposes that “clinical practice guidelines have real potential to help clarify the knowledge base for clinical practice and to improve the quality and effectiveness o f medical care” (Field and Lohr, 1992). A review of the most rigorous studies o f the effectiveness of strategies to improve the dissemination and application of health care knowl­edge by physicians concludes that strategies then in common use were incompletely tested (Lomas, 1988). Although empirical evidence of ef­fectiveness similarly is lacking, it is reasonable to expect that public health practice guidelines have potential to improve the quality and ef­fectiveness of public health practice.
The IO M  asserts that clinical practice guidelines which possess eight desirable attributes are more likely to be perceived as trustworthy, us­able, and effective in achieving desired health outcomes. Good prac­tice guidelines are demonstrably (Field and Lohr, 1992)(Appendix A):
• Valid-supported by strong evidence linking recommendations to outcomes.
• Reliable or reproducible-prepared using procedures and decision rules that would lead different experts to the same conclusions based on the same evidence.
• Applicable-useful in populations that potential users would con­sider relevant to their practices.
• Flexible-allowing for practitioner judgment and patient prefer­ences.
• Clear-presented in unambiguous language and easy-to-follow logic.
• Multidisciplinary-prepared with input from relevant disciplines and stakeholders.
• Up to date-reflecting the most recent evidence.
• Docum ented- published along with explicit statements on as­sumptions, process, rationale, evidence, and decision rules.
Rationale fo r  
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D evelopm ent at 
CDC
CD C develops guidelines to influence others to take actions which will reduce preventable morbidity and mortality from diseases and other health conditions. The specific “triggers” for developing a spe­cific guideline are numerous and variable. Frequently, a guideline is de­veloped in response to an emerging health problem such as hantavirus pulmonary syndrome or multidrug-resistant tuberculosis. Guidelines also are developed in response to requests from constituents such as health care providers or public health officials. The passage o f a new law or the development o f regulations might prompt the development of a guideline. Another trigger might be new surveillance data; several vaccine recommendations were revised in response to changes in dis­ease epidemiology identified by surveillance data. The results of a re­search study or series o f studies might precipitate the development of a guideline, for example, the appropriate use o f folic acid for prevention of neural tube defects. Some guidelines were developed because of a new technology, e.g., varicella vaccine. This list is not exhaustive nor are the triggers mutually exclusive.
Broadly speaking, the audience for a guideline is anyone who can take the recommended actions. This audience includes many groups and in­dividuals listed on page 16 (see section on public health practice at CDC).
Different approaches are used to develop guidelines depending upon the circumstances. Some guidelines are developed by Federally char­tered advisory committees, e.g., the Advisory Committee for Immuni­zation Practices (ACIP), the Advisory Committee for the Elimination of Tuberculosis (ACET), and the Hospital Infection Control Practices Advisory Committee (HICPAC). Some of these committees are com­posed of individuals appointed by the Secretary, D HH S, others in­clude ex-officio members from other government agencies, and liaison members from non-federal organizations with an interest and expertise in the topic. Some guidelines are developed by ad hoc advisory groups. Still others may be developed by CD C staff.
Many o f CD C guidelines are developed in collaboration with other or­ganizations, especially other Public Health Service agencies such as the National Institutes o f Health, the Food and Drug Administration, and the Agency for Health Care Policy Research. Some guidelines are pub­lished in draft form in the Federal Register for comment. At times, public meetings are held at CDC to obtain comments from the public on a proposed guideline.
The guidelines development process varies from topic to topic, pro­gram to program, and committee to committee. Generally speaking, CD C staff conduct a literature and data review and summarize it for the benefit o f outside advisors and other CD C staff. Meta-analyses, or systematic reviews, are sometimes performed. Based on these summa­ries, policy options, treatment options, etc., are debated. Decision analyses, cost-effectiveness analyses, or other quantitative approaches
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to decision making are being used increasingly at CDC. Other inputs include legal review, public comments, societal values, and expert judg­ments about feasibility.
Characteristics common to virtually all CD C guidelines include an openness to input and extensive and repeated review by people both within and outside o f CDC. Most CD C guidelines are published in the Morbidity and Mortality Weekly Report (MMWR). The topics of CD C guidelines reflect the agency’s program-specific funding priori­ties which include (1) infectious diseases such as HIV infection, vac­cine preventable diseases, sexually transmitted diseases, and tuberculosis and risk factors for antimicrobial resistant infections; (2) chronic diseases such as breast and cervical cancer and diabetes and risk factors for chronic disease such as poor nutrition, smoking, and lack of exercise; (3) injury prevention and control; (4) reproductive health, maternal and infant health; (5) environmental health; (6) occu­pational health; (7) international health; and (8) epidemiology and health statistics.
CD C develops a broad range o f documents that could be called guide­lines. Guidelines developed by CDC over the years generally have been highly regarded within and outside the health care and public health communities, and may frequently be considered the standard of preventive health care. However, the format and content of CD C guidelines have never been standardized. Plans for disseminating the guidelines are sometimes not formulated in advance. The extent to which C D C  guidelines are followed varies greatly. There is no stand­ardized approach to assessing the impact o f CD C guidelines; although many CD C programs have used surveillance systems, surveys, or other indicators to measure impact.
C D C guidelines are currently developed by chartered advisory com­mittees, ad hoc groups, and CDC staff. The processes used vary widely across topics which generally reflect the agency’s programmatic respon­sibilities. The rationale for recommendations ranges from expert opin­ion to “best available evidence” as determined by explicit rules of evidence. The process for developing the guidelines and the rationale for the recommendations are not always made clear to the user. For these reasons, CD C must do better.
This guide is offered as an aid to CD C staff for improving the guide­lines planning, development, and dissemination process, recognizing that with the tremendous range o f topics, varying levels o f scientific data, and urgency for development of some guidelines, a single ap­proach to guideline development at CDC cannot accommodate all situations.
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Specific ethical issues may arise in the context o f any of the 13 guide­line development tasks. For example, the isssue o f conflict o f interest is addressed in the sections o f this document dealing with selecting guide­line panels (page 39) and aiding group interaction (page 65). More­over, the professional conduct o f CD C staff engaged in guideline development are guided by standards o f ethical conduct for employees of the executive branch of the federal government (Title 5, Part 2635, Code of Federal Regulations).
In general, however, CD C staff involved in guideline development must be guided by the basic moral principles o f (1) respect for auton­omy in decision-making o f patients, clients, and practitioners, (2) beneficience— enhancing the welfare o f others, (3) nonmaleficience- avoiding harm to others, and (4) justice-equity in the distribution of benefits and risk (Hahn, 1994). Weed argues that advocacy in the form of public health recommendations can be justified in terms of the principle o f beneficience found in the guidelines (Weed, 1994). W ith respect to nonmaleficience, clinical practitioners, patients, pay­ers, and others have continued to voice concerns about the potential harms of clinical practice guidelines. The catalogue o f potential harms include (1) insensitivity to differences in patient populations and prac­tice settings, (2) threats to professional autonomy, income, credentials, and hospital priviledges, (3) disincentives to independent thinking and innovation, and (4) inappropriate rationing o f health care. (Woolf,1993). In the mid-1960s, Hill argued that judgment is important in making public health recommendations; and in his mind, different lev­els o f evidence were required for public health action, depending on who was affected by those actions (Coughlin and Beauchamp, 1996).
There are numerous controversies surrounding guidelines develop­ment. For example, some contend that the terms guide, guideline, guidance, and recommendation have different shades of meaning in common usage. Others argue that there is no substantive difference in the meaning of these words.
Controversy also surrounds the issue o f distinguishing clinical guide­lines from public health practice guidelines. Some argue that clinical guidelines, which relate to the diagnosis and treatment of illness in in­dividuals, are qualitatively different from public health practice guide­lines, which relate to prevention and health promotion among populations. Others contend that clinical guidelines are a subset of public health practice guidelines, which relate to all phases of health promotion and disease prevention for individuals and populations.
In parallel with these ongoing controversies about language and con­text, a consensus is emerging among CDC staff and external partners that future guidelines developed at CD C can be improved while main­taining a balance between the complementary goals o f scientific rigor, feasibility in terms of time and development costs, and practicality in use.
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Planning and Coordinating  
the Process
The way guidelines are developed can strongly affect their potential for use by the intended audience. Thus, the entire process from introduc­tory decisions through revisions and implementation requires careful planning and coordination (Field and Lohr, 1992). Certain steps are central to guideline development. Groups, however, may differ some­what on the emphasis that the steps are given and the sequence in which they are performed. The steps in planning and coordinating guideline development can be categorized broadly as introductory deci­sions (about the topic, the authors, and its purpose), assessment of the public health or clinical appropriateness of the proposed guideline (based on evidence, expert opinion, and decision rules), assessment of public policy issues (related to resource limitations and feasibility), and guideline document development and evaluation (Woolf, 1992).
Answers to the following questions can help plan and coordinate the process:
• Is the topic appropriate for developing a guideline?
• Is there a source of evidence on which to base the guideline?
• Is a technical workplan being developed?
• Is an administrative workplan being developed?
• Have existing guidelines on potential topics been identified and summarized?
The recommendations outlined below provide general suggestions for group planning and coordinating of the process of guideline develop­ment.
• Identify and summarize existing guidelines on potential topics.
• Select a guideline topic.
• Select a panel structure with guidance from OGC.
• Select panel members and chairperson.
• Define the purpose and scope o f the guideline.
• Collect and synthesize evidence.
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• Devise a method to deliberate and then make judgments and rec­ommendations.
• Write, edit, and format the guideline for review.
• Provide for peer review, legal review, and input from private citi­zens who have an interest in the topic. Document the planned re­view process, including the criteria for selecting reviewers.
• Prepare completed guideline for dissemination and follow up.
Historically, CDC-sponsored guidelines have been developed by (1) Federally chartered advisory committees, (2) ad hoc expert panels which are convened to develop a particular guideline, (3) staff o f the sponsoring CIO, and (4) some combination o f the categories de­scribed in items 1-3. Although there are more similarities than differ­ences, the planning and coordinating for guideline development efforts at the CD C vary depending on the development group.
The Federal Advisory Committee Act (FACA) must be kept in mind when considering the creation o f a guideline panel which includes non­government employees. This includes groups convened to  develop guidelines or to provide input to the guideline developers. Generally, the FACA governs the formation and functioning of groups which in­clude non-government employees, convened for the purpose o f obtain­ing consensus advice or recommendations on issues or policies which are within the scope of an agency’s responsibilities. Therefore, whether the group is a formally chartered advisory committee or not, may im­pact which methods o f group interaction and decision-making will be appropriate. Chartered advisory committees are free to reach consen­sus on advice and recommendations to the agency. Other types of groups may not provide consensus advice and recommendations to the agency. Advice and recommendations may be obtained through the individual input of outside experts. However, there are group models where consensus recommendations, such as guidelines, may be generated for the public health community, or other external constitu­encies. I f  groups are formed outside the FACA, and include non-gov­ernment employees, it will be necessary to consult with the Office of the General Counsel.
Examples o f the steps used by the groups listed in items 1-3 above are outlined below.
ACIP is an example of a federally chartered advisory committee. Guideline topics are chosen by the committee, with assistance from C D C staff. Developments at the Food and Drug Administration (FDA) (e.g., a manufacturer’s submission o f a product for regulatory approval) may prompt a review of a new vaccine. A memo is circulated periodically to committee members, organizational liaisons, and CDC- wide to elicit topics for consideration. The starting point for ACIP rec­
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ommendations may be labeling and package inserts o f licensed vac­cines or a previous ACIP recommendation on the same subject. That step is followed by:
• A thorough review of the scientific literature (both published and sometimes unpublished) on the immunizing agent and key preven­tion issues. A systematic review is done usually or a meta-analysis is done sometimes.
• Ascertaining the relevance and quality of published and unpub­lished data.
• An assessment of the morbidity and mortality o f the disease, the safety and efficacy of the vaccine, and the feasibility of its use. The scheduling o f immunizations is also considered. Cost-effectiveness and cost-benefit analyses are frequently performed to aid commit­tee decision making.
• An extensive review of existing recommendations by CDC staff, ACIP members, and outside expert consultants. Working groups are often formed to review the research data prior to presentation to the full committee.
• Public comments are solicited during the committee meetings and are considered in the decision-making process.
• All recommendations are subject to an exhaustive review and are made only after extensive dialogue among the committee, liaison members, and other concerned parties. All recommendations are also discussed at public meetings. Some recommendations are pub­lished jointly with other recommending bodies, such as the Ameri­can Academy of Pediatrics, American College o f Physicians, etc.
Ad hoc panels are convened to develop guidelines on particular topics.
Example: The U.S. Public Health Service (USPHS)/Infectious Dis­eases Society o f America (IDSA) Prevention o f Opportunistic Infec­tions Working Group. The USPHS-primarily through the efforts of the CD C and the National Institutes o f Health (NIH)— and the ISDA in 1994 recognized the importance o f preventing opportunistic infections and the need to consolidate information for health-care providers. In response, these organizations initiated an effort to de­velop comprehensive recommendations for the prevention o f oppor­tunistic infections in HIV-infected persons. The goal was to disseminate information on pathogens that can cause disease in pa­tients with H IV  infection and the chemoprophylactic regimens avail­able for preventing disease. Such Information about preventing exposure and preventing disease may have been published in journals that are not regularly reviewed by healthcare providers; and some of it may not have been published. Draft recommendations were reviewed by staff from CDC, N IH , and IDSA, as well as by members of other
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government agencies, community organizations, physicians caring for HIV-infected persons, and HIV-infected persons themselves.
These recommendations were discussed at a two-day meeting con­vened by the CDC, N IH , and IDSA in Atlanta in September 1994. Comments were solicited from the public and final recommendations were approved by the USPHS and IDSA. The recommendations were endorsed by the American Academy of Pediatrics, the Infectious Dis­eases Society of Obstetrics and Gynecology, and the Society o f Health­care Epidemiologists o f America.
C D C staff guidelines are developed in house in response to a particu­lar need and may be developed in collaboration with other groups.
Example: The Guidelines for School Health Programs to Prevent To­bacco Use and Addiction. These guidelines represent collaboration with experts from 29 national, federal, and voluntary agencies along with other leading authorities in the field o f tobacco-use prevention. The steps involved:
• An in-depth review of research, theory, and current practice in the area o f school-based tobacco-use prevention.
• CD C staff convening meetings o f experts from the fields of to- bacco-use prevention and education.
• A review of published research.
• Consideration of the conclusions o f the National Cancer Institute Expert Advisory Panel on School-Based Smoking Prevention Pro­grams and the findings o f the 1994 Surgeon General’s Report, “Preventing Tobacco Use Among Young People.”
In addition to this global planning which must take place, there will also be an assortment of managerial, or administrative, issues which must be decided and handled. While they may also vary to some de­gree, depending on the group, many of the issues are universal with guideline development. Unless the group is already well organized, like ACIP and HICPAC, certain mechanisms must be brought into place. For example, what will be the source o f funding for this project? Is the administration going to be coordinated internally or is a contractor go­ing to be hired to handle it? Will training be required and if so, how will it be handled? Will external consultants be needed during the process? An assortment of other issues also need to be resolved. Provi­sions must be made for dissemination, review, and clearance— e-mail, fax, conference calls. Publication requirements must be checked and projected costs obtained.
No matter who handles them, the administrative duties will also in­clude the need to arrange meetings and provide for any special require­ment (such as slides and audiovisual equipment) that presenters may
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need at the meetings. Notebooks will need to be assembled and materi­als distributed. A tracking system must be put into place. Staff must be identified to develop the agenda for the meetings, keep the minutes, and provide for public and financial disclosure, if needed. Arrange­ments for press releases and conferences may have to be made some­times. These issues represent just some of the basic housekeeping duties that may be required within the broader basic steps o f guideline development. It is essential that they be considered early on to ensure that the process runs smoothly.
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Assessing User Needs
The team planning a guideline development effort must justify com­mitting the required resources to the effort. Evidence o f perceived pressing needs (for knowledge, skills, and a good reason to change their practices) among potential users of the proposed guideline often is sufficient justification. Assessing user needs means finding out about the nature, extent, and determinants o f current practices regarding the candidate intervention, technology, or health problem of interest in the population of primary guideline users. Documenting the perceived educational and other needs of the target audience is a prerequisite for choosing a guideline topic. (See next section.) Also it gauges the level o f common concern and consensus on the potential utility o f the pro­posed guideline.
The potential utility o f a guideline will vary among categories o f users. Public health practitioners, clinicians, patients, administrators, payers, politicians, and other users of practice guidelines have different needs and expectations of what good will result from their use. The use of guidelines often are expected to improve population-based health status, individual health outcomes, and to reduce costs of care, practice variations, public expenditures, and inappropriate care. In the context o f this guide, guidelines are perceived as the starting point o f planned interventions designed to influence knowledge, attitudes, skills, and professional and organizational behaviors (Woolf, 1993).
Green and Kreuter have identified three categories o f factors that influ­ence behavior or professional practice: predisposing, enabling, and re­inforcing factors. Predisposing factors include the professional’s values, beliefs, attitudes, and perceptions about guidelines and their potential usefulness. These factors account for the professional’s motivation to use guidelines and confidence in being able to implement their recom­mendations. Enabling factors are the necessary skills and resources (fi­nances, staff, space, and educational materials) which the professional must possess in order to successfully implement the guideline’s recom­mendations. Reinforcing factors are the rewards or incentives that are anticipated or that actually follow as a consequence of a particular be­havior. They include reimbursements actually received, visible im­provements in patient or population health outcomes, support from colleagues, and feedback from patients or clients (Green and Kreuter, 1991, pp 408-416).
Practitioners are unlikely to use guidelines that do not meet a per­ceived need for credible information. Here we distinguish between a perceived need (the understanding among users that the guideline will be valued) and a socially judged need (the declaration by public health
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experts that the guideline should be valued). Indicators o f perceived need for a guideline may be presumptive or empirical. Presumptive in­dicators of need are conventional “triggers” o f guideline development efforts at CDC. These triggers were described previously in the back­ground section o f this document (See page 18) . Empirical indicators of practitioner needs for new knowledge, skills, and incentives would come from the results of surveys, focus group interviews, opinion polls, and analyses o f practice patterns based on claims or other admin­istrative data sources.
C D C staff may characterize or justify the need for a particular guide­line by providing explicit answers to the following questions about the proposed guidelines.
• W hat is the “trigger” that serves as the presumptive indicator of need for the guideline ( an emerging health problem, requests from constituents, passage of a new law or the development of regulations, new surveillance data, results o f a research study or se­ries o f studies, licensure of a new technology or vaccine, unex­plained or inappropriate practice variations, and recognition of an outdated guideline)? Is the guideline required by a legislative, ex­ecutive, or judicial mandate? Is the guideline needed to provide standards o f procedure and quality control in a CDC-funded grant program or other activity (e.g., STD, TB, immunization, prevention of disease during international travel )?
• Are empirical indicators of practitioner needs available ( e.g., re­sults o f surveys, focus groups, opinion polls, or analyses o f practice patterns based on claims or other administrative data sources)?
• Are data available on the nature, extent, and determinants o f cur­rent practices regarding the candidate intervention, technology, or health problem of interest among the population o f potential pri­mary guideline users?
• Is there an existing guideline on the same topic? Is it adequate? How well is it being followed? How will the proposed guideline be different?
These recommendations are based on the assumption that the intent o f the proposed guideline is to inform and possibly influence the pro­fessional practices of the target users.
• CD C staff should strive to supplement legislative, programmatic, and presumptive indicators o f need for guideline development with empirical evidence o f practitioner need. Empirical evidence o f practitioner need for the proposed guideline should be sought from primary or secondary sources of data derived from surveil­lance, surveys, focus groups, opinion polls, and analyses of practice
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patterns captured on claims or other administrative data bases. Guidelines which address empirically documented practitioner needs are more likely to be used than those which address pre­sumed needs.
• The potential costs and benefits of postponing a guideline develop­ment effort pending availability o f empirical evidence o f practitio­ner need should be weighed against the costs and benefits (including potential impact on disease prevention) o f proceeding on the basis o f presumptive indicators of need.
• The cost, feasibility, and potential utility o f telephone surveys and focus group techniques for collecting empirical evidence of practi­tioner needs should be considered.
• Because it is impossible to satisfy all needs and expectations of all potential guideline users equally well, first priority should be given to meeting the needs of the primary audience for a particular guideline. Usually, the primary audience for most CDC-sponsored guidelines is one or more categories of public health practitioners.
Empirical information about the needs o f practitioners is relevant to the assurance of at least three of the eight desirable attributes of guide­lines. Those desirable attributes are (1) applicability-i.e., covering pri­ority populations and a variety o f practice settings; (2) flexibility-i.e., allowing provider judgment and patient preferences; and (3) multi-dis­ciplinary content— i.e., shaped by input from diverse scientific disci­plines and affected stakeholders. Assessing the needs o f potential users o f guidelines is similar to conducting a health needs assessment in a community. The purpose is to determine potential guideline users’ per­ceptions o f their own needs, aspirations for the common good, and the role they themselves might play in changing their own professional practices (Green and Kreuter, 1991 pp 44-87).
Both qualitative and quantitative methods can be used to assess user needs.
In most needs assessment situations, applications o f the two types of approaches are combined. For example, qualitative methods often are used to improve the quality, validity, and interpretation o f data gath­ered by quantitative approaches (Steckler, 1992).
Qualitative methods rely on techniques adopted from the social sci­ences to elicit an “insider’s view” (study participants or participant ob­servers) o f how members o f a group under study perceive their own needs for guidelines, how they are likely to react to such guidelines, and what positive or negative consequences they expect to result from the use of those guidelines. Such methods include community forums or workshops, focus group interviews, nominal group process, key in­formant interviews, and archival research. The section o f this guide en-
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titled Aiding Group Interaction and Decision Making (See page 67) discusses the strengths and weaknesses of several qualitative methods in the context o f eliciting and combining group judgments. Many of the same principles apply when those methods are used to elicit and to characterize the needs o f potential users for proposed guidelines.
Community forums or workshops assemble interest groups for inten­sive meetings to discuss issues surrounding proposed guidelines and to reach an understanding among the participants about needs, scope, for­mat, timetables, and roles. Focus group interviews are informal ses­sions in which eight to 12 potential users o f a proposed guideline are asked to discuss their thoughts and feelings about the issue. Those thoughts and feelings are then used to help clarify the content, deliv­ery, and appeal o f the proposed guidelines. The nominal group process or technique elicits written responses to a single question without ver­bal interaction among group members. (See page 67). The technique would include small groups o f five to nine potential guideline users to assess target group perceptions o f need and obstacles to meeting that need. This technique reduces the tendency for the more socially power­ful to dominate the discussions and to bias the consensus that emerges.
Key informant interviews rely on in-depth, semi-structured interviews with individuals who are selected to participate because they have spe­cial knowledge or insight not available to others in their reference group-hence the label “key informant.” Recorded or written tran­scripts of the interviews are then analyzed to uncover themes and the relative importance of frequently mentioned issues relating to guide­line development and use (Hugentobler, 1992). Archival research ex­amines reports, newspaper clippings, correspondence, books, and other documents prepared by persons other than the researcher and kept in archival depositories such as libraries. Archival sources o f infor­mation about the needs of guideline users are important because they reveal changes in perceptions and practices over time (Wolcott, 1992).
Quantitative methods rely on numerical measurements and statistical techniques to estimate aggregate characteristics of the group under study and to draw inferences which can be generalized to a larger refer­ence population. Quantitative methods include sample surveys and the construction o f synthetic estimates from administrative data sources. In the remainder o f this section, we describe two examples of the use of surveys to assess user needs.
Examples of 
Quantitative Methods
In 1995 the Canadian Community Health Practice Guidelines (CHPG) Working Group developed practice recommendations for three public health activities: restaurant inspections, STD partner noti­fication, and immunization delivery. In each program area, a Canada- wide survey of public health units was done to document current practice and variability in practice across jurisdictions. For example, the 1991 practice survey o f immunization delivery methods inter­viewed provincial epidemiologists and other key persons involved in
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immunization programs to document province-specific variations in public/private health administration, legislation, monitoring sys­tem/coverage rates/surveillance, vaccine management and costs. The results o f the survey helped to define the educational needs o f public health units regarding immunization service delivery. For example, the survey showed that programs were not being formally evaluated; in­stead, program managers obtained information from local experience, trial o f new practices, and organized research projects (Gyorkos, 1995).
In 1991 the North Carolina Department of Health, Environment, and Natural Resources (DHENR) and the National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP) conducted a telephone survey o f counseling and referral practices among a statewide probability sample o f primary-care physicians. Re­spondents (n=514; 58.6% response rate) provided population-based es­timates of the proportion o f primary-care physicians who counsel and/or refer for treatment patients who smoke, abuse drugs or alcohol, or have diet- or nutrition-related problems. Although the survey was not conducted in support o f a specific guideline development effort, the DHENR, the N orth Carolina Medical Society, and N CC D PH P planned to use the survey results to identify and help address, perhaps through the medium of practice guidelines, the educational needs of primary-care practitioners with regard to health education and preven­tive services (CDC/M M W R, 1992).
C D C programs rely heavily on presumptive evidence o f need for a guideline— i.e., traditional “triggers” as described earlier in this sec­tion; empirical indicators o f perceived practitioner need for new knowledge and skills rarely are collected routinely or systematically.
Current Practice at 
CDC
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Choosing Guideline Topics
Guideline topics should be selected based on the need for guidelines and, secondarily, on the amount and quality of scientific evidence available to make writing guidelines feasible. The optimal guideline topic addresses the impact o f a specific technology on a health out­come using the societal perspective. The topic can focus on any num ­ber o f  different issues including the efficacy, effectiveness or cost-effectiveness o f  a technology, individual service, or population- based service. Recommendations should be based on the evidence link­ing the intervention with the health outcomes.
Topics may be categorized using any o f several categorization schemes and sub-schemes. Selection o f a scheme is often obvious as the purpose o f  the group developing the guidelines has a readily apparent mandate, e.g., ACIP for immunizations or the American Lung Association for tuberculosis. Among possible schemes are:
• Disease or injury (outcomes) —  chronic disease, maternal and child health, occupational health and safety, and injuries.
• Risk factor— behavioral or physiological risk factors (smoking, hy­pertension, etc.).
• Type of technology —  immunizations, education programs, toxin control, reminder systems, outreach.
• Users —  family practice physicians, nurses, educators, hospitals, managed care organizations
• Target population —  infants, inner city residents, elderly.
• Some combination o f the above
The IO M  has recommended that an explicit process be followed in set­ting priorities for guideline development (Field, 1995). The actual topic selection process can be accomplished by one or more o f the fol­lowing:
• A legislative, executive, or judicial mandate: For example, Con­gress may require the development o f guidelines directly or based on some criteria, such as Medicare resources expended.
• Agency priorities and responsibilities: CD C programs may need guidance for their own operations or to assure quality o f services. STD diagnosis and treatment guidelines, for example, are regularly issued to improve the management o f  those diseases. Other agency responsibilities, such as immunization, international traveler’s
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health, hospital infections, and school health education, lead di­rectly to guideline development.
• Process involving a task force or advisory committee: Certain ad­visory groups are constituted explicitly to prepare guidelines. The Advisory Committee on Immunization Practices (ACIP) is an ex­ample. Advisory groups may establish their own topic selection process.
• Surveys: Formal solicitation o f topics from users, experts, employ­ers, or managed care organizations.
The need for systematic thinking about criteria for topics requires pan­els to have clarity o f purpose. Prioritization o f topics can be done onthe basis o f qualitative as well as quantitative criteria. Quantitative cri­teria to consider include:
• Morbidity, mortality, or quality of life: The public health impact o f the disease or injury under consideration may be assessed by in­cidence, prevalence, mortality, severity, disability, and other mor­bidity.
• Preventability, treatability, or curability: Is there a technology which can improve the health outcome?
• Economic impact: Is this a costly outcome based on medical care costs and losses o f  productivity?
• Cost o f intervention: W hat is the cost of the prevention strategy or technology in the aggregate or on a unit cost basis?
• Controversy: There are often controversies about effectiveness and cost effectiveness o f  different approaches based on discipline (be­havioral, clinical, epidemiological, or environmental emphasis) or schools o f thought. Guidelines may provide the evidence to reduce disparities and increase effectiveness.
• Availability of evidence: The number and quality o f studies which have been performed for different technologies vary widely from extensive randomized trials to purely descriptive information. Evi­dence-based guidelines require the availability o f  high quality stud­ies, but not necessarily randomized controlled clinical trials.
• Variation in practice: W hen clinical practice varies from commu­nity to community there is also often variation in costs and health outcomes. Such variation in practice, costs, and outcomes may be due to high levels o f  inappropriate care. In these circumstances, guidelines may lead to more widespread use o f the more effective or cost-effective technique. While variations have not been exam­ined as closely for public health practices, they may also suggest technologies for which guidelines may improve outcomes.
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• New versus established interventions: In general, guidelines are more useful for newer technologies which have not become part o f standard practice. Sometimes, however, guidelines on making bet­ter use of old technologies are equally useful.
• A formal, explicit topic selection process should be adopted, when possible.
• The procedures and criteria for selecting topics should be docu­mented.
• Controversy, inappropriate current practice, discrepancies between expected practice (defined by meta-analyses) and actual practice, and unexplained practice variation are appropriate criteria for topic selection.
• The magnitude o f morbidity, mortality, preventability, decreased quality o f life, and cost to society are appropriate criteria for topic selection.
• Topics should not be selected unless sufficient data are available to provide evidence for a guideline except in unusual circumstances, such as rapidly emerging health problems or the development and imminent use o f unique, new, potentially life-saving technologies.
Recom m enda­
tions
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Selecting Guideline Panels
C D C ’s Office o f the General Counsel (OGC) should be consulted prior to the formation of a panel or workgroup to develop guidelines. Consider whether guidelines should be developed internally or exter­nally. If externally, determine whether the group must be chartered un­der the Federal Advisory Committee Act. I f  a non-chartered group is preferred, consult with the Office o f the General Counsel for guid­ance. The type o f group used may impact which methods o f group in­teraction and decision-making will be appropriate.
The selection process for panel members will vary depending on the type o f panel being used. Advisory Committee members are selected through a formal process, and are appointed as Special Government Employees or representative members. The selection o f regular employ­ees and other experts for non-chartered panels will be accomplished in a less formal process.
The composition of guideline panels can shape the recommendations themselves. From the size o f the panel to the characteristics o f the members, each decision may affect the group dynamics or potential bias o f the group as a whole. The importance o f an unbiased panel in­creases as the strength o f the scientific evidence declines (US Con­gress, Office o f Technology Assessment (OTA), 1994, p. 11).
One o f the primary goals in selecting panel members is to minimize threats to the validity of the conclusion. Bias occurs easily, often as a result of professional relationships to the technology under considera­tion. Organizational or professional representatives may well become advocates for specific organizational perspectives. It is only natural that a surgeon would be inclined to look more favorably on indications for surgery, or that someone managing a screening program would view the evidence for screening more favorably. There is evidence that sur­geons find more carotid endarterectomy cases appropriate than does a multidisciplinary team (Leape, 1992). Although such bias has not been documented for population-based recommendations, public health professionals can be anticipated to have preconceived prefer­ences which might bias the interpretation o f information.
• Possible sources for panel members include:
-  Well known experts in relevant methodologies (decision analy­sis, meta-analysis, cost-effectiveness) the particular discipline, or subject matter.
Points to  
Consider
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-  Representatives of specific organizations (e.g., American Asso­ciation o f Health Plans, American Academy of Pediatrics, American Heart Association, American Medical Association, schools of medicine and public health, and universities)
-  Researchers in relevant scientific fields (from universities, aca­demic medical and public health centers)
-  Representatives of one or more professional groups (e.g., physi­cians, nurses, podiatrists, educators)
-  Public health officials (e.g., local, state, CDC, PHS)
-  Consumers
-  O ther interest groups (e.g., groups representing women, racial and ethnic minorities, the elderly, the disabled, and others who may be disproportionately affected by the health problem or proposed intervention)
• Will the proposed panel members be able to (1) objectively review and assess the quality o f scientific evidence, (2) have familiarity with the prevention strategies under consideration, and (3) partici­pate constructively in group processes?
• Will those being considered result in a multidisciplinary group?
• Do those being considered represent the range o f culturally diverse populations which will likely be users or beneficiaries o f the guide­lines?
• Does any individual being considered have a stated opinion (pub­lished articles, editorials, or speeches) on the topic? I f  so, does the entire deliberative body represent a range o f  opinions? And is each out-spoken individual also open-minded and willing to listen to other opinions?
• Those who are most knowledgeable about the technology being as­sessed are usually the individuals who have extensive experience, publications, and well-established points o f  view. While they may be open to considering evidence, they may hold evidence to a dif­ferent standard i f  it contradicts a publicly stated point o f view.
• Those who are experts in reviewing and weighing evidence but are not subject matter experts may be in the best position to consider the quality o f evidence presented.
Recom m enda­
tions
In selecting panel members, there are tensions between the need for objectivity in reviewing evidence and the need for the input o f  experts with extensive experience and established positions on the guideline topic. The following recommendations should be considered when constituting a panel:
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• Consult O G C prior to the formation of a panel or workgroup to be sure that the proposed process or deliberations do not violate the Federal Advisory Committee Act.
• In general, panelists should represent relevant technical disciplines regardless o f whether they represent specific organizations. Panel­ists who serve as non-voting liaisons with affected private and gov­ernmental groups often are needed to assure a voice for the relevant viewpoints, i f  undue influence can be avoided.
• Regardless o f who is on a panel, outside technical experts should be solicited to assure that all relevant scientific evidence was consid­ered and interpreted objectively.
• Panelists should be asked to disclose and discuss possible conflicts o f  interest and biases.
• Where applicable, Individuals must comply with the Government Ethics Laws and Standards o f Conduct with regard to conflicting financial interests and other appearances o f bias. For non­employees, procedures should be established to identify and appro­priately deal with individual conflicts o f  financial interest or other potential sources o f  bias.
• Individuals with a clear vested (or conflict of) interest in a topic can better serve as resources to a panel to assure that all evidence has been presented and considered rather than as voting panelists.
• Panelists should consist o f individuals with methodologic expertise in assessing scientific evidence (epidemiologists, statisticians, and economists), and representatives o f likely primary users o f the guidelines (medical specialists, primary care and public health prac­titioners, and administrators).
• Consumer representation should be considered.
• The procedures and criteria for selecting panel members should be documented.
Multidisciplinary panels offer the advantage o f  providing more bal­anced perspectives. They should also represent the range o f  culturally diverse populations which will likely be users o f the guidelines. While bias is a potential problem with homogeneous panels, for instance o f physicians, heterogeneous panels with ethicists, consumers, and others raise concerns about their technical ability to interpret and use epidemiologic and other scientific evidence.
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variety of topics without having individuals with stated positions on is­sues before the panel, individual panel members can excuse themselves from voting on issues where they have previously established positions.
Federally chartered advisory committees (with or without rotating membership), e.g. ACIP, provide continuity of methodology and the knowledge base and are most suitable when an ongoing need is antici­pated. For recommendations requiring very specialized knowledge, such as laboratory procedures for diagnostic testing, a highly technical group, possibly consisting o f  internal CD C staff alone or in consult­ation with outside experts, may be desirable. When timeliness is im­perative, such as for an international outbreak, it may suffice to update previous recommendations or to adapt them based on recent informa­tion. Under similar circumstances it may be necessary to disseminate recommendations without extensive external review, or to issue in­terim guidance which later can be made final after more intensive re­view and revision. For more complex subjects or where synthesis o f  the literature is required, a panel is more suitable.
Consideration must also be given to the intended users o f  the guide­lines. Inclusion o f representatives from interest groups of likely users, either as voting or non-voting liaison members, should enhance the likelihood that the users will accept and implement the recommenda­tions because they will have confidence that their perspectives were considered during the panel’s deliberations. Nonetheless, it is often im­practical to include all interested parties on most panels.
To facilitate group processes, panels are often limited to 10 to 20 members. Nonetheless, the complexity o f  the tasks (topic selection, de­velopment o f rules o f  evidence, development o f  evidence-based mod­els, identification o f  alternative technologies, review o f literature, analysis and synthesis o f  the evidence, evaluation o f  effectiveness, costs, and safety, identification o f  research needs, and comprehension o f policy-related issues) may require skills which cannot be fully cap­tured in a small group o f individuals. Moreover, should panels be con­vened to write one or a limited number o f guidelines, the expertise gained as part o f  the guidelines-development processes will be lost.
The OTA has suggested the creation o f expert teams to support guide­line panels. These teams could study alternative strategies for perform­ing the panel’s tasks and develop a recommended set o f  methods based on empirical experience. CD C staff often provide staff support, though the creation o f clearly defined teams is not common. Another model for support would be formation o f  a center, e.g., in an aca­demic institution, which can perform staff support (convene meetings, perform literature review, conduct statistical analyses, and provide edi­torial and clerical support), or a contract to provide selected support functions.
The Cochrane Collaboration, an international network o f  individuals and institutions committed to preparing, maintaining, and disseminat­
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ing systematic reviews o f the effects o f health care, employs a Collabo­rative Review Group (CRG) to prepare a systematic review of random­ized controlled trials (RCT) and other evidence relating to a particular health care maneuver. The CRG starts with a group o f self-nominated individuals (health professionals, methodologists, and consumers) who share a common interest in an issue in the effectiveness o f health care. As an outgrowth o f one or more exploratory meetings, one or several teams decide to take on, for the rest o f  their careers, the task o f  prepar­ing and maintaining systemic reviews o f RCTs on that issue (Sackett,1994).
As described in earlier sections o f  the document, guidelines are written or at least approved by a recognized group or committee which has su­pervision over the guidelines development process. Some are federally chartered advisory committees (ACIP, HICPAC); others are less for­mal and may be composed o f CD C staff or selected experts. Some are collaborative activities between outside organizations (American Lung Association and American Thoracic Society) and CD C operating units e.g., the Division of Tuberculosis Elimination. Panels may be standing committees, may rotate membership, or be convened ad hoc.
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Defining the Scope of a Guideline
In defining the scope, guideline developers explicitly delimit, and usu­ally narrow, a broad topic. In doing so they must focus on the preven­tive, diagnostic, treatment, or rehabilitative issues which are (1) o f greatest interest to practitioners, the public, and other users, (2) most amenable to clarification by means o f systematic assessment and syn­thesis o f  scientific evidence, (3) in greatest need o f  having guidelines because o f conflicting claims o f effectiveness in published reviews, and(4) capable o f  being fully explored and resolved into clear and specific advice within the limitations of time and resources (Field, 1995).
Explicit answers to the following questions can help establish the scope or topic boundary o f  the guideline.
• W hat target population (age, gender, ethnicity or race, socioeco­nomic status, etc.) and service settings (state or local health agency, community, home, workplace, hospital, ambulatory clinic) will the guideline encompass?
• W hat population-specific outcome measures (risk factor preva­lence, morbidity, mortality, quality o f  life) or individual health condition (healthy, at-risk and asymptomatic, symptomatic, dis­eased) will the guideline aim to improve?
• W hat intervention (population- or individual-based), essential pub­lic health service (see page 108 of glossary) or provider practice will the guideline aim to improve?
• W hat characteristics (safety, effectiveness, appropriateness, cost, feasibility o f implementation, or patient preferences) o f  the inter­vention or practice options should be used to define good-, better, and best-practices?
• Who are the guideline users (public, legislator, agency manager, lay advocate, methodologist, clinician) whose knowledge, prac­tices, behavior, or decisions will the guideline attempt to address?
• How much time, staff, and other resources are available to com­plete the task?
• W hat is the scope o f existing guidelines on the same topic and what information gap would be filled by the proposed guideline?
• W hat new work has been done since publication o f the existing guidelines?
Points to  
Consider
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• CD C staff should prepare explicit answers to the questions in the Points to Consider as early in the guideline development planning process as is feasible.
• Using preliminary answers to those questions, guideline planning staff should conduct a preliminary assessment o f  the amount and quality o f the scientific evidence o f  effective practices and imple­mentation approaches that is likely to be available under alterna­tive scenarios o f  a guideline whose scope varies from narrower to broader.
• Preliminary decisions taken by the guideline planning staff before an official panel is convened should be revisited as soon as possible after the panel leadership is appointed and the members are con­firmed.
• W hen the use o f  a high-volume practice o f unproven effectiveness is widespread, relevant guidelines should address issues o f the safety and effectiveness o f the practice. For example, guidelines on the prevention and control o f prostate cancer should address the use o f the prostate specific antigen (PSA) test.
• Issues related to the implementation o f  guidelines (cost, cost-effec­tiveness, staffing, insurance coverage, and patient preferences) should be taken into account whether or not these issues are used to define best-practices.
These recommendations emphasize the role o f  CDC staff during the critical phase o f  planning, financing, and preparing for the guideline development effort prior to the convening o f  an expert panel or other form of deliberative group. Because empirical evidence suggesting that any o f  the approaches to defining the scope o f a guideline described be­low is more or less effective than another is not available, these recom­mendations reflect a narrative synthesis o f  the professional opinions o f the experts whose work is cited.
Approaches to  
D efin ing the  
Scope o f a 
Guideline
Legislative Approach
Public and private agencies which sponsor the development o f guide­lines have used several alternative approaches to defining the scope o f  a guideline. These approaches can be put into three broad categories based on the primary source o f  influence on decisions about the scope o f a guideline. The categories are (1) legislative approach, (2) expert panel approach, and (3) internal staff approach. More often than not, however, elements o f  each approach are combined in the process o f  de­fining the scope o f a guideline. These three approaches are illustrated by reference to the work o f selected governmental agencies and private groups which sponsor guidelines.
The general scope o f guidelines sponsored by the Agency for Health Care Policy and Research (AHCPR) is prescribed in the agency’s
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authorizing legislation. For example, the law requires special attention to meeting the needs o f the Medicare program. However, the specific scope o f  each guideline sponsored by the Agency has been determined jointly by an appointed expert panel and Agency staff using a process already described. Schriger, one o f two participating methodologists, described the procedure used by the panel on Low Back Pain to define the scope of its guidelines. The time between the selection o f the panel and the first meeting was used by the methodologists, panel chairper­son, and agency staff to negotiate a panel budget and appropriate scope o f work which could be accomplished by means o f four panel meetings, each lasting 1.5 to 3 days, during a 12-month period. Final decisions about the elements o f  guideline scope were made during the course o f the first meeting. The methodologist’s most important edu­cational role with respect to guideline scope was to restrain tendencies by both the Agency staff and the panel chair to expand the scope o f the guideline. (Schriger, 1994, p 118).
Most guideline development efforts depend on the expert panel, which is convened to judge the quality o f  the science and to compose the recommendations, also to define the scope o f  the guideline at the beginning o f deliberations. This process is exemplified by the guide­line development efforts o f  the National Heart, Lung, and Blood Insti­tute (NHLBI), the USPSTF, the Canadian Community Health Practice Guidelines (CHPG) Working Group, and the Council on Linkages Between Academia and Public Health Practice, Guideline Development Project for Public Health Practice (GDPPHP). Each o f these groups has used a group o f  key questions to narrow the scope o f the guideline topic.
This approach is exemplified by the Consensus Development Confer­ence Program o f the N IH , Office o f  Medical Applications o f  Research (OMAR). It uses a planning committee made up o f two to three non­government researchers, an agency staff person, and a staff person from the sponsoring institute(s). The planning group identifies four- to-six key questions to be answered at the conference. The questions usually relate to efficacy, risks, clinical applications, and avenues for fu­ture research. The wording o f the questions frames the scope o f the re­sulting consensus statements.
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and 5% for use by patients and/or parents. Clinical conditions were the focus of 90% and procedures were the focus of 10%. Among di­mensions of intervention that were not mutually exclusive, 77% em­phasized primary prevention, 43% screening, 44% diagnosis, 40% treatment, and 2% rehabilitation. Presumably, current guideline devel­opment efforts at CD C reflect this variability o f  approaches to defin­ing the scope o f guidelines.
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Clarifying the Method and 
Analytic Framework
After the CD C program (usually) or expert panel has chosen a guide­line topic and defined its scope, the participants should choose a guide­line development method, define the analytic framework, collect and assess evidence o f effectiveness (or lack thereof) o f  candidate practices, and compose recommendations that will help potential users make de­cisions about adopting (or discontinuing) those practices. A guideline development method is a set o f  rules o f procedure for collecting evi­dence o f  effectiveness o f  a health practice and for making group deci­sions about the quality and sufficiency o f  that evidence in supporting specific practice recommendations.
W oolf has delineated four categories o f  guideline development meth­ods. The categories are (1) informal consensus, (2) formal consensus, (3) evidence-based, and (4) explicit— an evidence-based method which incorporates mathematical modeling. Experts are more likely to consider evidence-based (and explicit) methods valid in content, repro­ducible, and scientifically rigorous than consensus methods. In addi­tion, evidence-based (and explicit) methods are more likely than consensus methods to be costly, difficult to execute, and require more data and time to complete. Finally, critics o f  the more rigorous o f guideline development methods point to the frequency with which the absence o f  acceptable evidence leads to neutral recommendations nei­ther for nor against the proposed preventive practice. Most guideline development efforts use a combination o f  methods. Regardless o f the category o f  development method chosen, the expert panel must explic­itly define the guideline’s analytic framework (Woolf, 1992).
Defining the analytic framework refers to describing or illustrating the chain o f  causal reasoning which links the recommended health prac­tice to the desirable health outcomes in a defined individual or popula­tion by means o f credible evidence o f effectiveness. The analytic framework is an effective conceptual tool for planning, conducting, and communicating the results o f the guideline development process to potential users. It helps developers and potential users understand which parts o f  the supporting rationale for the practice recommenda­tions are based on empirical evidence and which components are based on theory, expert opinion, conventional standards o f practice, or other potential sources o f influence on the clinical and population- based practices (Woolf, 1994).
The analytic framework also makes it easier to compose the supporting rationale for each practice recommendation. A persuasive supporting
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rationale for a practice recommendation would summarize (1) the benefits, harms, and other outcomes that were considered; (2) why the outcomes were considered important; (3) assumptions about the rela­tionships between categories o f benefits, harms, and outcomes; (4) the types o f evidence ultimately used to support each recommendation;(5) and as one type o f evidence, the estimated effects o f the practices recommended.
Explicit answers to the following questions about the proposed guide­lines can help construct the analytic framework:
• W hat professional practices or intervention strategies are being considered for inclusion in the guideline?
• W hat categories of health outcomes (ultimate, intermediate, and surrogate) are the guidelines intended to influence?
• W hat specific guideline development methods (explicit, evidence- based, formal consensus, informal consensus) is most appropriate for the proposed topic?
-  W hat types o f evidence o f effectiveness are available to support the professional practices being considered?
-  How will the quality, quantity, and relevance o f the support­ing evidence o f effectiveness be assessed?
-  How will the hierarchy (or strength) of the evidence relate to the strength o f a recommendation for or against a proposed in­tervention?
• W hat assumptions about proposed practices, health outcomes, and their causal relationships are offered without scientific proof?
• W hat form of exposition (narrative or graphic— flow chart, influ­ence diagram, decision tree, or clinical algorithm) is most appropri­ate for describing the logical link between the practice recommendations, evidence o f effectiveness, and desirable health outcomes?
The following recommendations for defining the analytic framework for CDC-sponsored guidelines apply to all categories of guideline de­velopment methods. These recommendations emphasize the consen­sus among experts that guideline development methods should be evidence-based or explicit, whenever possible.
• Guidelines about preventive interventions should be based on a consideration o f relative benefits, harms, and costs, whenever possi­ble.
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• Many experts assert that evidence-based methods lead to guide­lines that are more valid (face or content validity) and credible than those resulting from consensus methods (informal or formal) (Field and Lohr, 1992).
• Evidence-based methods o f  guideline development are complex, time-consuming, and depend on skills that potential participants may not possess at the start o f  the process. Thus, when undertak­ing evidence-based methods, all participants must be suitably trained in the skills needed to carry out their particular tasks as early in the guideline development planning process as is feasible. The services o f a guideline development methodologist should be available to the panel.
• Just as every research study or epidemiologic investigation should be guided by a written analytic plan, so too every guideline devel­opment effort should be guided by a written analytic framework (narrative, algorithm, spreadsheet, etc.).
• The analytic framework should be defined by providing explicit answers to the questions listed in the preceding Points to Consider.
• CD C staff should consider the rules and regulations o f  other agen­cies such as the Food and Drug Administration (FDA). Vaccines, biologicals, drugs, and medical devices must meet statutory re­quirements regarding their safety and efficacy before their use is ap­proved. FDA approval is based on a biostatistical regulatory model, a special form of evidence-based model. Because guidelines on the use o f  these regulated products are based on an analytic framework which is, in part, prescribed by law, CD C staff and ex­pert panels working in this area should receive special training in the use o f this model (O’Neill, 1994).
Approaches to  
M ethod and 
A nalytic  
Fram ew ork
The analytic framework often is illustrated graphically (Figure 1) and Examples Fromserves as a useful guide for reviewing evidence of effectiveness, develop- Other Agenciesing recommendations, and explaining the supporting rationale. For ex­ample, an expert panel charged with developing guidelines for the use of estrogen replacement therapy to reduce morbidity and mortality (ul­timate outcomes) among post-menopausal women might choose to use an evidence-based methodology. The intermediate outcomes o f  in­terest might include reduction (of incidence or prevalence) o f heart dis­ease, osteoporotic fractures, and menopausal symptoms. The types of admissible evidence o f effectiveness might come from randomized con-
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trolled trials; prospective-, retrospective-, and cross-sectional observa­tional studies; expert opinion; and current practice.
Criteria for assessing the strength o f the evidence supporting a particu­lar recommendation might include indicators of quality (e.g., study de­sign), quantity (e.g.,effect size), and relevance (e.g., external validity or ability to generalize). Criteria for assessing the appropriateness of a rec­ommended practice in a particular setting might also include indica­tors o f  cost-effectiveness, ease o f  implementation, and preferences o f  affected providers, clients, and communities (Woolf, 1994).
Public and private agencies which sponsor the development o f guide­lines have used several alternative approaches to defining the analytic framework o f  a guideline.
Examples o f  alternative approaches to defining the analytic framework o f  a guideline are described below. Although the examples are grouped by W oolf s categories of methods, for convenience, the emphasis of the description is on the analytic frameworks rather than the overall method.
Informal Consensus
The analytic framework o f informal consensus methods usually cannot be discerned from the guidelines. Using this method, experts decide on what practices to recommend after informal discussions. The rec­ommendations are often not accompanied by explanations o f  the causal reasoning which links the recommended professional behavior, credible evidence o f  effectiveness, and the desirable health outcomes. Similarly, it may not be clear which parts o f the supporting rationale for a recommendation are based on empirical evidence and which com­ponents are based on theory, expert opinion, conventional standards o f  practice, or other potential sources o f influence on the clinical and population-based practices o f the intended guideline users. Because o f its simplicity and speed, this is the most common approach to guide­line development. Unfortunately, it is also the least valid (Woolf,1992).
Formal Consensus
The analytic framework o f  formal consensus methods is usually de­fined by a series o f  key questions. This analytic approach to developing guidelines was pioneered by the Consensus Development Conference Program of the National Institute for Health (NIH). The Consensus Development Conference Program of the National Institute for Health (NIH) aims to identify and disseminate clinically relevant find­ings emerging from N IH  research, often during initial technology dif­fusion and before guidelines are published. Consensus statements are either condition specific (e.g. melanoma or panic disorder) or technol­ogy specific ( e.g., dialysis or physical activity). The analytic approach to a consensus conference is framed by a series o f four to six questions
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related to efficacy, risks, clinical applications, and future research. For example, the key questions for a December 1995 conference on physi­cal activity and cardiovascular health were as follows:(NIH, 1995)
• W hat is the health burden o f  a sedentary lifestyle on the popula­tion?
• W hat type, what intensity, and what quantity o f  physical activity is important to prevent cardiovascular disease?
• W hat are the benefits and risks o f different types o f physical activ­ity for people with cardiovascular disease?
• W hat are the successful approaches to adopting and maintaining aphysically active lifestyle?
• W hat are the important questions for future research?
Answers to the framing questions are arrived at by an expert panel o f 20 to 30 members who make public presentations on the science and an executive panel o f 9 to16 members who draft the consensus state­ments. Consensus statements do not usually include references to the literature, nor the underlying rationale or evidence behind any recom­mendations or conclusions (US Congress, OTA, 1994).
The N IH  consensus process has been vigorously criticized because o f the explicit lack o f rationales and evidence which support the state­ments. Improvements in the process have been recommended (Field and Lohr, 1992).
Evidence-Based, Including Explicit Approaches
Evidence-based approaches to guideline development depend on ana­lytic frameworks that aim to explicitly link practice recommendations to the underlying scientific evidence of effectiveness. The explicit ap­proach, a subcategory o f  the evidence-based approach, is distinguished by its reliance on mathematical modeling and other formal analytic methods to generate estimates o f  the probability o f occurrence o f spe­cific benefits, harms, and costs o f alternative practices. This approach also uses a “balance sheet” to display the benefits, harms, and costs of each alternative practice along with the content and source o f neces­sary assumptions which are not scientifically disprovable (Woolf,1992).
• The Agency for Health Care Policy and Research (AHCPR)sponsors guidelines which focus on the diagnosis and management of clinical conditions e.g., congestive heart failure and low back pain. A HCPR guidelines are developed by independent expert pan­els using evidence-based methods. Panels use “evidence tables” to summarize important aspects such as the design o f relevant studies; and most panels describe the strength o f  the supporting evidence for conclusions and recommendations. Some A HCPR panels have
Clarifying the M ethod  and  Analytic Fram ework 51
used variations of W oolf s “evidence model” while others have used Eddy’s explicit approach (Eddy, 1990). Both o f these guide­line development methods require that the analytic framework be defined explicitly.
AHCPR-sponsored guideline recommendations are often illus­trated using a clinical algorithm or flow chart that shows recom­mended steps in diagnosis or management. Algorithms help guideline developers to specify the appropriate indications for a particular diagnostic or management strategy and to convey the scope of the guideline to the user at a glance. Two major criticisms o f  clinical algorithms include inflexibility and questionable valid­ity. To increase clinical flexibility, AHCPR-sponsored clinical algo­rithms include special counseling and decision nodes showing where major preference-dependent decisions occur. To increase the clinical validity o f  their algorithms, some AHCPR panels have used annotations which link recommendations and their expected outcomes to the literature through evidence tables that summarize the relevant studies (Woolf, 1992; US Congress, OTA, 1994).
• The U.S. Preventive Services Task Force (USPSTF) develops evi­dence-based practice guidelines for preventive care which can be appropriately delivered by primary care practitioners during a peri­odic health examination. Like the AHCPR guidelines, the USPSTF guidelines have used variations of W oolf s “evidence model” and Eddy’s explicit approach. Both of these guideline de­velopment methods require that the analytic framework be defined explicitly (US Congress, OTA, 1994). Specifically, the USPSTF has refined a method for reviewing evidence o f  effectiveness o f  a proposed intervention. The available evidence for or against the ef­fectiveness o f  the proposed intervention is classified into one o f five levels o f decreasing quality (I, II-1, II-2, II-3, III); and the re­sulting recommendation for or against routine use o f the interven­tion is classified into one o f four levels o f  strength (A,B,C,D)(Table 2)(USPSTF, 1996). CD C staff who support the work o f HICPAC have expressed some discomfort with the USPSTF. They would prefer to use categories A, B, or C to de­scribe the strength o f all recommendations including advice against the use o f an ineffective practice (Bill Martone, Personal Communication).
• The Canadian Com munity Health Practice Guidelines (CHPG) W orking Group developed practice recommendations for restau­rant inspections, STD partner notification, and immunization de­livery, which served as prototypes to develop a standardized approach. The analytic framework o f  the standardized approach was defined by an intervention-outcome grid in the form o f  a spreadsheet. Each row o f  the grid represents a specific interven­tion, each column represents an outcome (benefit, harm, or cost) and each cell represents the attributable effects o f  the intervention
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on the outcome. The grid specified at the beginning o f the process is used to specify selection criteria for the evidence to be reviewed. It is modified as a result o f  the evidence discovered during the process, and it is used at the end o f the process to summarize the relationship o f  the interventions, outcomes, and evidence o f  effec­tiveness.
Each resulting recommendation was reported along with its level o f  evidence from comparative studies, and justification or basis. Recommendations were classified as “plus” if  evidence from high quality comparative studies suggested that the intervention should be considered for inclusion in routine public health practice; “mi­nus” i f  the evidence suggested that it should not; and “question­able” i f  the evidence from comparative studies was lacking or contradictory and other grounds for a recommendation are unper­suasive or conflicting (Corber, 1994).
• The Council on Linkages Between Academia and Public Health Practice issued a report on the feasibility and benefits o f  practice guidelines for public health in October 1995. The Guideline De­velopment Project for Public Health Practice (GDPPHP) tested a guideline development model in each o f four health problems: (1) pre-school immunization, (2) lead poisoning prevention, (3) tuber­culosis treatment completion, and (4) ischemic heart disease pre­vention.
The project leaders and panel chairs developed a series o f  Critical Questions to guide the search for scientific evidence related to the 10 essential public health services (see page 108) in each program area. Reflecting on their experiences with the “essential serv­ices/critical questions model” for defining the analytic frameworks for each program area, the panelists concluded that the model may be useful for gathering evidence and also for conceptualizing and focusing future guidelines for public health practice. The panelists who participated in this feasibility study recommended that the “critical questions” of the future should be (1) based on issues of practice as well as theory, and (2) developed with the involvement o f  major stakeholders at the beginning o f  the process (Council on Linkages between Academia and Public Health, 1995).
• The FDA Biostatistical Regulatory Model aids the implementa­tion o f regulations concerning the standards for evidence o f effi­cacy and safety needed for the approval o f new drugs, vaccines, medical devices, and biologicals. For example, FDA scientists at the Center for Drug Evaluation and Research use the model to evaluate the quality, documentation, and adequacy o f clinical re­search evidence submitted by pharmaceutical sponsors in support o f  applications for approval o f  new drugs. Elements o f  the model including standards o f  evidence, documentation o f evidence, and the review process are clearly spelled out in sections o f  the Code o f Federal Regulations(CFR). The standards provide the framework
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Current 
at CDC
within which the agency approves or disapproves a new drug appli­cation which claims a specific outcome when the drug is used as prescribed in a specific target population (O’Neill, 1994).
Practice Current guideline development efforts at the CDC employ one or more o f the categories o f  guideline development methods de­scribed above. In response to a 1995 PHS survey, CD C staff iden­tified 96 CD C guidelines which were “intended to influence care to individuals” and were published in or after 1989. The respon­dents reported that 26% of the guidelines used a consensus method (informal or formal), 29% used an evidence-based method, and 40% used some approach in which neither a consen­sus nor evidence-based method was predominant (PHS Sponsored Guidelines Report Outline, 1995).
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Note: Numbers represent linkages.
Link 1: Evidence th a t estrogen reduces serum  lip id  levels?
Link 2: Evidence tha t low ering  serum  lip id  levels reduces the  incidence o f heart disease?
Link 3: Direct evidence th a t estrogen reduces the risk o f heart disease?
Link 4: Evidence th a t estrogen increases bone m inera l content?
Link 5: Evidence th a t increased bone m inera l content is associated w ith  decreased risk o f fractures?
Link 6: Evidence th a t fractures are associated w ith  increased m orb id ity?
Link 7: Evidence th a t fractures are associated w ith  increased m orta lity?
Link 8: Direct evidence th a t estrogen reduces the incidence o f fractures?
Link 9: Direct evidence th a t estrogen reduces m o rb id ity  ?
Link 10: Direct evidence th a t estrogen reduces m orta lity?
Link 11: Evidence tha t estrogen reduces m enopausal sym ptom s?
Link 12: E v id e n ce  tha t  e s t rogen  c au se s  en d o m e t r ia l  c an ce r?
Link 13: E v id e n ce  tha t  e s t rogen  c au se s  b reas t  can ce r?
* Reproduced from  (W oolf, 1994)
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Table 2. Rating Scales: From USPSTF
Quality of Evidence (of Effectiveness of the Intervention)*
I. Evidence obtained from at least one properly randomized controlled trial.II-1: Evidence obtained from well-designed controlled trials without randomization.II-2: Evidence obtained from well-designed cohort or case-control analytic studies, preferablyfrom more than one center or research group.II-3: Evidence obtained from multiple time series with or without the intervention. Dramaticresults in uncontrolled experiments (such as results of the introduction of penicillin treatment in the 1940s) could also be regarded as this type of evidence.III: Opinions of respected authorities, based on clinical experience; descriptive studies andcase reports; or reports of expert committees.
Strength of recommendations (for or against the intervention)"
A: There is good evidence to support the recommendation that the condition be specificallyconsidered in a periodic health examination.B: There is fair evidence to support the recommendation that the condition be specificallyconsidered in a periodic health examination.C: There is insufficient evidence to recommend for or against the inclusion of the conditionin a periodic health examination, but recommendations may be made on other grounds.D: There is fair evidence to support the recommendation that the condition be excludedfrom consideration in a periodic health examination.E: There is good evidence to support the recommendation that the condition be excludedfrom consideration in a periodic health examination.
* W ell-designed and conducted m eta-analyses w ere  also considered and w ere  graded accord ing to the qua lity  o f 
the studies on w h ich  they w ere based.
* *  Exact corre la tion  between level o f evidence and strength o f recom m endation did not occur. Level I evidence did 
not necessarily lead to  a grade A  recom m endation , nor did Level III evidence necessarily lead to  a grade D 
re co m m e n d a t io n .
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Identifying and Synthesizing  
the Evidence
Recommendations regarding public health practice should be based on the combined weight of the evidence from available scientific reports. To accomplish this objective, the available literature must be identi­fied, retrieved and synthesized to draw scientifically valid and practi­cally useful conclusions. The National Library of Medicine (NLM) has suggested a systematic process for identifying, retrieving, and man­aging literature that forms the basis o f a practice guideline (Auston,1994). The six steps are:
• Advance planning to define goals, tasks, staffing, and computer software needs.
• Preliminary searching to estimate content and volume of evidence expected.
• Comprehensive searching based on explicit statements o f topic scope, selection criteria, sources, and search strategies.
• Literature management of the retrieved citations in the form of a bibliographic database.
• Document retrieval and archiving of copies o f relevant documents.
• Final bibliography preparation to support panel deliberations and citations for evidence tables, guideline text, and appendixes.
The remainder of this section o f the guide focuses on issues related to synthesizing evidence o f effectiveness o f a candidate practice guideline. Research synthesis can be done qualitatively based on individual opin­ion or group consensus or more rigorously using the tools o f system­atic reviews or meta-analysis. The least rigorous approach to synthesizing evidence is through expert opinion, often obtained through committees. In its most basic form, this approach is qualita­tive without formal data collection or analysis. More rigorous, narra­tive literature reviews are conducted by experts in the field and written as expert opinion papers in journals and text books, for example. For these, however, the lack o f systematic rules for acquiring or consolidat­ing the evidence has led to questions about the validity o f such reviews (Antman, 1992).
Systematic literature reviews have been introduced as an appropriate method o f data collection and synthesizing evidence (Thacker, 1988; Pettiti, 1994). These reviews are based on rules to identify studies and collate information from studies. Such reviews are often the initial step
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Points to  
Consider
in meta-analyses where the data are synthesized quantitatively to give a numerical estimate o f effect.
Despite the strengths and weaknesses o f the alternative methodologies for combining evidence, systematic reviews and meta-analyes remain the best available tools for synthesizing evidence, particularly when re­sults from independent studies are inconsistent or primary data are not available for pooling.
Consensus on interpreting data requires some form of group judgment before public health guidelines are specified. Group judgment efforts for evaluating practices and procedures must bridge gaps and resolve disparity among research findings, define the state o f the art, and estab­lish public health policies. Expert panels must integrate, interpret, and weigh evidence, experiences, beliefs, and values, and then formulate guidelines and recommendations. Evidence may consist of systematic summaries, such as one finds in a meta-analysis, or more commonly a sparse patchwork o f contradictory research results o f varying quality.
In the final synthesis of evidence, the results o f the systematic reviews and meta-analyses are weighed together with other evidence (e.g., cost and ethical considerations) by experts in order to formulate policy and make recommendations.
The best group judgment efforts delineate their assumptions when confronted with inconsistencies, contradictions, and gaps in research. These group efforts provide a forum for participants to learn from each other and serve as effective means to disseminate findings through key opinion leaders within the group.
Systematic reviews of the literature are an important basis for develop­ing CDC guidelines and always should be used. Meta-analysis or quan­titative synthesis, a form of systematic review, should be used more regularly when appropriate. It encourages systematic thought concern­ing methods, outcomes, categorizations, populations, and interven­tions, and provides a way to synthesize evidence. Answers to the following questions can help determine the appropriateness o f meta­analysis:
• Are results from multiple independent studies inconsistent?
• Do multiple studies suggest an effect but no single study has suffi­cient power to demonstrate statistical significance?
• Is a quantitative synthesis needed for policymaking?
• Is it necessary to study multiple population characteristics (occupa­tion, age, gender, race, ethnicity, medical condition, or geography)?
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• Data synthesis including a systematic review of the literature, and where relevant and feasible meta-analysis, should be the basis for development o f all CD C guidelines.
• The questions to be addressed by the panel should be specific and manageable. Panelists should be involved in specifying the ques­tions to be addressed and responsibilities for task and project for­mat.
• Panelists should be provided with the most comprehensive scien­tific data possible. A summary description of the available studies should be provided and cited in the final panel statement.
• Process methodology, facts, assumptions, estimates, criteria for findings, and rationale should be documented. Findings should in­clude estimates o f outcomes expected if the panel’s recommenda­tions are followed.
In a traditional narrative review of the medical literature, a subject- matter expert reviews studies, decides which are relevant to a particular topic, and highlights findings in terms of results and, to a lesser de­gree, methodology. The potential limitations of this, or any approach to a literature review, include (a) bias due to reporting and publication policies, (b) the absence in published studies o f specific data needed for the review, (c) investigator bias due to subjective criteria for includ­ing studies, (d) the uneven quality of the primary data, (e) improper at­tention to statistical methods, and (f) biased interpretation of outcome. (Thacker, 1988).
Meta-analysis is not immune to the potential pitfalls noted for the tra­ditional narrative review. In addition, the approach may not be feasi­ble for developing guidelines that address complex topics such as nosocomial infection control. Nevertheless, the technique makes deci­sions apparent and makes explicit the potential impact of problems (e.g., bias) on the results and interpretation. Meta-analysis encourages systematic thought concerning methods, outcomes, categorizations, populations, and interventions and provides a way to synthesize evi­dence. Further, the method offers a mechanism for estimating the magnitude o f effect in terms o f a statistical measure (e.g., an odds ratio or relative risk) and an assessment of its significance.
The combination of data from several studies increases both the statis­tical power and ability to generalize, thereby enabling the researcher to assess more completely the impact o f a procedure or variable. Quantita­tive measures across subgroups of studies can provide insight into the
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nature of relationships between variables, offering mechanisms for de­tecting and exploring apparent contradictions and results. Finally, a systematic review should be less subjective than a narrative review, and although the procedure may not decrease investigator bias, it enables the reader to understand clearly how and why conclusions were drawn.
Systematic rules for conducting a meta-analysis include an explicit de­scription o f methodology so that results can be interpreted in light of any biases or limitations. (See Points to Consider for ways to help de­termine if meta-analysis is appropriate.)
Several approaches to meta-analysis share the same basic steps listed be­low:
• A clear statement of the problem and an explicit statement of the hypothesis to be tested.
• A clearly defined statement o f inclusion and exclusion criteria for admission o f studies.
• A methodology for locating research studies.
• The classification and coding o f study units to be combined in the meta-analysis.
• A quantitative measurement of study characteristics on a common scale.
• A quality assessment o f the methods used in the studies.
• Analysis and interpretation that include determining the homoge­neity of the data and, where appropriate, combining study results.
• The use o f appropriate statistical models.
• An interpretation o f results.
• The reporting o f the results (Thacker, 1988; Pettiti, 1994).
A particular problem facing those who use meta-analysis for policy for­mulation is the fact that studies in human populations (whether a sin­gle patient or a community) form a continuum of knowledge as new studies are applied to similar populations. This fluid nature o f ever-in­creasing data can be addressed by a cumulative meta-analysis in which results are updated as new information becomes available (Lau, 1992). This technique is particularly useful for studies (particularly trials) where the protocol may be modified in the process o f study comple­tion or where preliminary results may be disseminated (Henderson,1995).
Statistical issues related to combining data from multiple sources in meta-analysis are the subjects o f ongoing research (Antman, 1992; Ste­inberg, 1991). The most important statistical issues relate to the ques­tion o f which studies should be combined. Meta-analyses appropriate
60 CDC Guidelines: Im proving the Quality
for the public will usually be a combination o f randomized, controlled clinical trials (RCTs) and/or epidemiologic studies. In general, RCTs provide more compelling evidence than do cohort studies, and, in turn, cohort studies often provide better evidence than do case-control studies. In some situations, however, cohort studies may not be feasi­ble (rare disease or disease with long latency) or may be less helpful than case-control studies (technology assesment). Cross-sectional stud­ies and case series provide less evidence for etiologic reasoning (Hedges, 1985). Thus, when feasible, meta-analyses in public health should use RCTs. However, because o f the small number o f RCTs available to test hypotheses o f interest in public health or the time lag until results are available, the combining of data from cohort and case- control studies is sometimes desirable (Greenland, 1994). In such cir­cumstances, the statistical and epidemiologic issues are more complex and challenging to the meta-analyst (Hedges, 1985; Greenland, 1987; Greenland, 1994).
Like traditional narrative literature reviews, the usefulness o f meta­analysis depends, to a large extent, on the quality o f the studies that are synthesized. Methodologic concerns about meta-analysis include limitations in the quality o f the primary data and both selection and investigator bias in interpretation, but this is true for any literature re­view. Concerns more specific to meta-analysis include the appropriate­ness of combining data across studies, appropriate use o f statistical methods, variability between studies, development o f appropriate mod­els to measure such variability, and the role o f assessing study quality (Greenland, 1987; Greenland, 1994; Eysenck, 1994). Creative ap­proaches to addressing these concerns are being developed (Sterling, 1995; Emerson, 1990; Oxman, 1991). Finally, in controlled trials in which whole communities are randomized, a large enough number of eligible studies may never be available to support a meta-analysis.
A serious concern about quantitative literature reviews is that the re­ported objectivity may be more appearance than substance; no ap­proach to synthesizing information can eliminate investigator bias entirely. Both critics and advocates of meta-analysis recognize that an unwarranted sense o f scientific validity, rather than a more accurate understanding, may result from quantification.
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This page in ten tio n ally  le ft blank.
Aiding Group Interaction and 
Decision Making
Reaching a conclusion can be a difficult task for a group engaged in de­cision making, and in a multi-faceted decision like the development o f a scientific guideline, it can be even more difficult. Participants’ diver­sity in terms o f expectations, expertise, and stake in outcome, as well as their cultural diversity (both ethnic cultures and organizational cul­tures), contribute to the complexity o f group process. The techniques described in this section can aid groups in producing high-quality, sci­ence-based guidelines by allowing groups to take advantage o f the con­tributions o f all participants. The first step in the process o f planning for group activities is to determine whether assembling a group is the most effective way to accomplish a particular task. Groups should not be encumbered with tasks that individuals can accomplish more effi­ciently. Although groups are better at generating ideas, individuals are better at research, analysis, and careful crafting o f language (Moore,1994). Also keep in mind that the type o f decision making process used may depend on the group structure, and whether it is legally ap­propriate for the group to reach consensus.
Group interaction methods (or group process methods) improve pro­ductivity of meetings by helping groups focus on tasks and produce outcomes. Expert facilitators say that group interaction techniques im­prove the quality of virtually any kind o f meeting, but especially those between people without a history o f working together. For maximum usefulness, the group interaction method must be appropriately matched to the purpose o f the meeting and its participants (See Table 3). Although there is no evidence (yet) to suggest the superiority of any particular method in guideline development, group interaction methods generally enhance group process and decision making (US Congress, OTA, 1994).
In developing guidelines, group interaction methods can be used to(1) organize and manage the process o f guidelines development, (2) structure group meetings to balance power and manage bias by reduc­ing the potential for the most powerful or vocal group members to dominate the process, (3) provide a framework for group decision mak­ing, and (4) help groups generate more ideas than if they worked indi­vidually while moving the group toward decision making. A thoughtfully prepared plan for group interaction supports the intent to develop guidelines in a logical, systematic and accountable manner. Using techniques shown to be effective adds to the credibility o f the decisions made and facilitates effective and efficient working groups. Group interaction methodologies also provide documentation o f the
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development process which adds clarity and explicitness regardinggroup decision making.
• Is it legally appropriate for this type of group to reach consensus, or is the goal to obtain individual input?
• Are CD C staff and the panelists trained in the appropriate use of group interaction techniques?
• Are groups being assigned tasks that can be accomplished more ef­ficiently and effectively by group process rather than by individu­als?
• Considering what needs to be accomplished and the benefits and drawbacks o f various group process techniques, which interaction methods should be used?
• Is a skilled facilitator or mediator available who is trained in the group process technique and who does not have a vested interest in a particular outcome?
• Is there a plan for circulating materials to members in advance for review?
• Will there be written documentation o f the group interaction proc­ess?
• Provide appropriate training in group interaction techniques for CD C staff and panelists.
• CD C staff should plan for group interaction activities, assigning activities to groups which are appropriate for group work. Plan­ning staff should avoid encumbering groups with tasks that are more efficiently accomplished by individuals.
• Guideline planning staff should select group interaction tech­niques appropriate to the specific tasks to be accomplished and the nature o f the group or panel. An appropriately chosen group inter­action method supports and enhances a group’s process, manages bias, and facilitates accomplishment o f intended group tasks.
• Circulate materials in advance for review. (For specific techniques such as Delphi, follow exact protocol.) Groups will be more effec­tive if the individual participants have the opportunity to think, perhaps even write, before they are asked to contribute to the work of the group.
• Use skilled facilitators or mediators who are trained in the group process technique selected for the group activity. To add to the credibility of the guideline development process, facilitators and
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mediators should not be invested in a particular outcome and should be perceived as neutral and professional by group members. A facilitator with an understanding o f the particular topic, but not necessarily an expert, may also serve as the working group coordi­nator.
• An operational definition o f consensus should be specified as well as how to present less than full agreement of the panel’s findings.
• Maintain good written documentation o f the group interaction process, just as good research notes are maintained throughout the research and analytic process. Use group interaction methods which produce written documentation.
• Avoid voting as a method of seeking consensus. A better approach is to rank ideas and to encourage participants to react and add to the work o f others. I f  consensus is appropriate, use mediation tech­niques.
Approaches to  
Aiding Group  
In teraction
The principles outlined above and elaborated on below provide gen- Principleseral suggestions for group planning and process methods rather than support for particular methods. The recommendations reflect a narra­tive synthesis o f the professional opinions o f the experts whose work is cited. As the science o f group interactive process develops, evidence o f the superiority o f a particular method applied to guidelines develop­ment may become available. Also, new techniques may evolve to en­hance group interaction.
• Groups will be more effective if  the individual participants have an opportunity to think, and perhaps even write, before they are asked to contribute to the work o f the group. Allowing partici­pants to review materials, develop their thoughts, and formulate ideas in advance o f a meeting recognizes the diverse styles and needs o f group members in how they process and integrate infor­mation. Some people work best when they have time to reflect qui­etly while others are highly stimulated by group discussion. While groups are usually more effective than individuals in generating ideas, individuals are often more effective than groups in develop­ing ideas. Allowing time for individual thought, even during a process such as brainstorming by providing a few silent moments for reflection before discussion, can accommodate the needs o f in­dividuals and take advantage o f the strengths o f group work and in­dividual work.
• Groups generally prefer the opportunity to reflect a range of choices rather than voting. Group members may resist making a fi-
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nal selection among ideas, often preferring to offer a range o f op­tions rather than a final recommendation. Options generated by participants may need clarifying information or supporting re­search data that are unavailable at the time of the meeting. Forcing participants to vote to select options may be frustrating when the options cannot be fully developed during the meeting because o f lack of information or meeting time limitations. Voting also en­courages an atmosphere o f competition, stifling the opportunities for participants to react and add to the ideas o f others. Instead o f voting, it is preferable for participants to rank choices with a tech­nique such as multi-voting i.e, giving individuals multiple votes, where participants rank a set o f options. In some instances, it may also be helpful for participants to define their criteria for choosing options, thus identifying important underlying concepts that moti­vate their individual recommendations.
• The productivity o f a group can be enhanced by skilled facilita­tors. To add to the credibility o f the guideline development proc­ess, facilitators and mediators should not be invested in a particular outcome and should be perceived as neutral and profes­sional by group members. In instances where politically sensitive is­sues are at stake or in large meetings such as policy dialogues or public hearings, it may be advisable to use a professional outside fa­cilitator. In other instances, in-house staff trained in group process techniques may serve as facilitators keeping in mind the need for the facilitator to be neutral. A skilled facilitator can structure, or­ganize, and coordinate group meetings to ensure that: (a) all group members are given an opportunity to participate in discussions; (b) power among group members is balanced; (c) the group remains focused on important issues; (d) group meeting time is used effec­tively; (e) an appropriate written record of the group’s work is de­veloped.
• Good written documentation of the group interaction process should be maintained. Just as good research notes are maintained throughout the research and analytic process, written documenta­tion o f the group interaction process lends scientific credibility to the process o f developing guidelines. It is advisable to use group in­teraction methods which produce written documentation (e.g., a group memory recorded by a facilitator; participant lists produced by idea writing). Poorly articulated paper trails and chains o f evi­dence can make it difficult to discern from a vague rationale state­ment which parts o f the analytic logic are based on science or theory, the quality of evidence, and how it was interpreted. W rit­ten documentation can avoid misleading readers into thinking there is more or less scientific support for guidelines than is actu­ally the case (Pritzker, 1995). Decision analytic models can be used to guide and document decision-making processes.
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Few organizations issuing guidelines use formal, structured interactive group techniques to orchestrate the guideline process and make ex­plicit recommendations (US Congress, OTA, 1994). Studies have demonstrated that group composition and aspects of group process be­come increasingly important as the availability and strength o f evi­dence declines (Lomas, 1988). Many guideline processes are informal and organized around a series o f loosely defined steps: (1) a group of experts is assembled; (2) available literature is collected, summarized, and then reviewed by individual panel members; (3) meetings in a “roundtable” format are held where experts express opinions; (4) rec­ommendations are agreed upon, often by a vote; and (5) recommenda­tions are reviewed by outside experts and then are reconsidered by the group. O ther approaches to group interaction and decision making are available and two, Nominal Group Technique (NGT) and the Delphi technique, have been studied extensively. Five examples o f alternative approaches to group process, including N G T  and Delphi, are de­scribed below.
Nominal Group Technique.
N G T  is a single-question technique. First, a question is formulated and pilot tested to achieve responses with the desired level o f specific­ity and abstraction. Then, group members respond to the question by silently and independently generating ideas in writing. This aspect of the process gives the technique its name— individuals participating in the “nominal” group process are a group “in name only” and do not initially interact verbally. In the next step, a facilitator records individu­ally generated ideas on a flip chart. A serial discussion of the list of ideas follows. Finally, participants rank ideas and discuss the ranking pattern for the group.
This technique works best for groups o f 5 to 9 members in situations where there is uncertainty or disagreement about the nature o f a prob­lem and possible solutions. The technique was designed to circumvent factors, such as verbal aggressiveness and status, that have an adverse impact on groups (Moore, 1994). The technique has been widely used in human service organizations and in evaluation research (US Congress, OTA, 1994).
Advantages
• Easy to learn and use.
• Gives members a sense of being productive in a short time.
• Generates many ideas quickly.
• Produces a written record simultaneously with the process.
Specific Methods 
and Examples
Aiding Group Interaction and  Decision M aking 67
Disadvantages
• Does not allow for in-depth discussion, combination o f ideas, or explanation o f perspectives unfamiliar to the group. Thus, ideas may not be fully developed in the discussion session.
• Does not focus on a single issue.
• Useful for generating ideas but not for decision making.
• Can polarize a group, encouraging participants to become posi­tional or even adversarial.
• Often “majority rules” and this result may not be optimal in guide­line development.
Delphi.
This technique can help groups o f experts identify a range o f possible program alternatives, explore underlying assumptions or information leading to different judgments, and reach consensus on complex is­sues. Unlike N G T, the Delphi technique does not require the partici­pants to meet face-to-face.
The Delphi technique is not a method for reaching consensus or mak­ing a decision; rather, it is used to inform a decision maker o f expert opinion and supporting evidence for consideration (Linstone, 1975). Delphi is useful whenever it is desirable to have pooled judgment. In a conventional Delphi, a small monitor team designs a questionnaire which is sent to a larger respondent group. After the questionnaire is returned, the monitor team analyzes the results and, based upon the re­sults, develops a new questionnaire for the original respondent group. The respondent group is given at least one opportunity to re-evaluate its original answers based upon the analysis of the group response.
A real-time Delphi differs from a conventional Delphi in that, rather than taking weeks to conduct the process, it occurs during the course o f a meeting and is often aided by computer terminals for collection and analysis o f responses. CDC panels have used a version o f real-time Delphi to list, discuss, and rank priorities for issues such as managed care policy.
The Delphi process often varies according to whether the respondent group is anonymous; whether open-ended or closed-ended questions are used in the questionnaires; the number o f iterations of question­naires mailed to respondents; and the decision rules used to aggregate the judgments of the respondent group. The underlying theory o f Del­phi technique is that improvements in judgment with each Delphi it­eration occur because the most knowledgeable panelists confidently retain their judgments and anchor the median close to the true value.
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Advantages
• Can be used with a large group.
• Useful when there is a wide range of expertise within a group.
• Members can remain anonymous to each other.
• Produces a written record simultaneously with the process.
Disadvantages
• N ot a method for reaching consensus or making a decision.
• May reflect dogma rather than the best judgment of participants.
• M onitor team must be well trained in the technique and neutral in order not to manipulate the process and distort the result.
• Technique may emphasize consensus to such an extent that ex­treme but useful views are suppressed.
• If  conducted by mail or computer, the synergistic effect of face-to- face meetings is lost.
• If  a mail questionnaire is used, it takes an estimated 44.5 days to complete a Delphi (Delbecq, 1975).
Idea writing.
This technique recognizes that certain group goals can be achieved best by writing rather than by discussion. Idea writing typically in­cludes four steps: (a) Group organization - a large group is divided into working groups o f 4 to 5 individuals; (b) Initial response - partici­pants react in writing to a stimulus question or item and then place their pad (with the initial response) in the center o f the group.(c) W ritten interaction - each participant reacts, in writing, to what is written on each o f the other pads. (d) Analysis and reporting - partici­pants read the comments made in reaction to their initial response; the small working groups discuss the principal ideas that emerge from the written interaction; and the group summarizes the discussion in writ­ing. The process is especially useful for large groups and was used suc­cessfully with an international planning conference o f700 participants (Moore, 1994).
Advantages
• Controls verbal aggressiveness in a group.
• Allows people the opportunity to clearly phrase their thoughts be­fore speaking.
• Provides immediate written documentation.
• Focuses on a single topic.
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• Fast and easy to facilitate.
• Can be done by computer.
• Especially useful for large groups.
Disadvantages
• Participants M UST be willing to express themselves in writing (Warfield, 1976; Thissen, 1980).
• Technique does not develop or clarify ideas through discussion.
• Primarily used to react to issues, not for decision making.
Negotiated Mediation Techniques.
The traditional model for rule making is that of agency experts decid­ing the best way to regulate, offering the public an opportunity to comment, and then issuing binding rules. This process encourages ad­versarial, uncooperative behavior which was particularly true in regula­tory areas affecting the environment and the health and safety of workers. In an effort to improve this process, more government agen­cies are turning to a consensus-based approach. Variations on this ap­proach continue to evolve (Pritzker, 1995a). Negotiated rule making is done in the context of a FACA chartered committee.
Techniques used in this negotiated rule making process (sometimes called “reg neg”) have potential application in the process o f develop­ing guidelines. In negotiated rule making, after an issue is determined to be appropriate for reg-neg, a committee o f affected interested par­ties, including the agency, meets with a skilled mediator. The goal is to reach consensus on the proposed policy. The long-term benefits of the reg-neg process include: more innovative approaches that may re­duce compliance costs, earlier implementation, and increased coopera­tion between the agency and other affected parties. Negotiations that do not result in consensus can also be useful by narrowing issues in dis­pute, identifying information necessary to resolve disputes, ranking pri­orities, finding potentially acceptable solutions, and improving the agency’s understanding o f the real-world impact o f alternative options. Even in programs with no history of adversarial policy making, the agency may obtain a better factual basis for a position and a better un­derstanding o f the practical consequences of each option. Negotiations can also help enfranchise parties with important interests.
In government, there is documented evidence that the reg-neg process reduces costs and saves time. Using the reg-neg process, EPA estimates a time saving of 6 to 18 months as compared to the normal rule mak­ing process, along with a significant dollar savings from avoiding litiga­tion (Pritzker, 1995b).
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The Office o f Medical Applications o f Research at the National Insti­tutes o f Health has used the consensus process in developing clinical guidelines. A 1988 study o f a consensus conference on Cesarean birth indicates that a consensus process structured to emphasize scientific evidence lead to panel consensus that reflected this orientation while facilitating decision making (Lomas, 1988). Using a professionally trained mediator to conduct discussions for guidelines panels com­posed o f people with diverse interests aids the communication process and fosters opportunities for full participation by panel members.
Advantages
• Can reduce costs and save time of implementing guidelines.
• Suitable when interested parties hold widely varying interests.
• Consensus-building process that addresses underlying issues as well as achieving a decision.
• Suitable for complex, politically charged decisions that may in­volve the general public and others.
Disadvantages
• Requires highly trained, professional facilitators.
• May take several meetings over several months.
Decision Analysis, Influence Diagrams, Decision Diagrams.
Decision analysis, influence diagrams, and decision diagrams are types o f structural modeling that a group can use to help manage multiple, complex ideas. Decision analytic techniques provide an explicit, quan­titative, and systematic approach to decision making under conditions of uncertainty. At CDC, decision models are a component o f eco­nomic analyses used for policy analysis and guidelines development. Modeling techniques are used to structure policy questions, test hy­potheses, illuminate areas where research data is needed, and provide quantitative information of the cost-effectiveness o f public health pre­vention interventions. However, decision analytic methods do not sub­stitute for professional judgment or expertise even though they provide a framework for managing a large array of complex factors.
Groups engaged in guideline development may use decision analytic logic as a guide for reviewing evidence, developing recommendations, and explaining the rationale for guidelines. The methods can be used to define which questions must be answered to arrive at a recommen­dation, which types o f evidence and information are relevant to the analysis, and by what criteria evidence will be judged (Woolf, 1992). (See the section on Analytic Framework.)
Groups may also use decision analytic techniques to structure their process o f decision making (Woolf, 1992). In decision analysis, a
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graphical representation is created, often in the form o f a decision “tree” with “branches” representing different options. Influence dia­grams show factors that are important in a decision and diagram the interrelationships between factors in a model resembling a flow chart. Mathematical calculations resulting in estimates o f cost-effectiveness or cost-benefit can be performed for models i f  numerical values are as­signed to designate the probability o f certain events happening and the utility, or perceived usefulness, o f each possible outcome.
Decision models can be helpful to group decision making for several reasons:
a. Explicitness. Unlike intuitive decision making, the decision-analysis process requires that options be clearly stated, consequences be clearly identified, and uncertainties be recognized. Group decision rules may also be made explicit.
b. Comprehensiveness. When making a decision by intuition, a person is only able to simultaneously consider a limited number o f options and to process a limited amount of information. W hen a group of several members is engaged in decision making, the process becomes even more complex. Because the analysis process scrutinizes each part o f  a decision model for alternatives and outcomes, the process becomes more comprehensive than intuitive decision making can be.
c. Improved communication. To one expert, the word “rarely” may mean a 1% chance; to another, it may mean a 10% chance. The process o f decision analysis allows decision makers to understand and convey information clearly about aspects of a problem. W ith the use of formal decision analysis, it is also easy to document and justify the choices made.
d. Facilitated decision making. It is often difficult for a group to reach decisions, especially complex decisions with far-reaching conse­quences. The logical, rational process o f decision analysis lends struc­ture, organization, and reason to a difficult process.
e. Focus is encouraged. The process o f  decision analysis encourages group members to focus on truly important issues rather than on is­sues that merely seem to be important. Structuring a problem can clarify the significant issues involved in a decision. In mathematical models, conducting sensitivity analysis allows the decision maker to consider each variable in the model to determine the importance o f the variable in a particular outcome.
For some decisions, elaborate, mathematical models can provide a high degree o f structure and organization to the group process o f  mak­ing decisions. In other instances, a group may quickly develop less for­mal decision models to guide discussions and focus issues during group interaction and decision making.
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Advantages
• Can manage a large array of complex factors.
• Provides a high degree o f structure and organization.
• Group decision making rules are explicit.
• Comprehensively examines an issue.
• Uses a purely logical base.
Disadvantages
• Elaborate models take much time to develop.
• Serves as a framework but does not necessarily incorporate profes­sional judgment or expertise.
Current guideline development efforts at CDC reflect the variety of approaches to aiding group interaction illustrated by the samples de­scribed above. Historically, CDC-sponsored guidelines have been de­veloped by (1) Federally chartered advisory committees (e.g., ACIP),(2) ad hoc expert panels which are convened to develop a particular guideline, (3) staff of the sponsoring CIO, and (4) some combination of the categories described in items 1-3. Group interaction activities have used a variety o f formats— from informal discussions to a highly structured Nominal Group Technique process which was used for de­velopment o f Prevention Effectiveness Guidelines for economic analy­ses at CD C in 1993.
Table 3 summarizes the characteristics of each o f the group interaction methods discussed.
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Table 3. Characteristics of Group Process M ethod
Nominal Group Technique Delphi Idea Writing Negotiated Rule Making Decision Analysis
Groupcomposition Suitable for general audience, experts, or mixed
Suitable for general audience, experts, or mixed Suitable for general audience, experts, or mixed. A series o f techniques and processes. Can include experts as well as general public.
Technical process most suited when there is uncertainty among experts.
Group size Best for groups of 5-9. Can conduct concurrent small groups.
Best for groups o f 5-15. Can be used for groups o f 100. Best for groups of 5-6. Can conduct with concurrent small groups.
Techniques such as mediation are suitable for groups o f 2-4. Techniques such as policy dialog or public hearings are suitable for very large groups including the general public.
Typically a workgroup of 2-5 experts constructs the model and analyses results for presentation to policy-maker(s).
Method suitable for achieving consensus?
No. Based on voting. No. Used to inform a decision maker of expert opinion. No. Used to generate ideas and document reactions. Yes. Consensus is the focus o f these techniques. No. Based on decision rules and technical estimates. Informs a decision maker o f expert opinion.
Time required for process 1-2 hours for typical meeting. If done by mail, up to 6 weeks. If aided by computer, 4-8 hours.
1 hour for typical session. Some techniques such as mediation can take 2 hours to several meetings. The time required depends on the number o f parties and the complexity of issues.
Sometimes a quick estimate can be done in a few hours. A full decision analysis may require several months.
Specialrequirements None. Easily facilitated. Monitor team must be trained in the technique and maintain neutrality in formulating iterations o f questions.
Very easy to facilitate. Participants must be willing to express themselves in writing.
Highly trained, professional facilitators and mediators required.
Highly trained experts in decision modeling required.
Suitable for in­depthexamination of issues?
No. Good for generating ideas, but not for development o f ideas or in-depth discussion.
Yes. The use o f several iterations of questions allows experts to clarify position, criteria, and recommendations.
No. Good for generating ideas. No development of ideas or discussion. Generally used in conjunction with other meeting techniques.
Yes. The focus on consensus stresses the examination o f interests of parties as well as possible options.
Yes. Technique makes explicit all issues to be used as the basis o f a decision.
their sense of self-confidence in working together. Selecting group in­
teraction methods which address the various or changing needs of the 
group can maximize group productivity.
Identifying a Research Agenda
A research agenda is that list o f study questions or areas o f inquiry that should receive high priority for scientific investigation and funding. A research agenda for public health practice should be established within a broader strategic planning process. The research questions and needs can be identified at several points in the strategic planning process, in­cluding: 1) the review of health statistics relevant to the organizational mandate for prevention and control of disease or injury; 2) the review of important outside forces (e.g., social, economic, political, scientific, technological, environmental) to identify opportunities for and threats to achieving the mandate; and 3) the review of organizational capacity to respond to strategic needs. They can also be identified through vi­sioning or scenario-building exercises that identify potential circum­stances and allow for a description o f the ideal so that steps to achieving it can be more clearly defined (Bryson, 1993).
An evidence-based guideline development process follows the struc­ture of a strategic planning process. An organized approach is used to identify topics based on organizational goals and objectives. An ana­lytic framework identifies the practical alternatives for achieving the goals and provides a description of the causal reasoning linking the proposed practices and relevant health outcomes with evidence o f ef­fectiveness (Woolf, 1994). Filling in the data defines the benefits and barriers to each alternative. A spin-off benefit o f following an organ­ized approach is the systematic identification o f gaps in the scientific foundation for recommendations about practices and their implemen­tation (Woolf, 1994). Explicit frameworks, e.g., decision analysis, lend themselves to identification o f knowledge gaps and highlight the im­portance of specifying uncertainty in estimates and conclusions.
The recognition of inadequacies in data can establish the research needs and be an early step in identifying a research agenda. As one ap­proach to determining research needs, the guideline development proc­ess provides a deliberate methodology for addressing pertinent questions and building on existing knowledge o f the subject. Gaps in the scientific foundation should be reported in the discussion o f the guideline and can provide the basis for a relevant research agenda.
The agenda should be re-evaluated in an ongoing process that continu­ally addresses the most relevant questions. As guidelines are revisited, existing information will be reviewed and synthesized and current gaps in knowledge identified. In this way, a dynamic guideline develop­ment process feeds the research priority setting process that will pro­vide the new information necessary to improve the effectiveness of guidelines and renew the cycle.
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Example 1
Example 2
In September 1994 CDC convened a workshop to provide guidance on the public health threat of waterborne cryptosporidiosis (CDC,1995). Four topic areas were addressed in the workshop and the dis­cussions deliberately focused on summarizing the current knowledge in these areas and defining the information necessary to develop rec­ommendations. Where information was lacking, suggestions were pro­vided for the research methods appropriate to obtain the information. The workshop concluded that current knowledge o f waterborne cryp- tosporidiosis is minimal and does not provide a scientifically sound ba­sis for many of the decisions necessary in the public health response to infection.
Research needs were defined in disease reporting and outbreak study design and in the development o f dependable methods for detecting cryptosporidium in drinking water. [Note: while a workshop of ex­perts from a variety o f disciplines is not the ideal framework for evi­dence-based guideline development, it can be useful in situations where the evidence base is limited and timely recommendations are necessary.]
Using an evidence-based approach, the U.S. Preventive Services Task Force in 1989 published guidelines for postmenopausal estrogen re­placement therapy (USPSTF, 1989). The Task Force concluded that there was sufficient evidence that estrogen therapy can reduce bone loss in postmenopausal women, but that there was insufficient evi­dence regarding the prevention of fractures, reduction in cardiovascu­lar mortality, and the risk o f breast cancer and gallbladder disease. The recommendation was that estrogen therapy should be considered in as­ymptomatic women at increased risk for osteoporosis and without known contraindications. The 1996 edition of the Guide to Clinical Preventive Services (USPSTF, 1996) revisited the estrogen replace­ment guideline and updated the analytic framework used to assess this treatment (Figure 2)
In the new guideline the Task Force concluded that estrogen therapy after menopause relieves vasomotor and urogenital symptoms, pro­duces clinically important improvements in bone density and blood lipids, and is associated with significant reductions in the risk of heart disease and fracture. The Task Force gave a B recommendation (fair evidence to support the recommendation) that clinicians should coun­sel all women around the time of menopause about the possible bene­fits and risks of postmenopausal hormone therapy and the availability o f treatment options. Additional research needs were identified to in­clude more reliable estimates of the magnitude o f the benefits in car­diovascular disease and fracture risk, the appropriate duration of treatment, the benefits and risks in older women (over age 65) and non-white women, the effect of adding progestins, interactions with
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other risk factors, and the role o f postmenopausal hormone regimens in the risk of breast cancer.
• A systematic guideline development process should identify and R e c o m m e n d ahelp clarify the relative importance of controversies or gaps in t i o n sknowledge and help to establish a research agenda to determine de­sired practices and the best implementation strategies.
• The panel should recommend research needed to resolve issues of importance, especially those for which full agreement was not reached.
• A mechanism for periodic evaluation of guidelines should exist to facilitate changes in the guidelines, implementation strategies, and the research agenda.






RCT = randomized controlled trials; Pros-obs = prospective observational studies; Retr-obs = retrospective observational studies; 
Descr = uncontrolled descriptive studies.
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Updating Guidelines
How often a guideline should be reviewed and updated depends on several factors: how strongly current scientific evidence supports it, how quickly new scientific evidence is likely to become available, how effective the current guideline is, and changes in the practice environ­ment. A formula for updating guidelines is not appropriate. However, during the development process specific decisions should be made re­garding the time frame for updating the guideline. These decisions should consider the strength o f existing evidence, the level of contro­versy surrounding the guideline, and the expectations o f new scientific evidence. New guidelines should include a specific time frame for revis­iting the guideline for updating or reaffirmation. Unanticipated new evidence may accelerate the review process. Ongoing systematic re­views of the literature including cumulative meta analysis allow “real­time” updating o f scientific evidence.
Evidence suggesting that a guideline is not being implemented ade­quately or that it is not achieving the desired effect should also prompt review and updating. The assumptions on which a guideline is based or the development or implementation process may need re-evaluat­ing. The review should consider the factors discussed in the upcoming section on Encouraging the Adoption of Guidelines. Changes in the practice environment, such as the growth in managed care as a health care delivery system, should also prompt critical review of previously is­sued guidelines. Relevant perspectives should be addressed to improve interest in and compliance with the guidelines.
The planning of a research agenda also offers an opportunity to revisit guidelines. The systematic assessment o f the effectiveness of existing guidelines and o f the current scientific evidence can be valuable for identifying pertinent research needs
Answers to the following questions can help determine whether a guideline should be updated.
• How strong is the evidence on which the guideline is based?
• Is new scientific evidence available or expected soon?
• W hat level of controversy surrounds the guideline?
• Is the guideline effective?





• Based on the best available information at the time the guideline is issued, a statement should be included that indicates a time frame within which the guideline should be revisited.
• A guideline should be reviewed and updated when new evidence suggests that the guideline is incorrect or is ineffective or strength­ens the recommendation.
• Updating guidelines should be considered in the process of estab­lishing a research agenda.
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W riting the Guideline
The way guidelines are written can strongly affect their potential for ef­fective use. Planning for a successfully written document must begin early in the process and continue through the cycles of review and revi­sion. The writing process can be more easily managed if a work plan and time frame are developed and followed. Keeping to a schedule is important-getting timely reviews by setting a clear and reasonable time frame for review, evaluating comments, and incorporating the comments into the document. Good planning and adherence to the schedule can improve the final product.
In writing the guideline, a compelling case needs to be made to the us­ers of the guideline to effect its implementation. To do so, the docu­ment must answer the potential users’ questions. Major questions that all relevant users (e.g., society, clinicians, patients, health care plans) should be able to answer include the following: Is the problem rele­vant to me? Is it an important problem? Can I do something about it? Is it worth doing? Decisions or opinions that are based on weak evi­dence or expert opinion should be duly noted.
Guidelines should provide clear recommendations and employ cred­ible methods that document the rationale on which the recommenda­tions are based. The guidelines should be practical, yet specific, comprehensive, and flexible enough to be useful in everyday practice. The language, logic, and symbols used in the guidelines should be un­ambiguous and easy to follow. The length should be appropriate to the subject matter and the intended audience.
Formatting is defined as the presentation o f guidelines in physical ar­rangements or media that can be readily understood and applied by the intended users o f the guideline. Effective formatting means the guidelines will be delivered to the intended audiences in a way that promotes the reception, understanding, acceptance, application, and a positive impact. Guidelines can vary quite dramatically, both logically and graphically, in their modes o f presentation. The major approaches are freetext and formalized presentations, including if/then statements, algorithms, flowcharts, and decision trees (Field and Lohr, 1992).
No matter which format is used, all public health practice guidelines should contain basic components in their core presentation. These components include the relevance o f the health problem, the magni­tude o f the problem, the nature o f the intervention, the guideline de­velopment methods, the strength o f the evidence, cost effectiveness, a discussion of implementation issues (including current extent of imple­mentation), evaluation, and the recommendations of others.
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Points to  
Consider 





An explanation of how the guideline was developed and who partici­pated in the process should be provided (Field and Lohr, 1992) along with a contact person. Also, a one-page summary should be provided that addresses all of the basic components. The summary should be written using lay terminology, and it should be fully accessible to the general public. These components are considered the minimal require­ments of an effectively written guideline; they are not meant to be comprehensive. (A discussion o f these basic components follows the Points to Consider and the Recommendations.)
Several questions should be answered during the writing of a guideline.
• For whom is the guideline relevant? (For example, are the guide­lines for physicians, the public, healthcare workers, a combination audience, etc.?) Knowing the intended audience will play a signifi­cant role in how the guidelines are written, the approach, lan­guage, and style. In the case o f public health practice guidelines, the audience will be public health practitioners, such as state and local health department program managers and policymakers.
• Has the magnitude of the health problem been conveyed ade­quately?
• Has the guideline development process been described in suffi­cient detail to establish the credibility of the methods and the re­sults o f the data synthesis?
• Has the case been made to the intended audience that the quality improvement in public health practice is worth the costs o f imple­menting the guideline?
• Have implementation strategies been identified that establish the feasibility o f implementing the guideline?
• W hat measures and vehicles are available to monitor the extent of implementation and the effectiveness o f the guideline?
• Have the recommendations o f other relevant organizations been addressed?
• How will the guidelines be communicated to potential users? The main dissemination vehicles for CD C public health practice guide­lines are the M M W R/RR, journal articles, and the Federal Regis­ter. In addition, press releases on the guideline content are issued at the same time.
The following recommendations apply to all categories of guidelines regardless of the guideline development process.
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• Writers and editors should be familiar with the subject matter or have the ability to grasp the information, interpret it, and explain it (medical/science writers/editors).
• Length, format, layout, and style should be suitably matched to the intended audience, subject matter, intention o f the guideline, and dissemination vehicle.
• A work plan with time frame must be thoroughly thought out and adhered to so as to keep the project on schedule.
• CD C public health practice guidelines should address certain basic components: the relevance o f the health problem, the magnitude o f the problem, the nature of the intervention, the guideline devel­opment methods, the strength o f the evidence, the cost effective­ness, a discussion of implementation issues, evaluation issues, and the recommendations of others. A brief but complete summary and a contact source should be provided.
Since the main audience for public health practice guidelines is public health practitioners, such as state and local health department program managers and policymakers, and the main dissemination vehicles are the M M W R/RR, journal articles, and the Federal Register, the core guideline should be written at the level of professional practitioners in public health and clinical medicine. The document can subsequently act as the source for different presentation vehicles (brochures, news re­lease, and training materials) for specific audiences. In adapting the original document for different audiences, changes may need to be made, depending on the audience and presentation planned. Further discussion of the core components o f guidelines follows.
The guideline should state explicitly for whom the recommended prac­tices apply. A guideline is relevant to those who carry out the recom­mended practices (clinicians, sanitarians, health educators, etc.), those who benefit from the practice changes (i.e., the population affected), and those who assume risk or financial cost for the problem (health care purchasers, employers, local governments, etc.). A checklist (Ta­ble 4) should be completed to denote relevant categories for crossrefer- encing of the guideline.
The magnitude of a health problem can be defined in several ways and the greater the number o f perspectives addressed, the broader will be the recognition o f importance. Health problems that affect large num ­bers o f people, have catastrophic consequences, or require costly con­trol interventions are generally recognized as important. O ther factors that influence the perception o f importance include the transmissibil- ity o f the health event and potential for outbreaks, perceptions of blame (whether the responsibility o f an individual (e.g., a behavior) or an effect beyond individual control (e.g., an environmental hazard)), and the dramatic appeal and media attention. The importance of the
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health problem should also be considered in terms relevant to the per­sons or organizations for whom practice changes are being advocated. The magnitude o f the health problem can be reflected through meas­ures o f absolute risk, relative risk, severity, transmissibility, popularity, and costs.
A clear and explicit description o f what practices are being recom­mended should be provided in a distinctively marked location and preferably early on in the written document. The objectives o f the guideline should be included in this description. By presenting the guideline before the supporting documentation, a context is provided for assessing the documentation.
The methods used to arrive at the strategy being presented as a guide­line should be described in detail. Included should be a description of the decision-making body, their affiliations and their potential con­flicts o f interest; the methods used to select the decision-making body; the analytic framework used for choosing between guideline options; and the methods used for synthesis of existing data. The technical and other reviewers o f the guideline document should be identified.
W hat are the reasons or principles on which the recommended course o f action is being based? What can be expected from implementing the suggested recommendations? A clear explanation of what the scien­tific evidence shows about the effectiveness o f the intervention being proposed by the guideline should be provided. The results o f the data synthesis should be provided as justification for the decisions made. Recommendations should include explicit statements about the strength o f each recommendation and the quality o f the supporting evidence (see page 56 for example from the USPSTF). The data syn­thesis should address such issues as feasibility o f early recognition, effi­cacy of the intervention, effectiveness o f interventions (depends on adherence rate, scale o f adoption, and utilization rate in general popu­lation), approaches to implementation o f the guideline and the ability to generalize those approaches, and conclusions regarding the strength of the evidence supporting the guideline. A flow chart o f the practice options considered in the decision process would be worthwhile.
The guideline should include a statement on the cost effectiveness of implementing the proposed practices from the societal perspective. While the societal perspective is important for establishing public pol­icy, many individual practitioners and consumers for whom the guide­line is intended will not make decisions based on the societal implications and other appropriate perspectives (e.g., health depart­ments, health plans, employers, and consumers)should also be ad­dressed. W hen data are lacking to address a relevant perspective, the absence of data should be noted and the process used and conclusions drawn regarding value should still be presented. In establishing the value o f a guideline, other considerations include opportunity costs and downstream or domino effects, consumer satisfaction and quality
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of life, health services quality indicators (potentially used to compare providers), and liability implications.
The interventions being proposed should be explained in the context o f public health practice experience. Discussion of implementation is­sues should facilitate user decisions about the feasibility o f adopting the guideline. Who will need to do which work to implement the guideline? How can the guideline be integrated into current practices without substantial changes in staffing or routines? Is there flexibility for clinical judgment? W hat is the current level of implementation? W hat strategies could increase compliance with recommendations? W hat resources and procedures are necessary to maintain compliance?
How can successful implementation be measured? W hat level of com­pliance is realistic? Considerations for performance measurement should be addressed, including the tests and procedures for monitor­ing the implementation and the effect of the guideline. Describing the methods which identified the problem may be useful for defining the measures important for performance measurement (measures for sur­veillance).
If  other groups have recommendations in this area they should be men­tioned and discussed in the context of how they conform or differ from the recommendation being proposed. If  other groups are endors­ing this guideline that should also be mentioned.
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Table 4. Guideline Cross-Referencing Checklist
Setting User Target Population
□ clinic □ physician children
□ health department □ nurse adolescents
□ medical office □ other health care elderly
□ laboratory provider □ women
□ hospital □ health official □ pregnant women
□ workplace sanitarian minorities
□ community □ laboratory worker persons with disabilities
□ managed care plan researcher □ inner-city residents











□ behavioral risk factors 
reproductive health





86 CDC Guidelines: Im proving the Quality
Obtaining Critical Reviews and 
Public Comments
Obtaining critical reviews and public comments are essential steps in devising guidelines that are credible and useful and in anticipating the challenges o f acceptance and implementation (Field and Lohr, 1992). A multidisciplinary review process should include all key groups from the scientific, advocacy, and provider constituencies. Although poten­tially requiring more time and funds, such an approach can also help developers of guidelines better understand the situations in which guidelines will be implemented (Field and Lohr, 1992).
Review of draft guidelines by experts in the field and relevant organiza­tions and agencies that are involved in the area, or will be involved in the implementation, can provide broad input on content and policy is­sues. Review by relevant content experts can ensure scientific and clini­cal validity (Woolf, 1992). In addition, C D C ’s Office o f the General Counsel (OGC) usually reviews guidelines for legal considerations, ref­erences to liability or litigation concerns, discussions of federally char­tered advisory committees, references to laws, and other issues related to the functions o f the office.
In selecting groups for review and comment, many aspects need to be considered. They include the legal and social implications of the guide­line, the scope o f the guideline and all the groups and agencies that may be affected, both directly and indirectly. Questions that need to be answered include whether political support or regulatory follow-up will be needed and what role the advocacy community may play in the acceptance of the guideline. Activities such as draft document circula­tion, draft publication, and hearings can provide opportunities for in­cluding groups in the review and comment process. In some cases pretesting may be beneficial. Pretesting involves asking a small sample o f practitioners to use a guideline for a brief period and then collecting their suggestions on ways to improve the document.
Identification of reviewers for draft guidelines is an area in which groups may differ substantially in how they select participants, assum­ing that they have a process for reviewing draft documents at all. But whatever the approach, the process serves to broaden input (Field and Lohr, 1992).
In addition to review by experts in the field, proposed guidelines are often published in the Federal Register (FR) with a period available for comment. Guidelines publication in the FR is not usually required by law; it is used, however, as a convenient means for broad dissemina-
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tion. Open meetings or hearings are often scheduled for public com­ment.
Some guideline-related reports have specific legal requirements regard­ing review and comment. ATSDR, for example, is required by the Su­perfund Amendments and Reauthorization Act to have all studies and results of research, other than health assessments, peer reviewed before they are reported or adopted. The peer review for ATSDR must be completed, to the maximum extent practicable, within 60 days. In the case of research conducted under the National Toxicology Program, such peer review may be conducted by the Board o f Scientific Counsel­ors. In the case of other research, such peer review must be conducted by panels consisting o f no less than three nor more than seven mem­bers who are disinterested scientific experts selected for such purpose by the administrator of ATSDR or the administrator o f EPA, as appro­priate, on the basis of their reputation for scientific objectivity and the lack o f institutional ties with any person involved in the conduct of the study or research under review. Support services for such panels must be provided by ATSDR or the EPA, as appropriate.
Just as important as knowing who to involve in the review process is knowing when to involve them— before, during, or after the expert panel has completed its deliberations.
• Will scientific review by content experts and policy review by af­fected stakeholders be pursued simultaneously?
• Has a formal plan been developed for obtaining reviews by con­tent experts?
• Is public comment needed? If  so, has a plan been developed for ob­taining it?
• Have all the stakeholders in the process been identified and has consideration been given to the optimal time to bring them into the process?
• Should the guideline be pretested and revised during the develop­ment process?
• Are there specific legal requirements that need to be met?
The following recommendations apply to all categories of guidelines regardless of the decision-making authority.
• Use o f experts to review draft guidelines is especially critical in an­ticipating the challenges o f implementation and in devising guide­lines that are credible and useful.
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• The involvement o f a multidisciplinary group representing all stakeholders can help encourage acceptance of the guidelines.
• Draft guidelines should be reviewed by relevant content experts to ensure epidemiological, statistical and clinical validity as well as by relevant organizations and agencies to provide broad input on con­tent and policy issues.
• An effective and responsive guideline review and comment process should include public input, if appropriate.
Public and private agencies which sponsor the development of guide­lines have used several approaches for obtaining critical reviews and public comment. Open meetings, publication of the proposed guide­line for comment, peer review, and solicitation o f input from specific individuals or groups are examples o f the most common approaches.
Historically, CDC-sponsored guidelines have been developed by (1) Federally chartered advisory committees (e.g. ACIP), (2) ad hoc groups o f individual consultants which are convened to develop a par­ticular guideline, (3) staff o f the sponsoring CIO, and (4) some combi­nation o f the categories o f decision makers described in items 1-3.
Examples of how the groups listed in items 1-3 above have sought re­view and comment are described below.
The ACIP is an example of a Federally chartered advisory committee. Committee membership includes ex-officio members from the N IH , FDA, and liaison members from most organizations which are subject to or will implement the recommendations. All recommendations are are developed only after extensive information is gathered (research data, surveillance reports). Working groups are often formed to exten­sively analyze the research data for presentation to the full Committee. ACIP’s process for obtaining critical input includes extensive review by staff of the CDC, ACIP members and liaison members, and out­side expert consultants at all stages o f guideline development. Public comments are solicited during the open committee meetings and are considered in the decision-making process.
The Working Group which prepared the USPHS and Infectious Dis­ease Society of America (IDSA) Guidelines for the Prevention o f O p­portunistic Infections in Persons Infected with Human Immunodeficiency Virus is an example o f an ad hoc panel developing guidelines. This group’s process involved having the draft recommen­dations reviewed by consultants from CDC, N IH , and IDSA, as well as by members of other Federal and non-Federal agencies, community organizations, physicians caring for HIV-infected persons, and HIV- infected persons themselves. These recommendations were discussed at a two-day meeting convened by CDC, N IH , and IDSA and com­ments were solicited from the public. Final recommendations were ap­
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proved by USPHS and IDSA. The recommendations were also re­viewed and endorsed by the American Academy of Pediatrics, the In­fectious Diseases Society o f Obstetrics and Gynecology), and the Society o f Health Care Epidemiologists of America.
The Guidelines for School Health Programs to Prevent Tobacco Use and Addiction is an example o f guidelines developed by CD C staff. These guidelines were developed by CDC staff in collaboration with experts from 29 national, federal, and voluntary agencies and with other leading authorities in the field o f tobacco-use programs. To de­velop these guidelines, CD C staff convened meetings o f independent expert consultants from the fields o f tobacco-use prevention and educa­tion, reviewed published research, and considered the conclusions of the National Cancer Institute Expert Advisory Panel on School-Based Smoking Prevention Programs and the findings o f the 1994 Surgeon General’s Report, “Preventing Tobacco Use Among Young People.”.
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Encouraging the Adoption  
of Guidelines
A potential user adopts a guideline by deciding to accept and imple­ment the recommended practices. Guideline developers can influence a user’s decision to adopt the recommended practices by ensuring that the guideline is appealing and widely disseminated (Figure 3). A well- conceived guideline should anticipate the needs and concerns o f poten­tial users and build a compelling case for the recommendations (Field and Lohr, 1992). There are many factors, in addition to scientific evi­dence, that influence the appeal of guidelines (US Congress, OTA,1994). These factors include the relevance o f the health problem, the importance of the health problem, the credibility o f the process used to derive the recommended practices, the feasibility o f implementing the guideline and the value o f implementing the guideline. Dissemina­tion strategies include education through publication in journals, the lay news media, the electronic media, continuing education as with clinical peer detailing, and consumer information and incentives, both administrative and financial (US Congress, OTA, 1994).
As acknowledged in the Institute o f Medicine’s study on guidelines for clinical practice (Field and Lohr, 1992), scientific knowledge will continue to grow but will always remain an incomplete foundation for guidelines and implementation strategies. Although neither compre­hensive nor prioritized, the issues and methods outlined in this section can affect the adoption of guidelines.
• To get the attention o f those who need to review and apply guide­lines, the users and the populations for whom the guidelines apply must be clear.
• The health importance should be described from the range of rele­vant perspectives.
• Confidence in the guideline should be established through a de­scription o f the methods used, a summary of the existing scientific evidence, participation and endorsement of credible individuals and institutions, and a description o f relevant recommendations and guidelines already existing.
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Feasibility: W hen possible, guidelines should address a single, well-defined practice.
Value:
Dissemination:
Points to  
Consider
Appeal of the Guideline
• Guidelines should attempt to increase the performance of all users, not just the worst performers.
• Guidelines should leave room for practitioner judgment in a man­ner that is consistent with the strength o f the scientific evidence and with variation in risk and effectiveness in different populations.
• The costs and benefits o f implementing a guideline should be pre­sented from the societal perspective and other relevant perspec­tives, (public health clinics, local government, managed care organizations, private practitioners).
• Cost-effectiveness data should be used, when available, to influ­ence purchasers and providers o f care to establish financial and ad­ministrative incentives for use o f the guideline.
• The legal implications o f a guideline should be considered in its de­velopment and dissemination.
• Active dissemination strategies should be used for guidelines, when possible, including education of providers through local informa­tion networks and respected colleagues, consumer information campaigns, and administrative mechanisms to facilitate practice changes.
• The electronic Prevention Guidelines Data Base should be kept current as a venue for guideline dissemination.
Relevance
A guideline should include a clear statement of its audience. The use of a checklist o f categories (Table 4) can facilitate determination of relevance and cross-referencing of the guideline.
Importance
It is incumbent on those preparing guidelines to assure that the perti­nent information establishing importance is readily accessible to the us­ers. Parameters reflecting the importance of the health problem include:
• absolute risk: the total number o f cases, incidence, and prevalence
• relative risk: the population subgroups disproportionately affected
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• severity: magnitude o f the event, case-fatality ratio, drama of case reports, prematurity of outcomes, impact on quality of life
• transmissibility: propensity to cluster, to strike without warning, to be affected by environmental factors beyond individual control
• public interest/concern: which may be due to celebrity involve­ment or media attention
• costs: health care and human/social costs from all relevant perspec­tives (e.g., society, geopolitical unit, health system or office, em­ployer, individual)
Magnitude of Effect
A guideline that promises a major improvement in health or preven­tion of a catastrophic outcome will be more readily accepted than one that promises only a marginal effect (US Congress, OTA, 1994). The magnitude o f effect depends on both the health importance o f the problem and the effectiveness, not just efficacy, o f the intervention. A guideline should state the magnitude of the effect explicitly and should address as many different provider and consumer perspectives as possi­ble on importance.
Aspirin prophylaxis against myocardial infarction is an example o f im­portance and effect making for an appealing recommendation. The in­cidence, morbidity, and mortality of coronary artery disease are substantial. Adoption o f aspirin prophylaxis for those at risk of coro­nary artery disease was considerable (Krumholz, 1996) following a study o f U.S. male physicians that found a 47% reduction in the risk o f fatal and nonfatal myocardial infarction (Steering Committee of the Physician’s Health Study Research Group). The importance was readily apparent from the perspective o f public health, health care providers, and patients. The effectiveness o f this intervention was en­hanced by its simplicity and low cost, despite a possible increased risk o f hemorrhagic stroke.
Credibility of the Guideline
Credibility comes from the quality o f the methods used to develop the guideline, the credibility of the participants and sponsors, the strength of the scientific evidence supporting the guideline, the level o f agree­ment among existing guidelines and opinions, and the clarity o f pres­entation.
Quality Development Process
The methods used to develop the guidelines should be readily appar­ent and clearly stated. The methods include the criteria used for select­ing the decision-making body, the analytic framework used for identifying and choosing between guideline options, the approach to synthesis of existing data, and measures implemented to minimize real
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and perceived conflicts o f interest. The more systematic and demand­ing the methods, the more appealing the guideline is likely to be. If these methods are used in the development of serial guidelines (e.g., for a Federally Chartered Advisory Committee such as the ACIP), the methods should reference a readily accessible location where they are described in detail.
Respected Collaborators and Supporters
Guidelines issued by respected sources are more appealing than those from less credible sources. Credibility may be increased by broadening the constituency of organizations and individuals endorsing and pro­moting the guideline (Field and Lohr, 1992; US Congress, OTA, 1994; W eingarten, 1995). Medical associations (e.g., the American Academy of Pediatrics) frequently participate and endorse CD C guide­lines. Depending on the intended users, other participants may be viewed as credible sources. If  managed care is considered an important constituency, the endorsement of large health maintenance organiza­tions or their trade organizations may be worthwhile. Similarly, con­sumer organizations and business groups could be valuable allies in promoting a guideline and endorsement by credible consumer or busi­ness organizations may enhance the appeal o f a guideline. Multi-disci­plinary participation can involve hearings, review, pilot testing, and other activities that support the guideline development and dissemina­tion process (Field and Lohr, 1992).
Strength o f  Evidence
Decisions to change practices are usually made at the local or user level (Field and Lohr, 1992; US Congress, OTA, 1994). The more com­pelling the scientific evidence that supports the effectiveness o f a guide­line and an implementation strategy, the more likely the guideline will be accepted as a standard of care. This principle applies both to indi­vidual providers and to systems of care that establish their own prac­tice guidelines, such as managed care plans. Strong scientific evidence reduces the opportunity for conflicting recommendations coming from different interest groups with varying perspectives. W hen scien­tific evidence is lacking or equivocal, the appeal of a guideline depends on non-scientific issues and the credibility o f the proposing body is vulnerable. Guidelines should summarize the quantity and quality of scientific data and make clear the role o f these data in their develop­ment (Field and Lohr, 1992).
A guideline that reviews relevant recommendations and guidelines of other groups affords a context for its interpretation (Field and Lohr, 1992). In this context, differences can be explained and justified. If  a guideline differs from prevailing opinion or existing guidelines, then the strength of other factors such as the scientific evidence, must be particularly strong. Addressing competing guidelines can add credibil­
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ity and can highlight the strength or weakness o f current scientific evi­dence (US Congress, OTA, 1994).
Clarity
Guidelines will be more effective if they are explicit, and concisely worded. (US Congress, OTA, 1994) Clarity can be improved by for­mat as well as vocabulary and syntax. A format with easily identified subsections that address pertinent components, such as the charac­teristics described in this section, can improve the comprehension and usefulness o f the guideline.
Feasibility o f Implementation
Feasibility reflects the factors that make implementation easier. Such factors include keeping recommended practices as simple and focused as possible, integrating them into current practice as much as possible, accommodating effective quality improvement principles, addressing exceptions to recommended practices and flexibility for judgment, and describing potential administrative mechanisms to enhance implemen­tation (US Congress, OTA, 1994).
Simplicity
Guidelines that attempt to change a single, well-defined practice tend to be more successfully incorporated into practice than guidelines that address multiple behaviors and vaguely defined practices (US Con­gress, OTA, 1994). Unfocused guidelines that attempt to achieve mul­tiple, diverse objectives can become complex and lack clarity of purpose. For example, a guideline that recommends annual or biennial mammography for all women between 50 and 75 years of age will more likely be implemented than a strategy calling for annual breast ex­amination beyond age 40 with patient counseling about breast cancer and teaching o f breast self-examination. Differences in effectiveness aside, the latter recommendation includes multiple, complex activities that are poorly standardized.
Simplicity can also be addressed in the degree to which changes in cur­rent practice are called for in the guideline. A guideline that is inte­grated into current practices without substantial changes in staffing or routines will be more appealing than one requiring major structural changes (US Congress, OTA, 1994). Similarly, practice changes that require minimal effort to maintain will be more appealing than those requiring a high level of diligence and resources on an ongoing basis.
Quality Improvement
The opportunity to improve the quality of care is a fundamental incen­tive for implementation o f a public health guideline. W hen possible, guidelines should suggest methods for incorporating quality monitor­ing and improvement. For example, a key principle o f continuous
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quality improvement (CQI) is that guidelines are most effective when they focus on system changes designed to raise the average perform­ance o f all practitioners, as opposed to isolating and penalizing the worst performers (US Congress, OTA, 1994). Missed opportunities for vaccination could be tracked and physicians with low rates could be given incentives for increasing vaccinations. Alternatively, the rea­sons for under-vaccination could be determined and changes recom­mended that would improve the ability o f all physicians to vaccinate patients in need. If one o f the problems is not knowing who needs a vaccine at the time o f a visit, a flagging system could be proposed that would improve identification of children due for a vaccine so that it can be ordered (US Congress, OTA, 1994). This second approach gets at the root o f the problem and applies to all providers and not just the “bad performers.”
The ability to track performance is also central to CQI. The success of CQI relates to data-oriented decision making and ongoing feedback so that necessary modifications in the guideline can be implemented (Field and Lohr, 1992). Implementation o f guidelines at both the in­stitutional level and the national level should be considered part o f an iterative process that includes ongoing inquiry, refinement, and imple­mentation. Proposed guidelines should include realistic methods for measuring the implementation and effectiveness o f guidelines in order to facilitate this improvement process.
Flexibility
In the absence o f conclusive scientific evidence, guidelines represent current best practices, irrespective o f the rigor o f the development process. A guideline should leave room for clinical judgment by practi­tioners in a manner that is consistent with the strength o f the scientific evidence and the variation in individual risk and in practice effective­ness in different situations. The weaker the evidence and the greater the variation, the greater should be the flexibility. A guideline should address possible exceptions to recommended practices and the role of preferences o f relevant parties (patients, communities, employers, etc.) (Field and Lohr, 1992; US Congress, OTA, 1994).
Administrative mechanisms
Purposeful structuring o f administrative rules and procedures can fa­cilitate practice changes (US Congress, OTA, 1994). Delineation of potential administrative mechanisms within guidelines and recommen­dations may improve their implementation. Drug formulary commit­tees can influence the proper use o f medications by restricting access to certain drugs (US Congress, OTA, 1994). Automated reminders on computers and in medical records can increase awareness o f need for regularly provided services, like immunizations and cancer screening (US Congress, OTA, 1994). Standardized forms can also serve as re­minders for proper care in specific situations, such as a checklist for procedures and counseling during prenatal care visits or prescription
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information for certain medications. Administrative policies can in­crease guideline compliance by making procedures easier. Influenza vaccination was increased in settings where nurses had explicit instruc­tions for identifying and counseling patients and standing orders to provide influenza vaccination without active ordering by physicians (US Congress, OTA, 1994). Administrative and economic ap­proaches may be particularly effective when desired practices are clear and supported by consistent scientific evidence. A guideline that iden­tifies a variety of administrative mechanisms can facilitate implementa­tion by a wider range o f users.
Value of the proposed intervention
Value incorporates cost with the attributes of relevance, importance, quality, and feasibility. Value describes the net benefits of the pro­posed practices per unit of cost. A guideline should include a projec­tion of the value of implementing the proposed practices from a variety of perspectives (Field and Lohr, 1992). This statement o f value should help potential users clarify their personal or organizational rea­sons for implementing the guideline.
Perspective
The perspective defines the costs and benefits to be considered in im­plementing a guideline. A societal perspective is the broadest and con­siders costs and benefits from the standpoint o f the entire population (i.e., society). Public health and CD C would traditionally consider the societal perspective most appropriate for their constituency. Nonethe­less, attempts to intervene are usually at a level much smaller than the entire society, such as state or local health departments or hospitals, health maintenance organizations, and individual physician offices. While the societal perspective may be appropriate for the ultimate pur­pose, the perspective o f the health units being enlisted to achieve that purpose should also be considered (Field and Lohr, 1992). W hen the societal perspective drives the final decisions for the guideline, that de­cision should be explained and the impact of the guideline should be estimated from the other relevant perspectives. Altruism and public re­lations may drive some decisions of large health delivery systems, but ultimately, their interests are in the costs and benefits to their institu­tions and to their patients. Many clinical practitioners will not appreci­ate the national public health perspective if the implications for their practices and individual patients are not clear. The easier the costs and benefits can be identified from the users’ standpoint, the more readily the guidelines will be considered and implemented.
Legal Implications
Public health practice guidelines published by the federal government are frequently cited as evidence of the legal standard of care in litiga­tion settings. As such, recognition by a court that a federal recommen­dation is part o f the standard o f care in a given community provides a
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significant incentive for implementation. Standards of care carry liabil­ity implications that are powerful incentives for implementation (US Congress, OTA, 1994; W eingarten, 1995). Legal considerations can be a two-edged sword, however, as guidelines that are controversial can be contested in the judicial or litigation arena where scientific evi­dence may not be the primary concern (e.g., motorcycle helmet laws). Anticipating the possible legal implications o f guidelines is important. Accordingly, O G C should be consulted throughout the process of de­veloping guidelines. However, legal considerations should always be secondary to medical and scientific evidence relevant to the proposed guidelines.
Dissemination Strategies
Passive Dissemination
Passive dissemination of research findings and recommendations oc­curs through publication in professional literature, the lay media, and more recently, through electronic media such as the Internet. Current C D C guidelines are now accessible by the public through the Preven­tion Guidelines Data Base within the CDC home page on the World Wide Web. Passive dissemination is not, by itself, an effective means o f encouraging implementation unless the findings are dramatic and the effect is widely agreed to be clinically important and readily appli­cable. The use of aspirin for prophylaxis against morbidity and mortal­ity from myocardial infarction is a rare example o f effective passive dissemination. Myocardial infarction is widely accepted to be an im­portant condition and the intervention o f aspirin taken prophylacti- cally proved to be simple, inexpensive, and highly effective. In this instance, the scientific evidence and the source were credible and the findings were broadly publicized in the lay press, raising the awareness of consumers as well as providers. These circumstances led to the sub­stantial adoption of recommendations for aspirin prophylaxis in per­sons at high risk o f myocardial infarction (Krumholz, 1996). Generally, however, more active strategies will be necessary to improve adoption of guidelines (US Congress, OTA, 1994).
Clinical Peer Detailing
Local information networks and the recommendations o f respected colleagues are an important influence on clinical practice because nearly all clinical decisions are multi-factorial and depend on the unique characteristics o f the patient population and the practice envi­ronment (US Congress, OTA, 1994). Gaining endorsement from re­spected colleagues can allay some reluctance to change (Weingarten,1995). A specific approach to dissemination via peers is “detailing.” Detailing combines attractive dissemination features o f one-on-one in­teraction with a credible source and message tailored to the needs of the provider. Educational interventions are most likely to be successful in increasing guideline implementation when they provide opportu­
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nity for personal interaction, include respected clinical leaders, identify specific learning objectives, and when a guideline has strong support among colleagues (US Congress, OTA, 1994).
Consumer Information
In addition to changing the knowledge, beliefs, and practices of providers, consumer education is a valuable strategy for guideline dis­semination. When those who would benefit from a guideline are in­formed and demand the service, they are likely to influence provider decisions (US Congress, OTA, 1994). Health care systems, particu­larly managed care, are increasingly addressing patient satisfaction, and information can increase the patient’s sense of control and satisfaction with care. N ot only can consumers be valuable advocates for guide­lines, but the information strategy serves an important ethical obliga­tion for informed consent (US Congress, OTA, 1994).
Financial and Administrative Incentives
Financial incentives for adherence to a guideline appear to be effective at both the individual provider and the institutional level. Favorable re­imbursement policies can motivate changes in practice by providers (US Congress, OTA, 1994). The reduction in length o f hospitaliza­tion following implementation o f prospective, diagnosis-related pay­ment for inpatient services under Medicare in 1984 demonstrates how financial incentives at the institutional level can effectively change provider practices (US Congress, OTA, 1994). Performance report cards, such as the Health Plan Employer Data and Information Set (HEDIS), are indirect incentives used by purchasers of health care to assure adherence to quality care standards by health plans (National Committee for Quality Assurance, 1996). Competitive and reim­bursement incentives such as these at the organizational level can be translated to administrative and financial incentives at the provider level.
Practice profiling, the data-oriented review and feedback o f provider practice patterns and outcomes, is a specific administrative mechanism designed to reduce practice variation and bring conformity with guide­lines and standards o f care (US Congress, OTA, 1994). The strategy is most effective when individualized, presented by a respected peer, and provided in a context for peer practices. The providers must agree with the proposed practices. This approach tends to be more effective when attempting to increase a particular practice, in contrast to discon­tinuing an unnecessary practice (US Congress, OTA, 1994). The feedback information is most useful when it identifies a process that can be changed (e.g., below average use o f inhaled steroids for asthmat­ics) instead o f an outcome that may have numerous interrelated causes (e.g., asthma death rates).
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Intensity o f  Dissemination
The greater the dissemination effort, both in terms o f venues and quantity, the more effective will be the implementation o f a guideline (US Congress, OTA, 1994). To be successful, a guideline must ad­dress the range of influences relevant to the practice being addressed. Combinations o f intervention strategies are more effective than single interventions strategies.
• Follow-up of Dissemination
Continued efforts must be made to assess the effectiveness o f dissemi­nation efforts and to identify opportunities for changes (US Congress, OTA, 1994). Even effective dissemination strategies may benefit from ongoing promotional efforts to remind users o f the guideline.
Figure 3. Framework for Encouraging th e  Adoption of Guidelines
Appeal D issem ination  S tra teg ie s  U sers
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Glossary
Administrative issues. Issues o f resource mobiliza­tion and process control complementary to the central scientific tasks of guideline development.
Advocacy. W orking for political, regulatory, or or­ganizational change on behalf o f  a particular in­terest group or population.
Alternative approaches. Examples o f different ways o f accomplishing the same guideline develop­m ent task.
Analytic framework. A  flow chart, influence dia­gram, decision tree, or clinical algorithm used to describe or illustrate the chain o f causal reason­ing which links a recommended health practice to the desirable health outcomes in a defined in­dividual or population by means o f credible evi­dence o f effectiveness.
Archival research. Examining reports, newspaper clippings, correspondence, books, and other documents prepared by persons other than the researcher and kept in archives (e.g., libraries). Archival sources can reveal changes in practitio­ner perceptions and practices over time.
Assessment. Estimation o f the relative magnitude, importance, or value o f objects observed.
Attitude. A relatively constant feeling, predisposi- tion,or set o f beliefs directed toward an object, person, or situation.
Behavior. An action that has a specific frequency, du­ration, and purpose, whether conscious or un­conscious.
Belief. A statement or proposition, declared or im ­plied, that is emotionally and/or intellectually ac­cepted as true by a person or group.
Benefits. Valued health outcomes or improvements in quality o f life or social conditions having some know n relationship to health prom otion or health-care interventions.
Cinical preventive service. A  prim ary care clinicalpractice or preventive intervention screeningtest, counseling intervention, immunization, or chemoprophylactic regimen— for target condi­tions among asymptomatic individuals of all age groups and risk categories.
Community. A collective o f  people identified by com m on values and m utual concern for the de­velopment and well-being o f their group or geo­graphical area.
Community forums or workshops. Intensive meet­ings o f  interest groups assembled to discuss is­sues surrounding proposed guidelines and to reach an understanding among the participants about needs, scope, format, timetables, and roles.
Core functions o f public health agencies. Theunique functions o f public health agencies at all levels o f government: assessment, policy develop­ment, and assurance.
Assessment. Regular and systematic collection, assembly, analysis, and dissemination o f inform a­tion on the health of the com m unity, including statistics on health status, health needs, and epidemiologic and other studies o f health prob­lems.
Policy development. Prom oting the use o f the scientific knowledge base in decision-making about public health, leading in developing public health policy, and taking a strategic planning ap­proach to influencing the democratic political process to serve the public interest in good health.
Assurance. Assuring agency constituencies that services necessary to achive agreed upon goals are provided, either by encouraging actions by other entities (private or public), by requiring such ac­tion through regulation, or by providing services directly.
Cost-effectiveness. A measure o f the cost o f an inter­vention relative to its population impact, usually expressed in dollars per unit o f  health outcome achieved.
Decision analysis. An explicit, quantitative, system­atic approach to decision making under condi­tions o f  uncertainty.
Delphi technique. A m ethod o f sampling the opin­ions or preferences o f  a small num ber o f  experts, opinion leaders, or informants, whereby succes­sive questionnaires are sent by mail and the re­sults (rankings or value estimates) are summarized for further refinement on sub­sequent mailings.
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Desirable attributes o f guidelines. Quality charac­teristics which help to persuade users that guide­lines are trustworthy, easy to put into practice, and effective in achieving desired health out­comes.
validity Supported by strong evidence link­ing recommendations to outcomes. 
reliability or reproducibility Prepared using procedures and decision rules that would lead different experts to the same conclu­sions based on the same evidence. 
applicability [in practice] Useful in popula­tions that potential users would consider relevant to their practices. 
flexibility [in practice] Allowing for practi­tioner judgm ent and patient preferences. 
clarity Presented in unambiguous language and easy-to-follow logic. 
multidisciplinary process Prepared with in­put from relevant disciplines and stakehold­ers.
up to date [scheduled review] Reflecting the most recent evidence and including a writ­ten timetable for future revision. 
well documented Published along with ex­plicit statements on assumptions, process, ra­tionale, evidence, and decision rules.
Effectiveness. The improvement in health outcome that a prevention strategy can produce in typical community-based settings.
Efficacy. The improvement in health outcome that a prevention strategy can produce in expert hands under ideal circumstances.
Emerging health problem. Recently discoverd or re­discovered public health problem  such as such as hantavirus pulm onary syndrome or m ultidrug-re­sistant tuberculosis.
Enabling factors. Necessary skills and resources (fi­nances, staff, space, and educational materials) which the professional must possess in order to successfully implement the guideline’s recom­mendations.
Essential public health services A list o f ten catego­ries o f  public health activities which the US Pub­lic H ealth Service considers essential for m aintaining optimal com m unity health status. 
M onitoring health status to identify com­m unity health problems.
Diagnosing and investigating health prob­
lems and hazards in the community. 
Informing, educating, and empowering peo­ple about health issues.
M obilizing com m unity partnerships to iden­tify and solve health problems.
Developing policies and plans that support individual and com m unity health efforts. 
Enforcing laws and regulations that protect health and ensure safety.
Linking people to needed personal health 
services and assuring the provision o f health care when otherwise available.
Assuring a com petent public health and per­sonal health care workforce.
Evaluating effectiveness, accessibility, and quality o f personal and population-based health services.
Researching for new insights and innovative solutions to health problems.
Focus group interviews. Informal group interviews in which eight to 12 potential users o f a pro­posed guideline are asked to discuss their thoughts and feelings about the issue. Those thoughts and feelings are then used to help clar­ify the content, delivery, and appeal o f  the pro­posed guidelines.
Group process methods. Formal techniques for maximizing the contributions o f  all participants in the guideline development process.
Guideline development method. A set o f rules of procedure for collecting evidence o f effectiveness o f  a health practice and for making group deci­sions about the quality and sufficiency o f that evidence in supporting specific practice recom­mendations.
Informal consensus. Participants on an ex­pert panel decide on what to recommend on the basis o f open discussion during one or more meetings. Because the process is infor­mal, the recommendations are often not ac­companied by explanations o f  the causal reasoning which links the recommended pro­fessional behavior, credible evidence o f effec­tiveness, and the desirable health outcomes. 
Formal consensus. Participants on an expert panel decide on what to recommend by con­sensus during the course of a structured two and one-half day conference. The meetings
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provide greater structure to the analytic process than the informal consensus method. Consensus statements do not usually include references to the literature, nor the underlying rationale or evi­dence behind any recommendations or conclu­sions.
Evidence-based. The evidence-based m ethod aims to explicitly link practice recommendations to the underlying scientific evidence o f effective­ness.
Explicit method. A subcategory o f the evidence- based m ethod w hich relies on mathematical m odeling and other formal analytic methods to generate estimates o f  the probability o f  occur­rence o f specific benefits, harms, and costs o f  al­ternative practices.
Guideline development task. An activity or piece of work that results in a product needed to plan, de­velop, disseminate, and encourage users to adopt a guideline. The C D C  guideline development process is divided into 13 discreet tasks.
Planning and coordinating the process. Definin- ing objectives, mobilizing resources, and oversee­ing activities to ensure timely and efficient achievement o f defined objectives.
Assessing user needs. Finding out about the na­ture, extent, and determinants o f current prac­tices regarding the candidate intervention, technology, or health problem o f interest in the population o f prim ary guideline users; and guag- ing the level o f  com m on concern and consensus on the potential utility o f  the proposed guideline. 
Choosing guideline topics. Deciding on the top­ics that should be given priority for guideline de­velopment and explaining the rationale for each choice.
Selecting guideline panels. Choosing the mem­bers and leaders o f the panel o f  experts and other participants who will assess the scientific evi­dence and formulate guideline recommendations. 
Defining the scope of guidelines. Delim iting the target population, outcomes, and interven­tions which are (1) of greatest interest to specific practitioners, the public, and other users, (2) most amenable to clarification by means o f sys­tematic assessment and synthesis o f  scientific evi­dence, and (3) capable o f being fully explored and resolved into clear and specific advice within the limitations o f  time and resources.
Clarifying the method and analytic framework. Justifying the use o f  one or more guideline devel-
opm ent methods (informal consensus, formal consensus, evidence-based, or explicit) and de­scribing or illustrating the chain o f causal reason­ing which links the recom m ended health practice to the desirable health outcomes in a de­fined individual or population by means o f  cred­ible evidence o f effectiveness.
Identifying and synthesizing the evidence. Seek­ing, collecting, and assessing the quality and quantity o f  empirical evidence o f the effective­ness o f  a proposed intervention for ensuring a de­sirable health outcome in a defined population. Empirical evidence o f effectiveness must be sys­tematically identified, synthesized, and docu­mented using methods that minimize bias and maximize precision.
Aiding group interaction and decision making.Using formal techniques to maximize the contri­butions o f all participants in the guideline devel­opm ent process. Group interaction methods add clarity and explicitness to group decision mak­ing, balance power among participants, m ini­mize bias, and ensures docum entation o f decision rules and products.
Identifying a research agenda. Identifying a list o f study questions or areas o f inquiry that should receive high priority for scientific investigation and funding. The prim ary source o f  study ques­tions is the analytic framework, its assumptions, and presumed causal linkages for which existing evidence is inadequate.
Updating the guideline. Deciding on a timeta­ble for revising the guideline to reflect new scien­tific knowledge. The timetable is determined by the strength o f current supporting evidence and expectations about new discoveries, effectiveness o f the guideline, and changes in the practice envi­ronm ent.
Writing the guideline. Preparing a docum ent written with unambiguous language and easy-to- follow logic that provide clear recommendations and docum ent the rationale on which the recom­mendations are based.
Obtaining critical reviews and public comment.Obtaining input from content and policy ex­perts, practitioners, advocates, and the public about the scientific accuracy, completeness, and ease o f im plem entation o f the draft guidelines. Revising the draft guideline in response to such feedback from potential users and other inter­ested persons can increase the credibility o f  the guidelines.
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Encouraging adoption o f the guideline. En­suring that the guideline is appealing, widely disseminated, and encourages potential users to accept and im plem ent the recommended practices.
Health outcome. A medically or epidemiologically defined characteristic o f  a patient or health prob­lem in a population that results from health pro­m otion or care provided or required as measured at one point in time.
Health promotion. A planned com bination o f educa­tional, political, regulatory, and organizational supports for actions and conditions o f  living con­ducive to the health o f individuals, groups, or communities.
Idea writing. This technique prom otes group interac­tion in large groups by w riting rather than by dis­cussion. The large group is divided into working groups o f 4 to 5 individuals; participants react in writing to a stimulus question or item and then place their pad (with the initial response) in the center o f the group; each participant reacts, in writing, to what is written on each o f  the other pads; participants read the comments made in re­action to their initial response; the small working groups discuss the principal ideas that emerge from the written interaction; and the group sum­marizes the discussion in writing.
Implementation. The act o f converting guideline rec­om m endations into actions through policy, regu­lation, and organizational incentives.
Influence diagrams. Diagrams o f factors that are im­portant in a decision and the interrelationships between factors in a model resembling a flow chart. M athematical calculations can be per­formed for models if  numerical values are as­signed to designate the probability of certain events happening and the utility, or perceived usefulness, o f each possible outcome.
Intervention. The part o f  a health strategy, incorpo­rating m ethod and technique, that actually reaches a person or population.
Key informant interviews. In-depth, semi-structured interviews with individuals who are selected to participate because they have special knowledge or insight not available to others in their refer­ence group hence the label “key inform ant.”Recorded or written transcripts o f  the interviews are then analyzed to uncover themes and the rela-
tive importance o f frequently m entioned issues relating to guideline development and use.
Meta-analysis. D ata from multiple studies are synthe­sized to give a statistical measure (e.g., an odds ra­tio or relative risk) o f effect and an assessment o f its significance. The com bination o f data from several studies increases both the statistical power and ability to generalize.
Narrative literature reviews. Expert opinion papers, in journals and text books, which lack systematic rules for acquiring or consolidating the evidence. In a traditional narrative review o f the medical literature, a subject-matter expert reviews studies, decides which are relevant to a particular topic, and highlights findings in terms o f results and, to a lesser degree, methodology.
Need (professional). An estimate o f  the knowledge, skills, motivation, and incentives that a practitio­ner requires to encourage use o f a proposed guideline.
Negotiated rule making techniques. A  consensus- based approach in which a committee o f affected interested parties (agency regulators and the regu­lated parties), meets with a skilled mediator. The goal is to reach consensus on the proposed pol­icy. Negotiations that do not result in consensus can also be useful by narrowing issues in dispute, identifying inform ation necessary to resolve dis­putes, ranking priorities, finding potentially ac­ceptable solutions, and improving the agency’s understanding o f the real-world impact o f alter­native options.
Nominal group process or technique. A technique which elicits w ritten responses to a single ques­tion w ithout verbal interaction among group members. The process would include small groups o f five to nine potential guideline users to assess target group perceptions o f  need and obsta­cles to meeting that need. It reduces the ten­dency for the more socially powerful to dom inate the discussions and to bias the consen­sus that emerges.
Planning. The process o f defining needs, establishing priorities, diagnosing causes o f problems, assess­ing resources and barriers, and allocating re­sources to achieve objectives.
Policy. Objectives and rules guiding the activities of an organization and providing authority for allo­cation o f resources.
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Predisposing factors. Professional’s values, beliefs, at­titudes, and perceptions about guidelines and their potential usefulness. These factors account for the professional’s motivation to use guide­lines and confidence in being able to implement their recommendations.
Prevention effectiveness. A systematic effort to asses the impact o f public health policies, programs, and practices on costs and health health out­comes.
Prevention program. A set o f planned activities over time designed to achieve specified objectives in terms o f health problems prevented.
Program evaluation. An assessment o f the processes, impacts, and outcomes o f program activities in relation to the objectives, standards o f accept­ability, and expectations of stakeholders.
Public health practice guideline. A systematically de­veloped statement which helps policy-makers, public health practitioners, clinical practitioners, health agencies, and the public decide on appro­priate actions to (1) prom ote health, (2) prevent disease, disability, and prem ature death, and (3) improve quality o f life o f members o f a defined population. Appropriate actions may target indi­viduals or whole communities at risk for adverse health outcomes.
Public health practice. Organized com m unity effort (public and private) to address the public interest in health by applying scientific and technical knowledge to prevent disease and prom ote health.
Qualitative methods for assessing needs. Tech­niques adopted from the social sciences to elicit an “insider’s view” (study participants or partici­pant observers) o f how members o f a group un­der study perceive their own needs for guidelines, how they are likely to react to such guidelines, and what positive or negative conse­quences they expect to result from the use o f  those guidelines.
Quality assessment. M easurement o f  professional or technical practice or service for comparison with accepted standards to determine the degree o f ex­cellence.
Quality assurance. Formal process o f implementing quality assessment and quality im provement in
programs to assure stakeholders that professional activities have been performed appropriately.
Quality of life. The perception o f individuals or groups that their needs are being satisfied and that they are not being denied opportunities to achieve happiness and fulfillment.
Quantitative methods for assessing needs. N um eri­cal measurements and statistical techniques that estimate aggregate characteristics of the group under study and support inferences which can be generalized to a larger reference population.Such methods include sample surveys and syn­thetic estimates from administrative data sources.
Reinforcing factors. Rewards or incentives that are anticipated or that actually follow as a conse­quence o f a particular behavior. They include re­imbursements actually received, visible improvements in patient or population health outcomes, support from colleagues, and feed­back from patients or clients.
Research agenda. A list o f study questions or areas of inquiry that should receive high priority for sci­entific investigation and funding.
Self-efficacy. A construct from social learning theory referring to the belief an individual holds that he or she is capable o f  perform ing a specific behav­ior.
Stakeholders. People who have an investment or stake in the outcome o f an intervention or pro­gram and therefore have reasons to be interested in the evaluation o f the program.
Strategy. A plan o f action that anticipates barriers and resources in relation to achieving a specific objective.
Systematic literature reviews. Reviews based on rules to identify studies and collate inform ation from studies. Such reviews are often the initial step in meta-analyses.
Value. A preference shared and transm itted within a community.
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APPENDIX A: DESIRABLE ATTRIBUTES OF CLINICAL PRACTICE GUIDELINES1
Attribute Explanation
VALIDITY Practice guidelines are valid if, when followed, 
they lead to the health outcomes projected for 
them. A prospective assessment of validity will 
consider the substance and quality of the 
evidence cited, the means used to evaluate the 
evidence, and the relationship between the 
evidence and recommendations.
Strength of Evidence Practice guidelines should be accompanied by 
descriptions of the strength of the evidence and 
expert judgment behind them.
Estimated O utcom es Practice guidelines should be accompanied by 
estimates of the health and cost outcomes expected 
from the interventions in question, compared with 
alternative practices. Assessments of relevant 
health outcomes will consider patient perceptions 
and preferences.
RELIABILITY/ Practice guidelines are reproducible and reliable (1)REPRODUCIBILITY if—given the same evidence and methods for 
guidelines development—another set of experts 
produces essentially the same statements and (2) If- 
--given the same clinical circumstances—the 
guidelines are interpreted and applied consistently 
by practitioners (or other appropriate parties).
CLINICAL APPLICABILITY Practice guidelines should be inclusive of 
appropriately defined patient populations as 
evidence and expert judgment permit, and they 
should explicitly state the population(s) to which 
statements apply.
1 IOM (Institute of Medicine). Summary. Table 1. In Guidelines for Clinical
Practice: From Development to Use. M.J. Field and K.N. Lohr, editors. Washington,
DC: National Academy Press, 1992.







Practice guidelines should identify the specifically 
known or generally expected exceptions to their 
recommendations and discuss how patient 
preferences are to be identified and considered.
Practice guidelines must use unambiguous 
language, define terms precisely, and use logical 
and easy-to-follow modes of presentation.
Practice guidelines must be developed by a process 
that includes participation by representatives of key 
affected groups. Participation may include serving 
on panels that develop guidelines, providing 
evidence and viewpoints to the panels, and 
reviewing draft guidelines.
Practice guidelines must include statements about 
when they should be reviewed to determine whether 
revisions are warranted, given new clinical evidence 
or professional consensus (or lack of it).
The procedures followed in developing guidelines, 
the participants involved, the evidence used, the 
assumptions and rationales accepted, and the 
analytic methods employed must be meticulously 
documented and described.
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APPENDIX B: PROVISIONAL INSTRUMENT FOR ASSESSING CLINICAL
PRACTICE GUIDELINES1
KATHLEEN N. LOHR AND MARILYN J. FIELD
Division o f Health Care Services
The Institute of Medicine (IOM) of the National Academy of Sciences has been 
engaged since the beginning of 1990 in two projects relating to the development, 
implementation, and evaluation of clinical practice guidelines. One IOM committee defined 
practice guidelines as "systematically developed statements to assist practitioners and 
patients in choosing appropriate health care for specific clinical conditions." It also 
delineated several desirable attributes of guidelines that are intended to help users 
understand the elements of a sound guideline and to recognize good (or not-so-good) 
guidelines.
These aspects of guidelines were discussed in Clinical Practice Guidelines: Directions for 
a New Program (IOM, 1990) and Guidelines for Clinical Practice: From Development to 
Use (this report).
The first IOM study committee discovered that no explicit method was available for 
assessing existing or emerging practice guidelines. At Ieast one instrument was being 
tested to assess some aspects of guideline development (AMA, 1990), but nothing existed 
to judge the quality, reliability and validity of the content of the guideline itself. Therefore, 
one task the second IOM committee undertook was to develop an "assessment instrument" 
that could be used by various parties in formal evaluations of guidelines.
The next sections of this document describe, first, the purposes of the "provisional" 
assessment instrument and, second, its development. The discussion covers several 
features of the instrument and its application, notes several cautions and caveats about 
the present form , all of which warrant further consideration. Finally, the document 
presents the instrument itself, in three operational parts—a general information sheet, the 
full instrument, and a summary evaluation sheet. The instrument is termed provisional 
because the committee firmly believed that more experience needs to be accumulated by 
testing it on different kinds of guidelines.
PURPOSES OF THE ASSESSMENT INSTRUMENT
The central purpose of the IOM's instrument for assessing clinical practice 
guidelines is to provide an explicit method for examining the soundness of such guidelines 
and to encourage their systematic development. By assessment is meant a prospective 
judgment of the soundness of both the process used in developing a guideline and the 
resulting guideline. The intent is to avoid situations in which a guideline that is not
MOM (Institute of Medicine). Appendix B. In Guidelines for Clinical Practice:
From Development to Use. M.J. Field and K.N. Lohr, editors. Washington, DC: National 
Academy Press, 1992.
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consistent with the scientific evidence is nonetheless "rated" as good on procedural criteria 
alone.2
More concretely, the IOM intended to operationalize its attributes of good guidelines 
and to provide a standardized approach and structure for the assessment of a guideline 
document. The resulting form is not simple. Therefore, the IOM does not expect practicing 
physicians or other clinicians, patients, other nonprofessionals, or policymakers to apply 
this instrument. Rather it expects individuals (or groups) with three types of expertise to 
apply it---namely, those with clinical experience with patients who have the conditions or 
problems covered by the guideline document, those with research experience in the 
conditions or technologies covered, and those with methodologic skills in developing 
guidelines. Any final or overall judgments of a guideline document emerging from the 
application of this instrument would be reported in simpler, summary form in ways that 
would convey the relative soundness (or lack of it) of a given guideline document to all 
potential users of the guideline.
The IOM committee sees three possible uses of this instrument: as an educational 
tool, as a self-assessment tool, and as a means of judging guidelines before their 
adoption. The Agency for Health Care Policy and Research (AHCp R) may want to use this 
instrument, or one like it, in directing the work of its guidelines-development panels; the 
agency may also wish to employ it in judging the products of those panels or the guidelines 
developed by other groups, such as medical specialty societies. Furthermore, other groups 
may wish to review existing or draft guidelines of their own against this instrument, in an 
effort to identify guidelines warranting revision or defects in draft guidelines that warrant 
correction before they are put into final form. Finally, if an organization were to be created 
for the express purpose of certifying or otherwise reporting on the soundness of particular 
guidelines, it might wish to employ the instrument as part of its review activities.
DEVELOPMENT PROCESS
The concept of the instrument originated during discussions with members of the 
AHCPR staff about their responsibilities for practice guidelines under the Omnibus Budget 
Reconciliation Act of 1989. In seeking to respond to those early ideas, the IOM committee 
went through four steps.
First, with the aid of an outside consultant, staff drafted a set of questions to 
operationalize the eight conceptual attributes of good practice guidelines identified in the 
IOM's 1990 report on guidelines.3 (Discussions of these attributes introduce sections of 
the assessment instrument.) Second, these questions were combined with background 
information and instructions for users and subjected to considerable internal and external
2Evaluation of the eventual impact of guidelines is a separate step. Both IOM 
reports (1990 and this one) include discussions of evaluation.
3Anne-Marie Audet, M.D., of the Health Institute. New England Medical Center. 
Inc., served as consultant during the initial stage of the project.
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review, as described below. Members of the IOM committee twice reviewed drafts of the 
assessment instrument during this time.
Third, IOM staff used the critiques and suggestions of reviewers to revise the 
instrument, and it, together with background material, was subjected to external review 
according to IOM and National Research Council (NRC) procedures. Fourth, the 
instrument was revised in response to that external review, resulting in the provisional 
questionnaire and other forms incorporated into this document.
Initial Reviews
An interim draft of the instrument was sent to AHCPR in December 1990 and was 
subsequently forwarded to several professional societies that had volunteered to review 
and test the instrument against guidelines of their own. By June 1991, the committee had 
received more than 15 separate responses and commentaries. Responses included a 
lengthy summary review provided by IMCARE (Internal Medicine Center to Advance 
Research and Education), which had solicited reviews from the 231 internists then in its 
Guideline Network. IMCARE also sent the document to 147 physicians who requested 
more information and received 65 responses from network members who reviewed and, 
in many cases, applied the instruments to real guidelines.
Reactions to the draft instrument were extremely varied. With respect to format, 
instructions, ease of use, and similar issues, positive comments included the following:
•  "Well written-concise.”
•  "The instrument was easy to apply and the definitions of attributes were helpful in 
driving the assessment."
•  "The meaning of each attribute, the instructions, and response categories were
generally clear."
•  "Overall, the instrument provides a precise algorithm for examining the degree to 
which a clinical guideline meets defined aspects of seven attributes. In our opinion, 
the instrument can be used for its intended purpose. In addition, application of an 
instrument such as this is, in itself, a thought-provoking exercise for individuals 
active in developing clinical practice guidelines."
By contrast, negative comments were of the following kind:
•  "The form seems excessively lengthy and not particularly user-friendly."
"The instructions are verbose and redundant, and almost legalistic. They are not 
user-friendly."
•  "This instrument was very confusing, almost 'impossible.’”
•  "Instrument of intellectual torture. Beyond Bureaucracy! . . . This makes me feel
stupid!"
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A form that accompanied the instrument asked reviewers to indicate the time (in 
person-hours) needed to apply the assessment instrument to a guideline of their choice. 
Among 59 individuals in the IMCARE group who evidently applied the instrument to an 
actual guideline and completed the form, 13 said that the instrument took under two hours 
to apply, 38 said two to three hours, and 8 said four hours or more. Several commentators 
indicated that their learning curve was quite steep and that repeated use of the instrument 
would make it simpler and less time-consuming to apply.
In rating the overall difficulty of understanding or using the assessment instrument, 
the majority of respondents indicated that it was moderately to very difficult. In addition, 
the great majority found the instrument good or at least somewhat helpful in helping them 
reach an overall judgment of the strengths and weaknesses of the guideline they were 
evaluating. Finally, more than half indicated that the instrument definitely should be 
revised; most of the rest were uncertain or had no opinion, and only about I in 10 advised 
abandoning the effort.
Among the more concrete recommendations for revisions were the following: (l) add 
more "don't know" or "not applicable" responses to certain questions, (2) simplify and 
shorten the instructions; (3) include a "prologue" containing pertinent information from the 
first IOM (1990) report on guidelines, which defines key terms and similar concepts; (4) 
consider adding an attribute related to endorsement by appropriate affiliated or outside 
organizations; and (5) clarify exactly who the intended users are. In addition many 
reviewers offered comments on the draft instrument itself, chiefly observations about the 
wording of questions and the addition of response categories. More general suggestions 
included employing the instrument to help generate guidelines (rather than rate them) and 
using the instrument to guide an assessment process (without necessarily requiring that 
the instrument be completed in full).
Final Reviews
In accordance with IOM and NRC procedures, the revised instrument was subjected 
to an external, anonymous review by a panel similar to the full IOM committee. The 
"provisional" form in this document reflects the reactions of this group of seven experts, 
and many of their comments have been incorporated into the discussion presented here.
IMPORTANT FEATURES OF THE PROVISIONAL ASSESSMENT INSTRUMENT 
Attributes of Practice Guidelines
Types o f Attributes
Four attributes identified in the first IOM report on practice guidelines concern the 
substance of the guidelines—clinical applicability or scope, clinical flexibility, 
reliability/reproducibility, and validity. Four others—clarity, multidisciplinary process,
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scheduled review, and documentation—have more to do with process. This instrument 
explicitly incorporates all attributes but documentation; that attribute is captured in 
questions directed at the other seven. Each attribute is described in the text of the 
instrument.
Implicit Weight Accorded to Different Attributes
As discussed below, this instrument has no explicit or quantitative scoring system. 
The attributes are implicitly weighted, however, according to the number of main questions 
used to cover them. Of a total of 46 questions, validity has 22 questions; clarity, 8; 
multidisciplinary process. 4; clinical flexibility, 4; reliability and reproducibility, 4; clinical 
adaptability. 3; and scheduled review, 1. By this rough metric, validity is accorded by far 
the major emphasis in the document, reflecting the committee's concern for finding a way 
to judge the soundness of the guidelines themselves rather ' than just the acceptability of 
the development process.
Q uestions and R esponse Categories
Questions
Most of the seven attributes are dealt with through one or more questions that tap 
specific "dimensions." For example, validity is divided into five issues: (1) strength of the 
scientific evidence and professional consensus; (2) qualitative and quantitative statements 
about health benefits and harms or risks; (3) qualitative and quantitative statements about 
expected health costs or expenditures; (4) the extent to which specific recommendations 
are justified by the estimates of benefits, harms, and costs provided in the guidelines and 
the extent to which those estimates are supported by the evidence amassed in the 
guidelines document; and (5) potential conflicts among existing guidelines, if any.
The instrument has 46 descriptive questions related to the seven attributes. 
Generally they pertain to the presence of information about the attribute or about a 
particular dimension of an attribute. Several questions have additional "items" designed 
to help assessors think about key points implied by the main question and whether a 
particular dimension of an attribute is satisfactory or not.
Responses to Questions
Responses to each question are typically "yes" or "no" for questions asking about 
the presence or absence of certain information, features, or development processes. If the 
answer is "yes," a follow-up question asks about the quality of that information, feature, or 
development process---essentially whether the information provided is satisfactory or not. 
If the answer to the main question is "no," the follow-up question probes the significance
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of the absence of information, a particular feature, or development process and asks 
whether the omission is important or not.
Satisfactory. Assessors can judge information about a particular attribute as 
satisfactory if all critical elements have been considered and presented. For example, the 
discussion or description should be thorough and comprehensive; the guideline 
developers should have based their work on appropriate and correct information (e.g., 
from the literature review); and they should have used appropriate methods (e.g., for 
evaluating the strength of the scientific evidence or reaching professional peer 
consensus).
Conditionally satisfactory. The description or discussion of an attribute or dimension 
is conditionally satisfactory if some, but not all, of the critical elements have been 
considered and presented. For example, the discussion of a particular aspect of an 
attribute such as scheduled review may be vague or incomplete. Alternatively, guidelines 
developers may have disregarded important information (about, for instance, likely risks 
to patients from the use of a technology) in reaching their recommendations, or they may 
have improperly used certain kinds of methods. These problems with the guideline 
document may not prevent a clinician from using it or understanding its recommendations, 
but they may affect its overall usefulness or call certain recommendations into question. 
Revisions would be presumed to improve the guidelines, but they would not be mandatory.
Unsatisfactory. The description or discussion about a specific attribute is 
unsatisfactory if most of the critical elements have not been considered or presented. For 
example, well-known pieces of clinical information (or the views of multiple specialists with 
an interest in the guideline topic) may have been ignored; methods of analysis may have 
been misapplied; or recommendations may be based on faulty information or poor logic, 
or both. In such a case, it would be difficult if not impossible to judge the quality of the 
process of guideline development or the soundness of the resulting guidelines and 
recommendations (or both); certainly assessors could not mark those attributes as 
satisfactory. Serious thought must be given to augmenting or revising the guidelines 
document before it is promoted further.
Omissions. Omitting a description or discussion about a specific attribute or 
dimension may be unimportant if that omission seems likely to have no demonstrable 
effect either on the ability of a guideline user to apply the guideline effectively in the 
clinical decision-making process or on the capacity of the assessor to make an 
independent assessment of the quality of that attribute. Omitting such a description or 
discussion is of minor importance if it seems likely to affect negatively the ability of a 
guideline user or of evaluators to apply the guideline effectively or independently to assess 
its quality. Finally, omitting such a description or discussion is a major omission if the 
absence of such information essentially prevents guideline users or evaluators from 
applying the guideline effectively or even making an independent evaluation about the 
soundness of the guidelines document itself (at least on that particular feature).
Special Cases
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Special cases may arise in which information appropriately is omitted from the 
guideline because the question or item is not applicable or is inappropriate (given 
responses to earlier items, for instance). In such an instance, the assessor is asked to 
mark the response category most appropriate for the given case (e.g., not applicable). In 
other situations, assessors may find it difficult to arrive at a single answer to the question, 
especially if the guidelines document being evaluated is very complex or if necessary 
background information appears to be missing. "Comments" sections are provided 
throughout for assessors to record additional remarks or qualifying statements, to highlight 
areas not well covered by the instrument, and to note special factors that should either be 
followed up or taken into account in the overall judgment about the guidelines document. 
Finally, if assessors conclude that the guidelines document is so complex, clinically 
esoteric, or methodologically sophisticated that it warrants additional, outside expert 
review, they are asked to note that at the end of the full instrument and also on the 
summary evaluation sheet.
Alternative Approaches to Responses
The main type of response used in this form is categorical (e.g., satisfactory, 
conditionally satisfactory, and unsatisfactory). Some reviewers noted that this approach 
is inherently constraining and requires definitions of the three categories, which may not 
be interpreted consistently. Furthermore, these categories do not allow assessors to 
distinguish guidelines that more properly should be characterized as excellent or 
outstanding. To overcome some of these drawbacks, an approach to responses based on 
a scale might be tested.
For example, a five- or even seven-point scale might be adopted, with one end of 
the range described as excellent (exemplary, highly satisfactory, or a similar superlative) 
and the opposite end described as poor (inferior, or very unsatisfactory). The equivalent 
approach might also be tried for the responses concerned with omissions of information. 
The committee believes this change warrants testing at some point in the future 
development of this form.
R esponse  Scoring
After considerable debate and consideration of reviewers' comments, the committee 
concluded that this instrument should not be "scored" in any quantitative way. Thus, it 
does not propose any formal weighting or numerical scoring scheme for the main 
questions, nor does it suggest a particular threshold, cutpoint, or floor against which 
current guidelines might be judged acceptable or unacceptable. If most responses to the 
questions are "satisfactory" (or "unimportant omissions"), however, one might reasonably 
conclude that such a guidelines document would be sufficient for most clinical situations. 
Alternatively, if most responses were unsatisfactory (or major omissions), one would 
probably argue that the guidelines document needed to be revised before it could be used 
effectively.
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The committee was of the view that a defensible scoring system could not be 
designed a priori in any case, regardless of whether scoring would be purely categorical 
or more quantitative. Review and testing of the assessment instrument itself—with 
revisions as necessary—will be required before a sensible scoring system can be 
proposed. Moreover, different users of the assessment instrument may have legitimate 
reasons to differ on where they would establish such cutpoints. Provision of information 
on the quality of guidelines documents appears to be more in the public interest than is 
making "one-size-fits-all" judgments on behalf of others.
In the same vein, no single question is treated as the signal of a "fatal flaw." That 
is, for no question will a response of "no,MMunsatisfactory," "major omission" by itself render 
the guidelines document unacceptable. Some committee members believed that certain 
questions, especially those relating to validity, should be so designated. However, the 
questions that seem to be the most likely candidates for this level of decisiveness4 were 
added in response to the external review of the draft document; therefore they have not 
yet been reviewed or tested further. The committee believes designating these (or other) 
items as potentially "fatal" is premature.
R esponse Aggregation and Display
General Comments
Information obtained from applying the instrument might eventually be arrayed in 
one or more qualitative, summary displays or tables, as might be done, for instance, by a 
Consumer Report article. This might provide a rough indicator of whether the guidelines 
document could be used effectively in clinical situations. One reviewer, for example, 
suggested that a report for busy practicing physicians might usefully include "a graphic 
summary of the degree to which each attribute was successfully achieved, e.g., a bar 
representing the percent of key items within each attribute that were deemed satisfactory 
. . .; and . . . a brief, narrative summary assessment."
Summary Evaluation Sheet
The committee did not pursue the design of such displays, chiefly because such an 
effort was seen as premature for an instrument that itself warrants additional testing and 
application. As an intermediate step, however, the instrument does include a "summary 
evaluation sheet," which is actually a set of pages that condense the findings of the
4Two questions that might be candidate "fatal flaw" items, when responses to them were unacceptable (i.e., 
"no"), are the following from the validity section:
•  Generally, the estimates of benefits, harms, and costs are consistent with the evidence presented in the 
guidelines document. (Yes, completely; yes, partially; or no) (Question 28)
•  Each major recommendation is consistent w ith the estimated benefits, harms, and costs of the service or 
intervention (and thus with the strength of the evidence). (Yes, completely; yes. partially; or no) (Question 31).
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assessment from the primary questions in the instrument. It is filled out only after the full 
instrument has been completed.
In the present version, "better" answers are recorded to the left of the response 
column, "worse" answers to the right. Thus, a quick scan of this sheet may provide an 
overall sense of the quality of the guidelines. Put another way, a clinician or other user 
ought to be able to apply the guideline effectively if all dimensions of the seven attributes 
(or, at a minimum, all seven attributes) are judged to be "satisfactory" and all omissions 
of information are considered "unimportant," as those terms were defined earlier. In this 
(ideal) situation, all notations on the summary sheet would be on the far left. By contrast, 
if many or most notations are on the right side of the response column, the user might wish 
to employ the guidelines only selectively or to request clarifications or revisions.
Several reviewers noted that completing the summary evaluation sheet is 
essentially a clerical task, provided the main part of the assessment instrument has been 
legibly and fully completed by one or more experts (as discussed earlier). The committee 
agrees and thus suggests that junior or clerical staff be given this responsibility, and that 
the instructions on the form indicate that users might wish to do so. Alternatively, the 
instrument or at least the recording of responses to its questions) might be computerized. 
In that case, the summary sheet could be an automatic product of the computer program. 
The value in pursuing more fully the possibilities of computerization of this form might be 
considerable.
FINAL CAUTIONS AND CAVEATS 
The Ideal: Enemy of the Good
Some commentators noted the IOM's recognition in its 1990 report that most (if not 
all) guidelines in existence today would "fail" to meet the ideal of this instrument. 
Reviewers were concerned that "prematurely imposing excessive rigor" would discourage 
some guideline developers.5
5Comments from the American Nurses Association were particularly to the point: 
the criteria used to judge the adequacy of guidelines establishes a high standard that 
likely would seldom be achieved in reality. Several questions need careful 
consideration prior to accepting the criteria in this instrument:
1. Do the criteria . . . create false expectations of quality which is not achievable with 
current fiscal restrictions in health care?
2. What are the potential legal and regulatory ramifications of accepting these criteria 
as representative of quality practice?
3. How would these criteria eventually influence the costs of care through the pursuit of 
considerable evidence regarding the "best" method of treatment?
4. Are these guidelines intended to weed out bad practice. or is the intention to 
demonstrate the "best," often misinterpreted as the "only" way of practicing'?"
(K. S. O'Connor, Division of Nursing Practice and Economics, American Nurses
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At least one reviewer warned that the assessment process should not be used as 
a "second level expert panel" and cautioned that designing the assessment instrument 
process itself would take some care. The IOM committee agrees and, in that light, 
emphasizes that the educational uses of the instrument are more important than its 
assessment applications (in the near term at least).
U sers of the A ssessm en t Instrument
Busy practicing physicians or other clinicians are not the intended or anticipated 
appliers of this assessment instrument. Neither are policymakers, patients, or other 
nonprofessionals, although all may have some interest in the results. Assessors are 
expected to have, individually or collectively, expertise in three areas: clinical experience 
with patient populations covered by the guideline, research experience about the 
conditions or technologies covered by the guideline, and methodological expertise with 
techniques and processes of guideline development.
Because no one individual is likely to possess all three kinds of expertise, 
experience with the instrument may suggest that a "group," "panel," or "study section" 
approach will be needed to apply it satisfactorily. In this way, different individuals would 
be responsible for different parts of the assessment (particularly to determine validity). 
Furthermore, turning the full assessment into a review or evaluation that would be 
understandable to patients, practitioners, or policymakers will be a separate step, as noted 
earlier.
This provisional instrument thus proceeds on several assumptions. First, assessors 
(individually or collectively) are sufficiently schooled either in the methodologic issues 
inherent in guidelines development or in the clinical issues related to the main topic of the 
guidelines document that they are able to complete the bulk of the assessment instrument 
unaided. Second, questions about clinical topics or methods can be referred to appropriate 
experts when necessary and without undue delay. This kind of referral is particularly 
important if the AHCPR or some other entity acquires a specific mandate to certify or ratify 
guidelines from whatever source. Third, in some cases, having a dual or parallel (i.e., 
simultaneous) review may be a desirable tactic. Fourth, junior staff may well be used to 
assemble relevant material, perhaps to do an initial check of the document itself, perhaps 
to evaluate the document for the attribute of clarity, and to complete the summary 
evaluation sheet. Finally, the experts assembled or asked to apply the instrument (in its 
current form or any future, modified form) will be carefully trained in its use.
Availability of Supporting Material
Guidelines documents would become unmanageably long and unworkable for busy 
clinicians if all the information leading to specific recommendations were included in the
Association. in a letter to Marilyn Field, IOM study director, dated May 20, 1991.)
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guideline itself. Nevertheless, the availability of such information somewhere is important. 
Meeting this expectation presents a difficult conflict for guideline developers, and it 
seriously complicates the task of assessing guidelines.6
At this time, the committee takes the position that as much information as possible 
should be synthesized into a guideline document, even if the formal guideline made widely 
available to practitioners and clinicians is a streamlined version. The assessment process 
is then to be directed at the complete document (with whatever supporting materials may 
be submitted with it), not the clinician's version. This stance accords with the committee's 
general goal of assessing the underlying quality of the guideline itself, not just the process 
by which it was developed.
For any of the uses to which the present instrument is put, the committee thus 
assumes that relevant documentation will be in the assessors' hands. This assumption is 
particularly important when the guidelines to be assessed have been developed by others, 
and especially if those organizations have approached AHCPR or another certifying entity 
with a specific request for ratification of the guidelines. Hence this instrument assumes that 
the pertinent information concerning the guidelines document-including information related 
to the process of development itself-is available for any review effort, with no provision for 
"later" or "on request" submission of information.
A consequence of this assumption is that this instrument is directed at "guideline 
documents," however those documents might be construed by the developers. Some 
guidelines may be contained within a single report, monograph, or other publication. Other 
guidelines may incorporate related publications by reference, particularly when developers 
have used a standardized methodology that is described elsewhere. Primary and 
secondary publications, reports, and records relating to the development of the guideline 
document being assessed should be assembled before the assessment exercise begins. 
This might include, for example, reviews and syntheses of the relevant scientific literature, 
but such a requirement would not extend to individual research reports and articles 
themselves.
Nevertheless, the committee recognizes that published guidelines may 
be "incomplete" because of limitations placed on the authors by editors and 
publishers (e.g., space constraints) and that important documentation may 
not be present. Therefore, if the instrument is applied to published guidelines developed 
by a group that does not deliberately seek to have its guidelines so assessed (and
6For example, the AHCPR Forum panel that has been working on the issue of 
managing depression in community-based settings started originally with 50,000 
citations to the literature, reviewed between 4,000 and 6,000 articles, and based its 
guidelines document on about 400 relevant articles (J. J. Strain, member of the IOM 
committee, in a memorandum to Kathleen Lohr and Marilyn Field, dated June 17, 
1991). There is no possibility that assessors of the guideline document could replicate 
that experience or even undertake to review the final set of relevant articles.
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volunteer the supporting material as assumed above) additional material may need to be 
gathered from those authors in order to apply this instrument fairly.
Standardized Format V ersus Narrative Evaluation
Regardless of what approach to assessing guidelines is finally adopted and what 
level of expertise the evaluators possess, several basic complexities must be 
acknowledged. For instance, simply assessing whether guide line developers explain or 
document a certain piece of information does not allow one to discriminate a 
comprehensive disclosure from one of poor quality. Similarly, lack of disclosure may have 
a significant or only, trivial impact on the clinical usefulness and validity of a guideline. No 
structured instrument of practical length is likely to be able to accommodate these nuances 
across guideline documents of many different types. Thus some narrative, global 
assessment may always be desirable, if not absolutely necessary, if assessments of 
guidelines are to be useful for a wide set o audiences.
In developing the instrument, the committee asked the first set of reviewers to 
comment on a "handbook" approach as an alternative to the formal instrument. This 
approach would provide guidelines assessors with some instructions about the attributes 
of guidelines to be evaluated and would require them to prepare a narrative evaluation 
statement, but it would not produce specific responses to specific questions.
Some respondents preferred the "objective, criterion-based" review (i.e. the formal 
instrument), noting that it might yield "a more standardized
evaluation strategy" and "potential benefits such as greater efficiency and reliability, a 
more readily digested assessment of the strengths and weaknesses of a guideline, and 
the ability to draw more 'objective' comparisons among a collection of guidelines." Given 
that no clear preference for the handbook approach emerged, the committee did not 
pursue this approach further. However, the desire expressed by several reviewers for a 
narrative, summary statement about a guideline document probably reflects some 
discomfort with an assessment strategy based solely on the question-and-answer format 
of the present instrument.
Further Pretesting and Experience with the Instrument
In developing this instrument, the committee recognized the need for more practical 
experience with it. The present version incorporates revisions suggested by the large 
number of reviewers, mainly from medical specialty societies, who critiqued an earlier 
version and in some cases applied it to actual guidelines, as well as changes pursuant to 
the IOM/NRC review. Nevertheless, the committee takes the view that further application 
and pretesting of this provisional form should be conducted.
That testing should determine answers to the following questions: Is the instrument 
too long and too complicated for practical routine use? Does experience applying the 
instrument as an assessment tool make it easier to use, as several reviewers believed it 
might? Can shortcuts be found in applying it? For instance, is it useful to have junior staff
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make an initial check to determine whether all relevant materials appear to be in the 
guidelines document package or to make a first-assessment pass through the guidelines 
document itself? Are the results of the assessment consistent with results of any pretests 
or early evaluations of the guidelines in actual practice?
The present committee takes no stand on how extensive such pre- or pilot-testing 
might be---for instance, on the number of guidelines that should be assessed to determine 
the reliability, validity, and practicality of the current form. Two factors are relevant. First, 
the committee had neither the time nor the resources to pursue these issues further (and 
certainly not to carry out such activities itself). Second, it considers that such testing might 
need to be specific to the potential user groups and that setting a priori rules risks making 
them too rigorous or too confining for all purposes.
THE PROVISIONAL ASSESSMENT INSTRUMENT
The form reproduced in the last part of this appendix has three main parts. First is 
a general information sheet, with space for the following items to be briefly described: 
clinical diagnoses or conditions; health practices, services, or technologies; target 
populations; primary settings of care; primary types of clinicians targeted; stated purposes 
of the guideline; source, author, or developer of the guideline document; person to contact 
for further information about the guideline document; date of issue of the guideline 
document; and name/affiliation of assessor(s). The second section is the fu ll instrument 
itself, with self-contained instructions. The third section is the summary evaluation sheet.
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ASSESSMENT INSTRUMENT
PART ONE. GENERAL INFORMATION SHEET
TO THE ASSESSOR: Please complete this sheet with brief statements about the
content of the guideline document you are reviewing. Use whatever information can be 
found in the document. If you cannot find the relevant information or are uncertain about 
the appropriate response, indicate "not specified” or "uncertain.”
TITLE OF GUIDELINE DOCUMENT____________________________________________
1. Clinical diagnoses or conditions
2. Main health practices, services, or technologies considered
3. Target populations (e.g., age, sex, income level, health status)
4. Primary settings of care (e.g., primary or specialty; nursing home)
5. Primary types of clinicians targeted (e.g., profession; specialty)
6. Stated purposes, aims, or goals of the guideline document
7. Source, author, or developer of guideline document
8. Individual to contact for further information about the guideline document (name, 
organization, phone number)
9. Date of issue of the guideline document
10. Name/affiliation of assessor(s)
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PART TWO. ASSESSMENT INSTRUMENT
Background
This instrument itself has seven sections, each corresponding to one of the seven 
attributes of guidelines to be evaluated. Each section begins with a brief definition of the 
attribute and then is divided into segments that deal with important dimensions of that 
attribute.
Instructions: Illustrative Example
Each segm ent begins with a descriptive question that you should  answ er yes or no. The responses will then direct you to move to a specific next question. Space is provided for "Comments" throughout the instrument.
For example, in the section on clinical applicability, the first question reads (in part) 
as shown below, and you are instructed to check "yes" or "no" and then answer the 
appropriate subquestion:
1. THE GUIDELINE DOCUMENT DESCRIBES THE PATIENT POPULATIONS TO WHICH THE GUIDELINES ARE MEANT TO APPLY.
 Yes (Go to 1.1)  No (Go to 1.2)
1.1. THE DESCRIPTION OF THE PATIENT POPULATIONS IS:
 Satisfactory  Conditionally satisfactory  Unsatisfactory (Specify)
Comments:
>> GO TO QUESTION 2 >>
1.2. OMISSION OF A DESCRIPTION OF THE PATIENT POPULATIONS IS:
 Unimportant omission  Minor omission  Major omission
In some circumstances you are asked to judge a set of variables---specific elements 
to consider in evaluating an attribute---and to arrive at a "global" answer to a particular
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question. When this occurs, you should (1) start with the set of items that are identified 
alphanumerically (e.g., la, lb, . . .) and answer them directly and then (2) combine those 
answers into a summary evaluation to determine whether the guideline document has dealt 
with that particular issue in a satisfactory, conditionally satisfactory, or unsatisfactory 
manner.
You should then go on to the next question or to the next section, as directed. In the 
absence of a specific direction, go to the very next question.
Definitions of Terms
The questions in this instrument ask for three different types of responses. The meaning 
of these response categories is as follows:
Yes and no . Most of the main questions concern the presence of a discussion or 
piece of information about a particular attribute. Generally, the "yes" and "no" responses 
direct you to answer follow-up questions. For these items, response choices are 
"satisfactory," "conditionally satisfactory," and "unsatisfactory," or "unimportant omission," 
"minor omission," and "major omission." These terms are further defined below.
Satisfactory. You can judge information about a particular attribute as satisfactory 
if all critical elements have been considered and presented. For example, the discussion 
or description should be thorough and comprehensive; the guideline developers should 
have based their work on appropriate and correct information; and they should have used 
appropriate methods.
Conditionally satisfactory. The description or discussion of an attribute or dimension 
is conditionally satisfactory if some, but not all, of the critical elements have been 
considered and presented. For example, the discussion of a particular aspect of the 
attribute may be vague or incomplete; alternatively, the guidelines developers may have 
disregarded important information in reaching their recommendations or improperly used 
certain kinds of methods. These problems with the guideline document may not prevent 
a clinician from using it or understanding its recommendations, but they may affect its 
overall usefulness or call certain recommendations into question. Revisions would be 
presumed to improve the guidelines, but they would not be mandatory or essential.
Unsatisfactory. You can determine the description or discussion about a specific 
attribute to be unsatisfactory if most of the critical elements have not been considered or 
presented. For example, well-known pieces of clinical information (or the views of multiple 
specialists with an interest in the guidelines topic) may have been ignored; methods of 
analysis may have been misapplied; or recommendations may be based on faulty 
information poor logic, or both. In such a case, it would be difficult if not impossible to 
judge the quality of the process of guideline development or the soundness of the resulting 
guidelines and recommendations, or both; certainly they could not be assessed as 
satisfactory, and serious thought must be given to augmenting or revising the guideline 
document before it is promoted further.
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Unimportant omissions. You can regard the omission of a description or discussion 
about a specific attribute or dimension of an attribute as unimportant if it (1) is likely to 
have no meaningful impact on the ability of a guideline user, such as a practitioner or 
patient, to apply the guideline effectively in the clinical decision-making process and (2) 
does not prevent you from easily and independently assessing that aspect of the guideline 
document.
Minor omissions. The omission of a description or discussion about a specific 
attribute or dimension is of minor importance if it (1) is likely to have only a little negative 
impact on the ability of a guideline user to apply the guideline effectively in the clinical 
decision-making process and (2) does not prevent you from assessing that aspect of the 
guideline document.
Major omissions. You can determine the omission of a description or discussion 
about a specific attribute or dimension to be a major problem if it (1) is likely to prevent a 
guideline user from applying the guideline effectively in the clinical decision-making 
process or (2) prevents you from making an independent assessment about that aspect 
of the guideline document.
Not applicable or don't know. In some situations, the question may not be applicable 
to the guideline document you are evaluating. When that occurs, simply mark "NA" for "not 
applicable" or "DK" for "don't know."
Comments.In other situations, you may find it difficult to arrive at a single answer 
to the question, especially if the guideline document you are evaluating is very complex 
or if necessary background information appears to be missing. In these cases, you can 
record additional remarks or qualifying statements about your response in the "Comments" 
sections.
Finally, if you believe that the guideline document is so complex, clinically esoteric, 
or methodologically sophisticated that it warrants additional, outside expert review, please 
note your comments at the end of the full instrument.
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I. CLINICAL APPLICABILITY
Clinical applicability, or the scope of the guideline, means three things in the context of this 
instrument. First, guidelines should be written to cover as inclusive a patient population 
as possible, consistent with knowledge about critical clinical and sociodemographic factors 
relevant for the condition or technology in question. To that end, the patient population(s) 
covered should be described as accurately and precisely as possible. Second, if patient 
populations that might be expected to be covered by the guideline are not, then the 
document discusses why those populations have been excluded; that is, it identifies the 
patient populations the guidelines are not meant to serve or apply to. Third, when the 
clinical conditions or problems covered by the guideline are likely to be complex, or when 
the guideline recommendations may be contingent on complex patterns of clinical factors, 
those points should be explicitly covered in the guideline document.
This attribute requires that two things be true about the guideline document. First, 
the guideline document accurately and precisely states how broad or narrow the patient 
population(s) are to which the guidelines are meant to apply, describes the actual 
population(s) to which statements apply, and describes the population(s) to which 
statements are not meant to apply. Population(s) may be described in terms of diagnosis, 
pathophysiology, severity of primary disease, presence of coexisting diseases, age, sex, 
race, social support systems, and other characteristics. Second, it notes and discusses 
any complex clinical issues that may arise for this patient population.
1. THE GUIDELINE DOCUMENT DESCRIBES THE PATIENT POPULATIONS TOWHICH THE GUIDELINES ARE MEANT TO APPLY.
 Yes (Go to Question 1.1) __ No (Go to Question 1.2)
1.1. THE DESCRIPTION OF THE PATIENT POPULATIONS IS:
 Satisfactory  Conditionally satisfactory  Unsatisfactory (Specify)
Comments:
>> GO TO QUESTION 2 >>
1.2. OMISSION OF THE DESCRIPTION OF THE PATIENT POPULATION(S) IS:
 Unimportant  Minor omission  Major omission
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Comments:
2. THE GUIDELINE DOCUMENT DISCUSSES COMPLEX CLINICAL PROBLEMS THAT CAN BE EXPECTED FOR THE POPULATION(S) COVERED BY THE GUIDELINES.
 Yes (Go to Question 2.1)
 No (Go to Question 2.2)
 Not Applicable (Go to Question 3)
2.1. THE DISCUSSION OF EXPECTED COMPLEX CLINICAL PROBLEMS IS:
 Satisfactory  Conditionally satisfactory  Unsatisfactory (Specify)
Comments:
>> GO TO QUESTION 3 >>
2.2. OMISSION OF THE DISCUSSION OF EXPECTED COMPLEX CLINICAL PROBLEMS IS:
 Unimportant  Minor omission  Major omission
Comments:
3. THE GUIDELINE DOCUMENT GIVES A RATIONALE FOR EXCLUDING PATIENT POPULATION(S).
 Yes (Go to Question 3.1)  No (Go to Question 3.2)
3.1. THE RATIONALE FOR EXCLUDING CERTAIN PATIENT POPULATION(S) IS:
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 Satisfactory  Conditionally satisfactory  Unsatisfactory (Specify)
Comments:
>> GO TO II. CLINICAL FLEXIBILITY >>
3.2. OMISSION OF THE RATIONALE FOR EXCLUDING CERTAIN PATIENT POPULATION(S) IS:
 Unimportant  Minor omission  Major omission
Comments:
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II. CLINICAL FLEXIBILITY
Clinical flexibility means that two mediating factors should be addressed, in the 
guideline document. First, it should identify major foreseeable exceptions to or options for 
applying the guidelines, if any exist. Second, it should discuss the role of patient 
preferences for different courses of health care for those conditions or technologies in 
which patient values and preferences may be important decision-making factors (for 
example, being able to choose in an informed way between surgery and watchful waiting).
This attribute requires the guideline document to discuss two topics. First are 
situations (if any) in which socially relevant factors permit an exception to be made in 
applying the guidelines. These factors could include the home and family situation of the 
patient, clinical constraints on the health care delivery setting (e.g., no intensive care beds, 
no 24-hour anesthesiologist), nonclinical constraints on the health care delivery setting 
(e.g., inadequate information systems), or all of these; if no such factors exist, the 
guideline document should say so. Second is the role of patient preferences for different 
possible outcomes of care, when the appropriateness of a clinical intervention involves a 
substantial element of personal choice or values on the part of the patient. For example, 
this discussion may include information as to major points on which preferences may 
diverge for the case in hand, specific points to consider in eliciting patient preferences, 
and means of integrating patient views in the decisionmaking process.
4. THE GUIDELINE DOCUMENT PROVIDES SPECIFIC INFORMATION ABOUTSITUATIONS IN WHICH CLINICAL EXCEPTIONS MIGHT BE MADE INAPPLYING THE GUIDELINES.
 Yes, the document gives information about clinical exceptions
(Go to Question 4.1)
 No, the document says nothing about clinical exceptions
(Go to Question 4.2)
4.1. THE INFORMATION OR STATEMENT ABOUT CLINICAL EXCEPTION IS:
 Satisfactory  Conditionally satisfactory  Unsatisfactory (Specify)
Comments:
>> GO TO QUESTION 5 >>
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4.2. OMISSION OF INFORMATION OR A STATEMENT ABOUT CLINICAL EXCEPTIONS IS:
 Unimportant  Minor omission  Major omission
Comments:
5. THE GUIDELINE DOCUMENT PROVIDES SPECIFIC INFORMATION ABOUT 
NONCLINICAL SITUATIONS IN WHICH EXCEPTIONS MIGHT BE MADE IN APPLYING THE GUIDELINES.
 Yes, the document gives information about nonclinical exceptions
(Go to Question 5.1)
 No, the document says nothing about nonclinical exceptions
(Go to Question 5.2)
5.1. THE INFORMATION OR STATEMENT ABOUT NONCLINICAL EXCEPTIONS IS:
 Satisfactory  Conditionally satisfactory  Unsatisfactory (Specify)
Comments:
>> GO TO QUESTION 6 >>
5.2. OMISSION OF INFORMATION OR A STATEMENT ABOUT NONCLINICAL EXCEPTIONS IS:
 Unimportant  Minor omission  Major omission
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Comments:
6. THE GUIDELINE DOCUMENT DISCUSSES THE ROLE OF PATIENT PREFERENCES, AS THEY RELATE TO HEALTH CARE DECISIONS IN THE PARTICULAR CASE THAT THE GUIDELINES COVER.
 Yes (Go to Question 6.1) __ No (Go to Question 6.2)
6.1. THE DISCUSSION OF PATIENT PREFERENCES IS:
 Satisfactory  Conditionally satisfactory  Unsatisfactory (Specify)
Comments:
>> GO TO QUESTION 7 >>
6.2. OMISSION OF DISCUSSION OF PATIENT PREFERENCES IS:
 Unimportant  Minor omission  Major omission
Comments:
>> GO TO III. RELIABILITY/REPRODUCIBILITY >>
7. THE GUIDELINE DOCUMENT DESCRIBES HOW PATIENT PREFERENCES 
WERE TAKEN INTO ACCOUNT DURING THE GUIDELINE DEVELOPMENT 
PROCESS.
 Yes (Go to Question 7.1) __ No (Go to Question 7.2)
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7.1. THE DISCUSSION OF HOW PATIENT PREFERENCES WERE CONSIDERED IN DEVELOPING THE GUIDELINE IS:
 Satisfactory  Conditionally satisfactory  Unsatisfactory (Specify)
Comments:
>> GO TO III. RELIABILITY/REPRODUCIBILITY >>
7.2 .OMISSION OF THE DISCUSSION OF PATIENT PREFERENCES IN DEVELOPING THE GUIDELINE IS:
 Unimportant  Minor omission  Major omission
Comments:
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III. RELIABILITY/REPRODUCIBILITY
Reliability and reproducibility for the purpose of assessing guidelines means that, given the 
same circumstances, essentially the same set of guidelines would be developed by a 
second group; further, the terms mean that, ideally, the guidelines are or would be 
interpreted and applied Consistently by practitioners or other appropriate parties.
Reliability and reproducibility of a guideline document is not likely ever to be 
assessable empirically. To approach these concepts, therefore, this attribute requires 
either that guidelines be subjected to some form of explicit, independent review by a group 
(or groups) other than the original developers, where that group (or groups) is equivalent 
in expertise and other factors to the original developers, or that the guideline 
recommendations have been pretested in some manner, or both. (Pretesting can be done 
in actual delivery settings or on prototypical cases.) If no such review or pretesting has 
been done, then the guidelines must explain the reasons.
8. THE GUIDELINES WERE SUBJECTED TO INDEPENDENT REVIEW BYEXPERTS OR OUTSIDE PANELS.
 Yes (Go to Question 8.1) __ No (Go to Question 9)
8.1. THE DISCUSSION OF INDEPENDENT REVIEW IS:
 Satisfactory  Conditionally satisfactory  Unsatisfactory (Specify)
Comments:
>> GO TO QUESTION 10 >>
9. THE GUIDELINE DOCUMENT EXPLAINS THE LACK OF INDEPENDENT REVIEW.
 Yes (Go to Question 9.1)  No (Go to Question 9.2)
9.1. THE EXPLANATION OF THE LACK OF INDEPENDENT REVIEW IS:
 Satisfactory  Conditionally satisfactory  Unsatisfactory (Specify)
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Comments:
>> GO TO QUESTION 10 >>
9.2. OMISSION OF AN EXPLANATION OF THE LACK OF INDEPENDENT REVIEW IS:
 Unimportant  Minor omission  Major omission
Comments:
10. THE GUIDELINES WERE PRETESTED IN SOME MANNER.
 Yes (Go to Question 10.1)  No (Go to Question 11)
10.1. THE DISCUSSION OF PRETESTING IS:
 Satisfactory  Conditionally satisfactory  Unsatisfactory (Specify)
Comments:
>> GO TO IV. VALIDITY >>
11. THE GUIDELINE DOCUMENT EXPLAINS THE LACK OF PRETESTING.
 Yes (Go to Question ll.1)  No (Go to Question l 1.2)
11.1. THE EXPLANATION OF THE LACK OF PRETESTING IS:
 Satisfactory  Conditionally satisfactory  Unsatisfactory (Specify)
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Comments:
>> GO TO IV. VALIDITY >>
11.2. OMISSION OF AN EXPLANATION OF THE LACK OF PRETESTING IS:
 Unimportant  Minor omission  Major omission
Comments:
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IV. VALIDITY: DEFINITION AND EVALUATION QUESTIONS
Validity of practice guidelines means, conceptually, that if they are followed. then 
they will lead to the health and cost outcomes projected for them. Validity must be judged 
primarily by reference to the substance and quality of the evidence cited, the means used 
to evaluate the evidence, and the relationship between the evidence and the 
recommendations. Validity is the most critical attribute and the most difficult to assess. Although this section contains 22 questions, questions 28 and 31 are, together, of special importance because  they constitute an overall evaluation of this attribute.
This attribute requires that five things be true for the guideline document. First, the 
collection, synthesis, and interpretation of scientific evidence must be documented and of 
satisfactory quality; ideally, each major recommendation will be described as based on 
"excellent," "acceptable," or "weak" evidence, or with a similar set of descriptive terms.
Second, both qualitative and quantitative statements about health benefits and 
harms/risks appear in the guideline document, and insofar as possible those estimates are 
tied to and justified by the evidence amassed as part of the literature review and analysis. 
For example, a qualitative statement about benefits might read "screening mammography 
should lead to a decrease in breast cancer mortality"; a similar statement about harms and 
risks might read "screening mammography can lead to false-positive results and to 
unnecessary work-up and anxiety." Quantitative statements might read, respectively, 
"screening mammography in women 50 years of age may reduce mortality from 20 percent 
to 60 percent" and "among one million women 40 to 50 years of age, radiation from 10 
mammography examinations can be expected to cause about 60 new breast cancers." In 
all cases, such statements should be based on evidentiary information insofar as possible, 
and appropriate qualifiers or caveats noted when the evidence is weak or conflicting or 
when the estimates are based on consensus techniques such as expert panels or group 
judgment methods.
Third, both qualitative and quantitative statements about expected health costs or 
expenditures appear in the guideline document; the same requirements about the link 
between the guideline estimates and the data sources should be met, and the same 
degree of specificity about patient groups should be observed. In addition, the document 
should be clear as to whether costs referred to are the total for the patient group or the 
per-patient figure. For example, "use of laparoscopic techniques to treat cholecystitis 
should reduce the direct and indirect costs associated with using cholecystectomy as the 
main patient management approach" might be a suitable qualitative statement concerning 
costs, and "use of laparoscopic techniques in the treatment of cholecystitis may reduce the 
costs of treatment as much as 75 percent by the end of the decade by reducing 
hospitalization and time for post-operative (i.e., post-cholecystectomy) morbidity and 
recovery'' might be an appropriate quantitative statement about estimated costs.
Fourth, specific recommendations are clearly tied to and justified by the estimated 
benefits, harms, and costs provided within the document.
Fifth, conflicts between this set of guidelines and any other independent sets (and 
their respective recommendations), if any, must be explicitly discussed.
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Strength o f Scientific Evidence and Professional Consensus
12. THE GUIDELINE DOCUMENT SPECIFICALLY DESCRIBES THE METHOD(S) USED TO COLLECT (I.E., IDENTIFY AND RETRIEVE) THE SCIENTIFIC EVIDENCE ON WHICH RECOMMENDATIONS ARE BASED.
 Yes (Go to Question 12.1)  No (Go to Question 12.2)
12.1. ASSESSOR: Respond to Items 12a-d, below, to assess the methods for 
collecting scientific evidence; then answer Question 12.1, using your best judgment 
as to the overall rating for this element of validity. Other factors you judge important 
should be specifically recorded under "Comments or Other Factors."
12a. The criteria used to include and/or exclude studies are:
 Adequate  Inadequate  Not given/described
12b. The search strategy is:
 Adequate  Inadequate  Not given/described
12c. The sources of information are:
 Adequate  Inadequate  Not given/described
12d. Major studies or other sources of information have been identified.
 Yes  No (Specify)  Don’t know
Now answer:
12.1. THE METHOD(S) OF COLLECTING SCIENTIFIC EVIDENCE IS:
 Satisfactory  Conditionally satisfactory  Unsatisfactory (Specify)
Comments or Other Factors:
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12.2. THE LACK OF A CLEAR METHOD FOR COLLECTING THE SCIENTIFIC EVIDENCE IS:
 Unimportant  Minor omission  Major omission
Comments:
>> GO TO QUESTION 13 >>
13. THE GUIDELINE DOCUMENT GIVES ADEQUATE REFERENCES OR CITATIONS TO THE SOURCES OF INFORMATION USED IN DEVELOPING THE GUIDELINES.
 Yes  No
Comments:
14. THE GUIDELINE DOCUMENT DISCUSSES IN GENERAL TERMS THE STRENGTH OF THE SCIENTIFIC EVIDENCE ON WHICH RECOMMENDATIONS ARE BASED.
Comments:
15. THE GUIDELINE DOCUMENT EXPLICITLY RATES THE STRENGTH OF THE SCIENTIFIC EVIDENCE.
 Yes (Go to Question 15.1)  No (Go to Question 15.2)
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15.1 ASSESSOR: Respond to Items 15a-15f, below, to determine whether the method 
used to rate the strength of the scientific evidence is adequate; then answer 
Question 15.1 below, using your best judgment as to the overall rating for this 
element of validity. Other factors you judge important should be specifically 
recorded under "Comments or Other Factors."
15a. Characteristics of studies used as a basis for guidelines have been described.
 Yes  No
l5b. Strengths and weaknesses of studies used as a basis for guidelines have been noted. 
 Yes  No
l5c. The way the characteristics, strengths, and weaknesses of studies used as a basis for 
guidelines have been taken into account (for instance, an explicit weighting scheme) has 
been clearly described.
 Yes  No
l5d. The way the characteristics, strengths, and weaknesses of studies used as a basis for 
guidelines have been taken into account (for instance, an explicit weighting scheme) is:
 Adequate  Inadequate  Not given/described
15e. The discussion in the document of possible threats to internal validity and reliability 
of studies included in the scientific evidence supporting the guidelines is:
 Adequate_Inadequate  No discussion given
l5f. The discussion in the document of possible threats to external validity and 
general izability of studies included in the scientific evidence supporting the guidelines is:
 Adequate  Inadequate  No discussion given
Now answer:
15.1. OVERALL, THE METHOD USED TO RATE OR WEIGHT THE SCIENTIFIC EVIDENCE IS:
 Satisfactory  Conditionally satisfactory  Unsatisfactory (Specify)
Comments or Other Factors:
148 CDC Guidelines: Improving the Quality
>> GO TO QUESTION 16>
15.2. THE LACK OF ANY GENERAL DISCUSSION OR EXPLICIT RATING OF THE STRENGTH OF THE SCIENTIFIC EVIDENCE IS:
 Unimportant  Minor omission  Major omission
Comments:
16. lF A FORMAL METHOD OF SYNTHESIS IS USED TO COMBINE THE 
SCIENTIFIC EVlDENCE QUANTITATIVELY OR OTHERWISE TO DEVELOP 
SUMMARY OUTCOME MEASURES THAT REFLECT THE STRENGTH OF THE 
s c ie n t if ic  EVIDENCE, THEN THE GUIDELINE DOCUMENT EXPLICITLY
d e s c r ib e s  t h e  m e t h o d .
 Yes, method used and described (Go to Question 16.1)
 No, method used but not described (Go to Question 16.2)
 No, no formal method of synthesis used (Go to Question 18)
16.1. ASSESSOR: Respond to Items 16a-16c, below, to determine whether formal 
methods for synthesizing scientific evidence are satisfactory; then answer Question
16.1 below, using your best judgment as to the overall rating for this element of 
validity. Other factors you judge important should be specifically recorded under 
"Comments or Other Factors."
16a. The meta-analytic method(s) is:
 Adequate  Inadequate  Not applicable/used
16b. The decision-analytic model(s) is:
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 Adequate  Inadequate  Not applicable/used
16c. Other systematic information synthesis method(s) is:
 Adequate  Inadequate  Not applicable/used
Now answer:
16.1 OVERALL, THE FORMAL METHOD(S) USED TO SYNTHESIZE OR COMBINE SCIENTIFIC EVIDENCE IS:
 Satisfactory  Conditionally satisfactory  Unsatisfactory (Specify)
Comments or Other Factors:
>> GO TO QUESTION 17 >>
16.2. OMISSION OF A DESCRIPTION OF THE METHOD(S) OF SYNTHESIZING THE SCIENTIFIC EVIDENCE IS:
 Unimportant  Minor omission  Major omission
Comments:
17. GIVEN THAT A FORMAL METHOD OF SYNTHESIS IS USED TO COMBINE THESCIENTIFIC EVIDENCE QUANTITATIVELY OR OTHERWISE TO DEVELOP SUMMARY OUTCOMES MEASURES, THE GUIDELINE DOCUMENT EXPLICITLY REPORTS THE RESULTS OF THAT SYNTHESIS.
 Yes, method used and results reported (Go to Question 17.1)
 No, method used but results not reported (Go to Question 17.2)
17.1. RESULTS OF INFORMATION SYNTHESIS ARE:
 Satisfactory (e.g., summary outcome measure(s) with confidence intervals or
discussion of uncertainty)
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 Conditionally satisfactory (e.g., summary outcome measure(s) without
confidence intervals or discussion of uncertainty)
 Unsatisfactory (e.g., outcome measure(s) are not interpretable, are inconsistent,
or are otherwise questionable or erroneous). (Specify)
Comments:
>> GO TO QUESTION 18 >>
17.2. OMISSION OF RESULTS OF SYNTHESIS IS:
 Unimportant  Minor omission  Major omission
Comments:
18. IF FORMAL EXPERT OR GROUP JUDGMENT TECHNIQUES ARE USED TO 
REACH PROFESSIONAL CONSENSUS, THEN THE GUIDELINE DOCUMENT 
EXPLICITLY DESCRIBES THE TECHNIQUES.
 Yes, techniques used and described (Go to Question 18.1)
 No, techniques used but not described (Go to Question 18.2)
 No, no formal expert or group judgment techniques used (Go to Question 19)
18.1. THE EXPERT OR GROUP JUDGMENT TECHNIQUES ARE:
 Satisfactory  Conditionally satisfactory  Unsatisfactory (Specify)
Comments:
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18.2. OMISSION OF A DESCRIPTION OF THE EXPERT OR GROUP JUDGMENT TECHNIQUES IS:
 Unimportant  Minor omission  Major omission
>> GO TO QUESTION 19 >>
Comments:
l9. GIVEN THAT EXPERT OR GROUP JUDGMENT METHOD(S) ARE USED TO REACH PROFESSIONAL CONSENSUS, THE GUIDELINE DOCUMENT EXPLICITLY GIVES INFORMATION ABOUT THE STRENGTH OF PROFESSIONAL CONSENSUS.
 Yes, techniques used and information given (Go to Question 19.1)
 No, techniques used but information not given (Go to Question 19.2)
19.1. THE INFORMATION ABOUT THE STRENGTH OF PROFESSIONAL CONSENSUS IS:
 Satisfactory (e.g., levels of professional consensus given for all major points in
the guidelines)
 Conditionally satisfactory (e.g., levels of professional consensus given for
some, but not all, major points in the guidelines)
 Unsatisfactory (e.g., levels of professional consensus are not interpretable, are
inconsistent, or are otherwise questionable or erroneous). (Specify)
Comments:
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>> GO TO QUESTION 20 >>
19.2. OMISSION OF EXPLICIT INFORMATION ABOUT THE STRENGTH OF PROFESSIONAL CONSENSUS IS:
 Unimportant  Minor omission  Major omission
Comments:
20. THE GUIDELINE DOCUMENT PROVIDES A QUALITATIVE DESCRIPTION OF THE HEALTH BENEFITS THAT ARE EXPECTED FROM A SPECIFIC HEALTH PRACTICE.
 Yes (Go to Question 20.1)  No (Go to Question 20.2)
20.1. THE QUALITATIVE DESCRIPTION OF HEALTH BENEFITS IS:
 Satisfactory  Conditionally satisfactory Unsatisfactory (Specify)
Comments:
>> GO TO QUESTION 21 >>
20.2. OMISSION OF A QUALITATIVE DESCRIPTION OF HEALTH BENEFITS IS:
 Unimportant  Minor omission  Major omission
Comments:
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21. THE GUIDELINE DOCUMENT PROVIDES A QUALITATIVE DESCRIPTION OF THE POTENTIAL HARMS OR RISKS THAT MAY OCCUR AS A RESULT OF A SPECIFIC HEALTH PRACTICE.
 Yes (Go to Question 21.1)  No (Go to Question 21.2)
Comments:
21.1. THE QUALITATIVE DESCRIPTION OF POTENTIAL HARMS OR RISKS IS:
 Satisfactory  Conditionally satisfactory  Unsatisfactory (Specify)
Comments:
>> GO TO QUESTION 22 >>
21.2. OMISSION OF A QUALITATIVE DESCRIPTION OF POTENTIAL HARMS OR RISKS IS:
 Unimportant  Minor omission  Major omission
Comments:
Health Benefits and Harms/Risks: Quantitative Information
22. THE GUIDELINE DOCUMENT PROVIDES QUANTITATIVE INFORMATION OR ESTIMATES ABOUT THE HEALTH BENEFITS TO BE EXPECTED AS A RESULT OF A SPECIFIC HEALTH PRACTICE.
 Yes (Go to Question 22.1)  No (Go to Question 22.2)
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22.1. THE QUANTITATIVE INFORMATION ABOUT THE HEALTH BENEFITS IS:
 Satisfactory (e.g., one or more measures of benefits, including accurate
summary or composite measures, with confidence intervals or discussion of 
uncertainty)
 Conditionally satisfactory (e.g., one or more measures of benefits, without
confidence intervals or discussion of uncertainty)
 Unsatisfactory (e.g., measures are not interpretable, are inconsistent, or are
otherwise questionable or erroneous). (Specify)
Comments:
>> GO TO QUESTION 23 >>
22.2. OMISSION OF QUANTITATIVE INFORMATION AND ESTIMATION OF HEALTH BENEFITS IS:
 Unimportant  Minor omission  Major omission
Comments:
>> GO TO QUESTION 24 >>
23. THE GUIDELINE DOCUMENT PROJECTS HEALTH BENEFITS OR OUTCOMES IN TERMS OF ADDITIONAL LIFE EXPECTANCY OR SIMILAR MEASURES, SUCH AS QUALITY-ADJUSTED LIFE YEARS.
 Yes  No  Not applicable/not necessary
Comments:
Appendix B: Instrument for Assessing Clinical Practice Guidelines 155
24. THE GUIDELINE DOCUMENT PROVIDES QUANTITATIVE INFORMATION OR ESTIMATES ABOUT THE POTENTIAL HARMS OR RISKS OCCURRING AS A RESULT OF A SPECIFIC HEALTH PRACTICE.
 Yes (Go to Question 20.1)  No (Go to Question 20.2)
24.1. THE QUANTITATIVE INFORMATION ABOUT POTENTIAL HARMS OR RISKS OCCURRING AS A RESULT OF A SPECIFIC HEALTH PRACTICE IS:
 Satisfactory (e.g., one or more measures of harms or risks, including summary
or composite measures, with confidence intervals or discussion of uncertainty)
 Conditionally satisfactory (e.g., one or more measures of harms or risks, without
confidence intervals or discussion of uncertainty)
 Unsatisfactory (e.g., measure(s) are not interpretable, are inconsistent, or are
otherwise questionable or erroneous). (Specify)
Comments:
>> GO TO QUESTION 25 >>
24.2. OMISSION OF QUANTITATIVE INFORMATION ABOUT POTENTIAL HARMS OR RISKS IS:
 Unimportant  Minor omission  Major omission
Comments:
Health Costs: Qualitative Description
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25. THE GUIDELINE DOCUMENT PROVIDES A QUALITATIVE DESCRIPTION OF 
THE HEALTH COSTS OR EXPENDITURES THAT ARE EXPECTED FROM A SPECIFIC HEALTH PRACTICE
 Yes (Go to Question 25.1) __ No (Go to Question 25.2 )
25.1. THE QUALITATIVE DESCRIPTION OF EXPECTED HEALTH COSTS OR EXPENDITURES IS:
 Satisfactory  Conditionally satisfactory  Unsatisfactory (Specify)
Comments:
25.2. OMISSION OF A QUALITATIVE DESCRIPTION OF EXPECTED HEALTH COSTS OR EXPENDITURES IS:
 Unimportant  Minor omission  Major omission
Comments:
Health Costs: Quantitative Description
26. THE GUIDELINE DOCUMENT PROVIDES QUANTITATIVE INFORMATION OR ESTIMATES ABOUT THE HEALTH COSTS OR EXPENDITURES THAT ARE EXPECTED AS A RESULT OF A SPECIFIC HEALTH PRACTICE.
 Yes (Go to Question 26.1)  No (Go to Question 26.2)
26.1. ASSESSOR: Respond to Items 26a-26e, below, to determine whether 
potential costs and expenditures have been estimated in a satisfactory manner; 
then answer Question 26.1, using your best judgment as to the overall rating for this
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element of validity. Other factors you judge important should be specifically 
recorded under "Comments or Other Factors.”
26a. The cost estimates are done for major subgroups of the patient population, 
e.g., major risk groups, and for major clinical (diagnostic, therapeutic, etc.) 
alternatives.
 Yes  No
26b. The cost estimates include all the services necessary to achieve the health 
benefits that are assumed to be achievable.
 Yes  No
26c. The cost estimates specify number(s) of services that may be added, 
substituted, and/or eliminated if the guideline recommendations are followed.
 Yes  No
26d. The cost estimates specify charges, production costs, or similar information 
for the services that may be added, substituted, and/ or eliminated if the guideline 
recommendations are followed.
 Yes  No
26e. The quantitative method(s) used to estimate costs is
 Appropriate  Inappropriate
Now answer:
26.1 THE QUANTITATIVE INFORMATION ABOUT EXPECTED HEALTH COSTS OR EXPENDITURES IS:
 Satisfactory (e.g., one or more estimates of costs, including accurate summary
or composite measures, with ranges of uncertainty)
 Conditionally satisfactory (e.g., one or more estimates of Costs without ranges
of uncertainty)
 Unsatisfactory (e.g., cost estimates are not interpretable, are inconsistent, or are
otherwise questionable or erroneous). (Specify)
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Comments or Other Factors:
>> GO TO QUESTION 27 >>
26.2. OMISSION OF QUANTITATIVE INFORMATION ABOUT EXPECTED HEALTH COSTS OR EXPENDITURES IS:
 Unimportant  Minor omission  Major omission
Comments:
>> GO TO QUESTION 28 >>
27. IF HEALTH BENEFITS ARE PROJECTED IN TERMS OF ADDITIONAL LIFE EXPECTANCY OR SIMILAR MEASURES, SUCH AS QUALITY-ADJUSTED LIFE YEARS, THEN THE COST PER UNIT OF EACH IDENTIFIED BENEFIT IS ESTIMATED.
 Yes, benefits projected in such terms and cost per unit estimated
 No, benefits projected in such terms but cost per unit not estimated
 Not applicable, benefits not so projected and cost per unit not estimated
28. GENERALLY, THE ESTIMATES OF BENEFITS, HARMS, AND COSTS ARE CONSISTENT WITH THE STRENGTH OF THE EVIDENCE PRESENTED IN THE GUIDELINE DOCUMENT.
 Yes, completely  Yes, partially __ No
Comments:
29. DOES THE GUIDELINE DOCUMENT MAKE MAJOR RECOMMENDATIONS?
 Yes (List below, and then go to Question 30)
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 No (Go to Question 31)
ASSESSOR: Briefly list in the space below the recommendations from the guideline 
document that the developers consider major. If the developers have not specifically 
indicated which are their major recommendations, please list those that you have used in 
answering the questions about the strength of scientific evidence.
30. THE GUIDELINE DOCUMENT EXPLICITLY DISCUSSES THE STRENGTH OF THE SCIENTIFIC EVIDENCE ON WHICH EACH MAJOR RECOMMENDATION IS BASED.
 Yes (Go to Question 30.1)
 No (Go to Question 30.2)
30.1. THE DISCUSSION OF THE STRENGTH OF THE EVIDENCE ON WHICH EACH MAJOR RECOMMENDATION IS BASED IS:
 Satisfactory for all recommendations
 Conditionally satisfactory-i.e., satisfactory for some but not all recommendations
 Unsatisfactory-i.e., not satisfactory for most or all recommendations
Comments:
>> GO TO QUESTION 31 >>
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30.2. OMISSION OF A DISCUSSION OF THE STRENGTH OF THE SCIENTIFIC 
EVIDENCE FOR EACH MAJOR RECOMMENDATION IS:
 Unimportant  Minor omission  Major omission
Comments:
31. EACH MAJOR RECOMMENDATION IS CONSISTENT WITH THE ESTIMATED BENEFITS, HARMS, AND COSTS OF THE SERVICE OR INTERVENTION (AND THUS WITH THE STRENGTH OF THE EVIDENCE).
 Yes, completely  Yes, partially  No
Comments:
Potential Conflict Among Similar Sets o f Guidelines
32. THE GUIDELINE DOCUMENT IDENTIFIES OTHER SETS OF GUIDELINES THAT DEAL WITH THE SAME CLINICAL CONDITION, TECHNOLOGY, OR TOPIC.
 Yes (Go to Question 33)
 No, but similar sets of guidelines are known to exist (Specify below and go to
Question 33.2)
 Not applicable, no similar sets of guidelines are known to exist (Go to V.
CLARITY)
33. THE GUIDELINE DOCUMENT IDENTIFIES POSSIBLE CONFLICTS AMONG EXISTING GUIDELINES AND THE REASONS FOR THEM.
 Yes (Go to Question 33.1)  No (Go to Question 33.2)
33.1. THE DISCUSSION OF POSSIBLE CONFLICTS AMONG GUIDELINES IS:
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 Satisfactory Conditionally satisfactory  Unsatisfactory (Specify)
Comments:
>> GO TO V. CLARITY >>
33.2. OMISSION OF A DISCUSSION OF SIMILAR GUIDELINES, OR OF POSSIBLE CONFLICTS AMONG GUIDELINES, IS:
 Unimportant  Minor omission  Major omission
Comments:
V. CLARITY
Clarity means that guidelines are written in unambiguous language and terms, that 
the logic of the recommendations is clear and straightforward, and that the guideline 
document has a clear and easy-to-understand structure and format. That is, clarity 
encompasses the language and the logic with which the guideline document is written and 
the way it is physically presented. Clarity applies to three content areas of guidelines: (1) 
a general framework in which health condition(s), health practice(s), patient care goals, 
and similar topics are defined and discussed; (2) presentation and discussion of the 
evidence used in developing the guidelines; and (3) recommendations.
More specifically, this attribute requires that, as described below, certain things 
about language and terms, logic, and structure must be true.
Language and Terms
The guidelines are written in unambiguous language. Vague terms are avoided 
when describing the patient populations, health conditions, the health interventions, and 
the recommendations. For example, expressions such as "severe bleeding” are avoided 
in favor of (or at least qualified by) more precise language, such as a "drop in hematocrit 
of more than 6 percent in less than 8 hours." Or, for instance, a recommendation such as 
"thyroid function tests should be obtained whenever appropriate" is replaced by a 
recommendation that includes the type of test, its frequency, and the specific 
circumstances under which it should be used, such as "once every 5 years in otherwise 
healthy adults more than 65 years of age."
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34. THE GUIDELINES DESCRIBE THE HEALTH CONDITION TO BE PREVENTED, 
DETECTED, OR TREATED IN UNAMBIGUOUS TERMS.
 Yes  No
Comments:
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35. THE GUIDELINES DESCRIBE THE OPTIONS FOR MANAGEMENT OF THE HEALTH CONDITION (I.E., THE HEALTH PRACTICE AND ITS ALTERNATIVES) IN UNAMBIGUOUS TERMS.
 Yes  No
Comments:
36. IF THE GUIDELINES GIVE MAJOR RECOMMENDATIONS, EACH IS WRITTEN IN UNAMBIGUOUS TERMS.
ASSESSOR: Refer to the list you developed for Question 29 in answering this 
question.
 Yes  No  Not applicable, no major recommendation given
Comments:
Logic
The guidelines are as comprehensive as possible in keeping with the attributes 
"clinical adaptability" and "clinical flexibility." Thus, the logic of the guidelines is such that 
all clinically important and relevant situations are handled in a consistent, reasonable, and 
easy-to-follow manner and that situations that are not covered are explained in a logically 
appropriate place in the guideline statement.
Recommendations are mutually exclusive; that is, they are consistent with each 
other. For example, a guideline does not recommend "aortic valvuloplasty, for an 
80-year-old man with end stage renal disease" in one place and "aortic valve replacement 
for an 80-year-old man with end stage renal disease" in another.
37. RECOMMENDATIONS ARE COMPREHENSIVE, INSOFAR AS THE EVIDENCE PERMITS, AND RECOMMENDATIONS THAT MIGHT BE EXPECTED ARE
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GIVEN. (That is, the recommendations collectively cover all clinically relevant circum stances.)
 Yes (Go to Question 38)  No (Go to Question 37.1)
Comments:
37.1. IF EXPECTED RECOMMENDATIONS SEEM TO BE MISSING, THE GUIDELINE DOCUMENT DISCUSSES WHY.
 Yes  No
Comments:
38. RECOMMENDATIONS ARE CONSISTENT. (That is, no two recom m endations in the guidelines conflict with each other.)
 Yes
 No (at least two recommendations appear to conflict with each other)
 Not applicable, no recommendations given
Comments:
Structural Clarity
The overall organization and appearance of the guideline document and the mode 
of presentation of the recommendations are easy for users to understand and follow. A 
structurally clear guideline is one in which the recommendations are easily accessible to
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the prospective user. That is, clinicians should not have to read, analyze critically, and 
distill a detailed manuscript in order to find needed recommendations. Structural clarity 
may be achieved through the use of a summary, special highlighting techniques, 
algorithms, or other methods.
39. THE GUIDELINE DOCUMENT USES CLEAR HEADINGS, INDEXES, LISTS, FLOW CHARTS, OR OTHER DEVICES TO IDENTIFY MAJOR TOPICS DISCUSSED.
Comments:
40. THE GUIDELINE DOCUMENT HAS A SUMMARY OR ABSTRACT THAT ACCURATELY REFLECTS THE METHODS, CONTENT, AND RECOMMENDATIONS OF THE ENTIRE DOCUMENT.
 Yes  No
Comments:
41. A USER OF THE GUIDELINE DOCUMENT CAN EASILY FIND EACH MAJOR RECOMMENDATION.
ASSESSOR: Refer to the list developed for Question 29 in answering this question.
 Yes  No  Not applicable, no major recommendation given
Comments:
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VI. SCHEDULED REVIEW
Scheduled review means that a statement specifying a date for review and possible 
revision of the guideline has been included in the guideline document. Revisions to 
guidelines should reflect new clinical evidence or changing professional consensus.
This attribute requires that the guideline document either (1) give a specific date for 
review and possible revision of the guidelines or (2) describe a process by which such a 
date might be established and the review and possible revision performed.
42. THE GUIDELINE DOCUMENT GIVES A SPECIFIC DATE FOR SCHEDULED REVIEW, GIVES OTHER INFORMATION CONCERNING A PROCEDURE BY WHICH SCHEDULED REVIEW MIGHT BE DONE, OR GIVES A SUNSET OR EXPIRATION DATE.
 Yes (Go to Question 42.1)  No (Go to Question 42.2)
42.1. ASSESSOR: Respond to Items 42a-42d, below, to determine whether the 
scheduled review date information is satisfactory, then answer Question 42.1 
below, using your best judgment as to the overall rating for this attribute of 
scheduled review. Other factors you judge important should be specifically recorded 
under "Comments or Other Factors."
42a. The target date for review is:
 Appropriate  Inappropriate  None given/discussed
42b. The rationale for the target date is:
 Appropriate  Inappropriate  None given/discussed
42c. The procedures suggested for determining when the guidelines should be 
reviewed are:
 Appropriate  Inappropriate  None given/discussed
42d. The guideline has a sunset provision that may dictate when a scheduled 
review should take place or that may indicate when the guideline will expire.
 Appropriate  Inappropriate  None given/discussed
Now answer:
42.1. THE SCHEDULED REVIEW DATE OR PROCEDURE FOR SETTING IT IS:
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 Satisfactory  Conditionally satisfactory  Unsatisfactory (Specify)
Comments or Other Factors:
>> Go to VII. MULTI-DISCIPLINARY PROCESS >>
42.2. THE LACK OF A SCHEDULED REVIEW DATE OR PROCEDURE FOR SETTING IT IS:
 Unimportant  Minor omission  Major omission
Comments:
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VII. MULTI-DISCIPLINARY PROCESS
A multi-disciplinary process for practice guidelines means that representatives of 
a broad range or practitioners, consumers or patients, and other groups likely to be 
affected by the guidelines have participated in the development process at some stage. 
These representatives can be individuals who have had direct responsibility for the 
guideline document or individuals who have reviewed that document or in other ways have 
contributed to it. This attribute intends that both methodologic and clinical disciplines be 
involved in the guideline-development process. This document cannot identify in advance 
all relevant participants, interested parties, or disciplines because each set of guidelines 
will differ in this respect.
This attribute requires that five things be true. First, some combination of individuals 
directly responsible for guidelines and those who have otherwise contributed to their 
development collectively represents all the key groups likely to affect or to be affected by 
the guidelines. Second, the guideline document describes the parties involved (including 
their credentials and potential biases); "the parties involved” is understood to mean 
participants in the actual development panel and those in review panels, public hearings, 
or other review forums. Third, potential biases and conflicts of interests have been
discussed or otherwise appropriately taken account of. Fourth, the methods used to solicit
panelists' views and arrive at group judgments have been described and are adequate and 
appropriate to the task of balancing views and potential biases. Fifth, the methods used 
to solicit outside review comments and present those to panelists have been described 
and are adequate to the task of making outside views clear to panelists.
43. PERSONS WITH APPROPRIATE CLINICAL AND METHODOLOGIC DISCIPLINES PARTICIPATED IN DEVELOPING THE GUIDELINE DOCUMENT--- THAT IS, A MULTI-DISCIPLINARY APPROACH WAS FOLLOWED.
 Yes (Go to Question 43.1)
 No (Go to Question 43.2)
 Don’t know or can’t tell (Go to Question 43.2)
43.1. ASSESSOR: Respond to Items 43a-43i, below, to determine whether the 
multi-disciplinary process is satisfactory; then answer Question 43.1 below, using 
your best judgment as to the overall rating for this element of multi-disciplinary 
process. Other factors you judge important should be specifically recorded under 
"Comments or Other Factors.”
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43a. An explanation, discussion, or rationale for selecting the guideline panel 
chairperson is given.
 Yes  No
43b. An explanation, discussion, or rationale for selecting the members of the 
guideline panel is given.
 Yes  No
43c. An explanation, discussion, or rationale for selecting other individuals directly 
responsible for the guideline document (such as consultants) is given.
 Yes  No
43d. The explanation(s), discussion(s), or rationale(s) for selecting the individuals 
covered in 43a-c is (are):
 Adequate Inadequate  Not applicable
43e. These individuals reflect all appropriate interest groups and disciplines.
 Yes  No  Can't tell
43f. One or more outside review panel(s) commented on or reviewed draft 
guidelines.
 Yes  No  Can't tell
43g. One or more public hearing(s) or similar review mechanism(s) were held to 
allow comment or review on draft guidelines.
 Yes  No  Can't tell
43h. Collectively, the review panel(s), public hearing(s), or other review 
mechanisms reflected all appropriate interest groups and disciplines.
 Yes  No  Can't tell
43i. If the answer to either question 43e or question 43h is "No" or "Can't tell," 
please record what groups or disciplines appear to have been omitted.
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Now answer:
43.1. THE MULTI-DISCIPLINARY APPROACH TO THE GUIDELINES DEVELOPMENT PROCESS IS:
 Satisfactory  Conditionally satisfactory  Unsatisfactory (Specify)
Comments or Other Factors:
43.2. THE LACK (OR APPARENT LACK) OF A MULTIDISCIPLINARY PROCESS IS:
 Unimportant  Minor omission  Major omission
Comments:
44. THE GUIDELINE DOCUMENT EXPLICITLY NOTES ANY POTENTIAL BIASES AND/OR CONFLICTS OF INTERESTS OF THE PANEL MEMBERS, OR STATES THAT BIASES AND CONFLICTS OF INTEREST WERE DISCUSSED AMONG PANEL MEMBERS OR OTHERWISE TAKEN INTO ACCOUNT.
 Yes, potential biases and/or conflicts of interest are noted
 Yes, a statement that biases and/or conflicts of interest were discussed is given
 No, no note or statement about biases and/or conflicts of interest is given
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45. OVERALL, POTENTIAL BIASES AND/OR CONFLICTS OF INTEREST APPEAR TO BE ADEQUATELY BALANCED OR OTHERWISE ACCOUNTED FOR IN THE GUIDELINE DEVELOPMENT PROCESS.
 Yes  No (Specify)  Don't know or can't tell
Comments:
46. THE GUIDELINE DOCUMENT DESCRIBES THE METHODS USED TO SOLICIT VIEWS OF INTERESTED PARTIES NOT ON THE GUIDELINES DEVELOPMENT PANEL AND TO PRESENT THOSE VIEWS TO THE MEMBERS OF PANEL.
 Yes (Go to Question 46.1) __ No (Go to Question 46.2)
46.1. THE METHODS USED TO SOLICIT VIEWS OF THOSE NOT ON THE PANELS AND PRESENT THOSE VIEWS TO PANELS ARE:
 Satisfactory  Conditionally satisfactory  Unsatisfactory (Specify)
Comments:
46.2. THE LACK OF A DESCRIPTION OF THE METHODS USED TO SOLICIT VIEWS OF THOSE NOT ON THE PANELS AND TO PRESENT THOSE VIEWS TO PANELS IS:
 Unimportant  Minor omission  Major omission
Comments:
PLEASE RECORD ANY SUMMARY JUDGMENTS OR OTHER COMMENTS YOU MAY NAVE AND ANY RECOMMENDATIONS FOR ADDITIONAL REVIEW.
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PART THREE. SUMMARY EVALUATION SHEET
Instructions and Key
ASSESSOR: Upon completing the entire assessment instrument, please record answers 
to the main questions (Questions 1-46) below. Circle the relevant answer, according to the 
following key:
KEY
Y = Yes; YQ = yes, but response qualified;
N = No; NQ = no, but response qualified;
S = Satisfactory, CS = Conditionally satisfactory, US = Unsatisfactory;
UN = Unimportant, MI = Minor omission, MA = Major omission;
NA = Not applicable
DK = Don't know, or can't tell
I. CLINICAL APPLICABILITY
Y N 1. Description of patient population
S CS US 1.1. Quality of description
UN MI MA 1.2. Omission of description
Y N NA 2. Discussion of complex clinical problems
S CS US 2.1. Quality of discussion
UN MI MA 2.2. Omission of discussion
Y N 3. Rationale for excluding patient populations
S CS US 3.1. Quality of rationale
UN MI MA 3.2. Omission of rationale
II. CLINICAL fl e x ib il it y
Y N 4. Information about acceptable clinical exceptions
S CS US 4.1. Quality of information or statement
UN MI MA 4.2. Omission of information or statement
Y N 5.. Information about acceptable nonclinical exceptions
S CS US 5.1. Quality of information or statement
UN MI MA 5.2. Omission of information or statement
Y N 6. Discussion of patient preferences in the health care decisions
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S CS US 6.1. Quality of discussion
UN MI MA 6.2. Omission of discussion
Y N 7. Discussion of patient preferences in guideline development
S CS US 7.1. Quality of discussion
UN MI MA 7.2. Omission of discussion
III. RELIABILITY/REPRODUCIBILITY
Y N 8. Independent review by experts or outside panels
S CS US 8.1. Quality of discussion
Y N 9. Explanation of lack of independent review
S CS US 9.1. Quality of explanation
UN MI MA 9.2. Omission of explanation
Y N 10. Guidelines pretested in some manner
S CS US 10.1. Quality of discussion
Y N 11. Explanation of lack of pretesting
S CS US 11.1. Quality of explanation
UN MI MA 11.2. Omission of explanation
IV. VALIDITY
STRENGTH OF THE SCIENTIFIC EVIDENCE AND PROFESSIONAL CONSENSUS
Y N 12. Method of collecting (identifying and retrieving) scientific 
evidence is specifically described
S CS US 12.1. Quality of method
UN MI MA 12.2. Lack of method
Y N 13. Adequate references to sources of scientific evidence
Y N 14. General discussion of strength of scientific evidence
Y N 15. Explicit rating of the strength of the scientific evidence
S CS US 15.1. Quality of rating method
UN MI MA 15.2. Lack of general discussion of rating method
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Y N NQ 16. If a formal method of synthesis is used, explicit description of 
the method
S CS US 16.1. Quality of formal method
UN MI MA 16.2. Omission of description of formal method
Y N 17. If applicable, the results of a formal synthesis of scientific 
evidence are explicitly reported
S CS US 17.1. Quality of results of the synthesis
UN MI MA 17.2. Omission of results of the synthesis
Y N 18. If applicable, the expert or group judgment techniques used for 
reaching professional consensus are explicitly described
S CS US 18.1. Quality of expert or group judgment techniques
UN MI MA 18.2. Omission of description of expert or group judgment 
techniques
Y N 19. If applicable, the strength of professional consensus resulting 
from use of group judgment techniques is reported
S CS US 19.1. Quality of information about strength of professional 
consensus
UN MI MA 19.2. Omission of explicit information about strength of 
professional consensus
HEALTH BENEFITS AND HARMS/RISKS: QUALITATIVE DESCRIPTION
Y N 20. Qualitative description of health benefits
U S US 20.1. Quality of qualitative description
UN MI MA 20.2. Omission of qualitative description
Y N 21. Qualitative description of potential harms or risks
S CS US 21.1. Quality of qualitative description
UN MI MA 21.2. Omission of qualitative description
HEALTH BENEFITS AND HARMS/RISKS: QUANTITATIVE 
INFORMATION
Y N 22. Quantitative information or estimates of health benefits
S CS US 22.1. Quality of quantitative information
UN MI MA 22.2. Omission of quantitative information
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Y N NA 23. Health benefits projected in terms of life expectancy or similar 
measures
Y N 24. Quantitative information or estimates of potential harms or 
risks
S CS US 24.1. Quality of quantitative information
UN MI MA 24.2. Omission of quantitative information
HEALTH COSTS: QUALITATIVE DESCRIPTION
Y N 25. Qualitative description of health costs or expenditures
S CS US 25.1 Quality of qualitative description
UN MI MA 25.2. Omission of qualitative description
HEALTH COSTS: QUANTITATIVE DESCRIPTION
Y N 26. Quantitative information or estimates of health costs or 
expenditures
S CS US 26.1. Quality of quantitative information
UN MI MA 26.2. Omission of quantitative information
Y N NA 27.If health benefits projected in terms of life expectancy or 
similar measures, costs per unit of each identified benefit also 
estimated
Y YQ N 28. Generally, estimates of benefits, harms, and costs are 
consistent with the strength of provided evidence
Y N 29. Major recommendations made in the guideline
Y N 30. Discussion of strength of the scientific evidence for each 
major recommendation
S CS US 30.1. Quality of discussion
UN MI MA 30.2. Omission of discussion
Y YQ N 31. Each major recommendation consistent with strength of 
scientific evidence
POTENTIAL CONFLICT AMONG SIMILAR SETS OF GUIDELINES
Y N NA 32. Other sets of guidelines identified
Y N 33. Possible conflicts among existing guidelines discussed
C CS US 33.1. Quality of discussion
UN MI MA 33.2. Omission of discussion












34. Language describing the health condition is unambiguous
35. Language describing the options for management is 
unambiguous
NA 36. Language for each major recommendation is unambiguous
37. Recommendations are comprehensive and present when 
expected
37.1. Reasons given for lack of expected recommendations





39. Guideline document uses clear headings, indexes, etc.
40. Guideline document has accurate summary or abstract
41. Users can find recommendations easily
VI. SCHEDULED REVIEW: DEFINITION AND EVALUATION QUESTIONS
Y N 42. Scheduled date for review or a procedure for arriving at
such a date is provided 
S CS US 42.1. Quality of the scheduled review date or procedure for
setting one
UN MI MA 42.2. Lack of a scheduled review date or procedure for
setting one
VII. MULTI-DISCIPLINARY PROCESS
Y N DK 43. Participation of persons in appropriate clinical and
methodologic disciplines
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S CS US 43.1. Quality of the multi-disciplinary approach
UN MI MA 43.2. Lack of a multi-disciplinary process
Y YQ N 44. Guideline document notes potential biases or conflicts 
of interest or indicates they were taken into account
Y N DK 45. Balance of potential biases or conflicts of interest
Y N 46. Description of the methods used to solicit views of 
those not on the guidelines development panel and to 
present those views to the panel
S CS US 46.1. Quality of methods used
UN MI MA 46.2. Lack of a description of methods used
SUMMARY JUDGMENT, OTHER COMMENTS, OR NEED FOR ADDITIONAL REVIEW:
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This page in ten tio n ally  le ft blank.
APPENDIX C: CDC/ATSDR FEDERALLY CHARTERED ADVISORY COMMITTEES *
Office of the Director
► Advisory Committee on Immunization Practices (ACIP)
1. Dixie E. Snider, M.D., M.P.H.
2. Gloria Kovach, Committee Management Specialist (639-3851/Fax 639-3036
► Advisory Committee to the Director, CDC (ACD, CDC)
1. Linda Kay McGowan (Acting)
2. Marge Carter, Program Specialist (639-2290/Fax 639-3941)
► CDC Advisory Committee on the Prevention of HIV Infection (CDC, ACPHI)
1. Helene D. Gayle, M.D. (Acting)
2. Connie Granoff, Program Specialist (639-8029/Fax 8600)
► National Vaccine Advisory Committee (NVAC)
1. Robert F. Breiman, M.D.
2. Gloria Kovach, Committee Management Specialist (639-3851/Fax 639-3036)
National Center for Chronic Disease Prevention and Health Promotion
Breast and Cervical Cancer Early Detection and Control Advisory Committee 
(BCCEDCAC)
1. Rebecca B. Wolf
2. Karen Norton (488-4751/Fax 488-4727)
Interagency Committee on Smoking and Health (ICSH)
1. Karen M. Deasy
2. Amy Garson, Staff Specialist (202-205-8500/Fax 202-205-8313)
► Technical Advisory Committee for Diabetes Translation and Community Control 
Programs (TACDTCCP)
1. Frank Vinicor, M.D., M.P.H.
2. Cheryl Shaw, Program Specialist (488-5004/Fax 488-5966)
National Center for Environmental Health
► Advisory Committee for Energy-Related Epidemiologic Research (ACERER)
1. Richard J. Jackson, MD, MPH
2. Nadine Dickerson, Program Specialist (488-7040/Fax 488-7044)
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► Advisory Committee on Childhood Lead Poisoning Prevention (ACCLPP)
1. Henry Falk, M.D.
2. Barbara Nelson, Program Analyst (488-7330/Fax 488-7335)
► Hanford Thyroid Morbidity Study Advisory Committee (HTMSAC)
1. Henry Falk, M.D.
2. Nadine Dickerson, Program Specialist (488-7040/Fax 488-7044)
National Center for Injury Prevention and Control
► Advisory Committee for Injury Prevention and Control (ACIPC)
1. Thomas E. Blakeney (Acting)
2. Iris Lansing, Program Specialist (488-4821/Fax 488-4338)
► Injury Research Grant Review Committee (IRGRC)
1. Richard W. Sattin, M.D., F.A.C.P.
2. Iris Lansing, Committee Management Specialist (488-4821/Fax 488-4338)
National Center for Health Statistics
National Committee on Vital and Health Statistics (NCVHS)
1. Gail F. Fisher, Ph.D.
2. Jackie Adler, Conference Assistant (301-436-7122/Fax 301-436-4233)
National Center for Infectious D iseases
Board of Scientific Counselors, National Center for Infectious Diseases (BSC, 
NCID)
1. Rosemary B. Ramsey
2. Diane Holley, Committee Management Specialist ( 639-0078/Fax 639-3853)
► Hospital Infection Control Practices Advisory Committee (HICPAC)
1. Julia S. Garner, R.N., M.N.
2. Karen Friend, Secretary (HIP) (639-6403/Fax 639-6458)
National Center for Prevention Services
► Advisory Council for the Elimination of Tuberculosis (ACET)
1. Helene Gayle, M.D.
2. Tracy Whitnell, Program Analyst (639-8006/Fax 639-8600)
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National Institute for Occupational Safety and Health
► Board of Scientific Counselors, National Institute for Occupational Safety and 
Health
(BSC, NIOSH)
1. Bryan D. Hardin, Ph.D. (Acting)
2. Judy James, Committee Management Specialist (639-4403/Fax 639-2196)
► Mine Health Research Advisory Committee (MHRAC)
1. Gregory R. Wagner, M.D.
2. Judy James, Committee Management Specialist (639-3794/Fax 639-2196)
► Safety and Occupational Health Study Section (SOHSS)
1. Contact: Roy M. Fleming, Sc.D.
2. Judy James, Committee Management Specialist (639-3794/Fax 639-2196)
► Workers' Family Protection Task Force (WFPTF)
1. Elizabeth A. Whelan, Ph.D.
2. Pam Graydon (513/533-8312)
Public Health Practice Program Office
► Clinical Laboratory Improvement Advisory Committee (CLIAC)
1. Edward L. Baker, M.D.
2. Julie Wasil, Committee Management Specialist (488-4651/Fax 488-7667) 
ATSDR Federal Advisory Committee
► Board of Scientific Counselors, Agency for Toxic Substances and Disease Registry
(BSC, ATSDR)
1. Charles Xintaras, Sc.D.
2. Diane Allgood, Secretary (639-0708/Fax 639-0586)
Federal Advisory Committees Utilized by CDC and ATSDR
Citizens Advisory Committee on Public Health Service Activities and Research at 
Department of Energy Sites (CACPHSARDES)
Fernald
1. Steve Adams
2. Nadine Dickerson, Program Specialist (488-7040) (Fernald)
• Hanford Health Effects Subcommittee (HHES)
Appendix C: CDC/ATSDR Federally Chartered Advisory Committees 183
1. Jim Carpenter
2. Linda Carnes (639-0730/Fax 639-0759) (Hanford Health Effects Subcomm - 
HHES)
• Idaho National Engineering Laboratory (INEL
1. Arthur J. Robinson, Jr.
2. Nadine Dickerson, Program Specialist (488-7040) (Idaho National 
Engineering Lab - INEL)
• Savannah River Site (SRS)
1. Paul Renard
2. Nadine Dickerson, Program Specialist (488-7040/Fax 488-7044) (Savannah 
River Site - s r s )
► Disease, Disability, and Injury Prevention and Control Special Emphasis Panel 
(Panel name determined by program conducting the SEP)
1. Burma Burch (CDC and ATSDR Contact)
2. Judi Cook, Committee Management Specialist (639-6389/Fax 639-6290)
* Most of th ese  com m ittees develop guidelines: 1 = executive secretary  and 2 = m anagem ent contact
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APPENDIX D: ACCESSING CDC PREVENTION GUIDELINES DATABASE
The Centers for Disease Control and Prevention maintains an electronic data base of 
recommendations and guidelines for disease and injury prevention in both clinical care 
and public health practice. With over 400 documents, the CDC Prevention Guidelines 
Data Base (PGDB) includes guidelines for the prevention and control of a wide range 
of conditions relevant to public health and clinical prevention. Some of the guideline 
topics are AIDS, cholera, disaster response, dengue fever, suicide, lung cancer, 
vaccine-preventable diseases, sexually transmitted diseases, birth defects, and 
malaria. About two-thirds of the documents in the data base are in their original form 
as published in CDC’s Morbidity and Mortality Weekly Report (MMWR). The others 
were published as CDC monographs, books or book chapters, brochures, or articles in 
peer-reviewed journals. Some of these other publications are not contained within the 
data base; however, a contact is identified so that the document can be obtained from 
CDC. The PGDB does include all of the ACIP immunization recommendations, the 
Guide to Clinical Preventive Services, CDC treatment guidelines for sexually 
transmitted diseases, and the entire "yellow book” (Health Information for International 
Travelers).
The PGDB is now widely accessible through the World Wide Web via CDC’s home 
page (http://www.cdc.gov/cdc.html) or directly
(http://wonder.cdc.gov/wonder/prevguid/prevguid.html). The PGDB is also available 
on CD-ROM as a stand-alone version with its own search engine. The main data base 
will be updated weekly and the CD-ROM version will be updated quarterly. The PGDB 
is accessible within CDC as indicated above. Additional information 
concerning the PGDB can be obtained through CDC WONDER Customer Support at 
(888)496-8347; or E-mail cwus@cdc.gov.
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